GPCRs in rat primary skeletal muscle cells by Haddad, Mansour Emil Goerge
Haddad, Mansour Emil Goerge (2012) GPCRs in rat 
primary skeletal muscle cells. PhD thesis, University of 
Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/14176/1/588070.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
Faculty of Medicine and Health Sciences
School of Biomedical Sciences
The University of
Nottingham
GPCRs in rat primary skeletal muscle cells
Mansour Emil Goerge Haddad
(Pharmacy.BCh, MSc)
MJ=n!C(~i I IPP.l.~,R-ey",.. • • .§I .JJ \,~ >',.'w,"". \) c '\I.
au E"-r '" '\ ,_.-, ......',' c·'- 'j-r'')E_.L:. \lv Iv.tU:L-.L · i.::..i' f\-
This thesis is submitted to the University of Nottingham
For the degree of Doctor of Philosophy
July 2012
Abstract
GPCRs are the largest family of proteins in the human genome and a target for huge
numbers of therapeutic drugs. However, the role of skeletal muscle in the action of these
drugs is unclear. Given the unique importance of GPCR signalling in terms of glucose
and fatty acid turnover in other tissues, it would be anticipated that GPCR identified to
influence metabolism in these tissues might well be expressed in skeletal muscle.
This study investigated the expression of genes encoding GPCRs in skeletal muscle and
in cultured preparations thereof. In particular, this study focussed on the expression and
signalling of adenosine receptors, a2-adrenoceptor, P2Y receptors and CBI cannabinoid
receptors and the impact of CBI receptor modulation upon insulin signalling in rat
primary skeletal muscle cells.
All experiments in this work looked at GPCR expression and their signalling; with
either tissues or cultured cells from rats. These experiments included:
1. Transcriptional profiling of skeletal muscle tissue in Wistar rats for GPCRs and
proteins in associated signalling pathways.
2. Signalling of GPCRs (adenosine, a2A-adrenoceptor, P2y) in rat primary skeletal
muscle cells.
3. Cannabinoid signalling pathways and cross-talk with insulin signalling.
4. CBI cannabinoid receptor antagonist/inverse agonist/agonist treatment of rat primary
skeletal muscle cells.
Expression of example members of the three major G protein coupling GPCR families
was observed in rat skeletal muscle tissue. mRNA encoding Gs- (A2Aadenosine receptor,
i
P2-adrenoceptor), Gi- (AI adenosine receptor, (l2A-adrenoceptor), and Gq-coupled (P2Y 1.
P2Y2 and P2Y6 receptors) receptors were detected using gene microarray (Agilent, all
ranked <10220 out of 41090). QRT-PCR (Taqman) identified (l2A-adrenoceptor and
CBI cannabinoid receptor mRNA expression at low level similar across myoblasts,
myotubes and skeletal muscle tissue.
Functional responses to example members of the three major G protein coupling
families of GPCR were also observed in rat primary skeletal muscle preparations. First,
treatment of myotubes with the non-selective adenosine receptor agonist NECA elicited
increases in cAMP, which were inhibited in the presence of the A2Badenosine receptor-
selective antagonist, PSB603. In contrast, the A2A-selective agonist, CGS21680 failed to
evoke a significant cAMP elevation in myotubes. Second, neither basal nor forskolin-
evoked elevation of cAMP was altered in the presence of the Ar-selective agonist, S-
ENBA. Third, the (l2-adrenoceptor agonist UK14304 inhibited forskolin-evoked cAMP
levels, however, rauwolscine did not prevent this effect. Treatment with UK14304 also
increased phosphorylation of ERK1/2; these responses, however, were inhibited by
rauwolscine. In addition, rauwolscine in the absence of other ligands also inhibited ERK
phosphorylation. Fourth, ATP and UTP, P2Y receptor agonists, elevated intracellular
calcium ion levels in myoblasts.
Although expression of mRNA for CBI cannabinoid receptors was detected in
myoblasts, myotubes and skeletal muscle tissue, forskolin-evoked elevation of cAMP
was unaltered in the presence of the CBI receptor-selective agonist ACEA or the
antagonist/inverse agonist rimonabant in cultured myotubes. AICAR-stimulated AMP-
activated protein kinase activity was also unaltered by ACEA. However, treatment with
ACEA increased activation ofERK1I2 and p38 mitogen-activated protein kinases; these
responses were significantly inhibited by rimonabant.
ii
Insulin treatment of myotubes increased the activation (phosphorylation) of
AKT/protein kinase B, glycogen synthase kinase 3(1 and ~, ERK1I2 and p38 MAP
kinases; however, pre-treatment with ACEA for 24 hours failed to alter these responses.
In conclusion, these studies indicate expression and functional responses to select
members of the three major G protein coupling families of GPCR in rat skeletal muscle
preparations. These findings also provided evidence for expression of functionally
active CB) cannabinoid receptors in skeletal muscle. However, they fail to support
previous reports suggesting an interaction between insulin and CB) receptor signalling
in these cells. The impact of CB) receptor function in skeletal muscle should be the
subject of further investigation.
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Chapter 1
Introduction
1
1 Chapter One: Introduction
1.1 GPCR
1.1.1 Definition
GPCRs constitute the largest family of proteins in the human genome consisting of
approximately 1000 genes. GPCRs are the richest targets for pharmaceutical drugs on
the market today, it is estimated that they are the targets of 30-50% of all medications
due to their vast and varied roles in regulating the body and their involvement in key
biological functions (Kobilka, 2007; Tilakaratne et al., 2005).
1.1.2 GPCR structure
GPCRs are diverse in structure and sequence homology. However, they have common
structural features including seven-transmembrane helices of 22-28 hydrophobic amino
acids that reside in the cell membrane, three extracellular loops with N-terminus (with
potential sites for glycosylation) and three intracellular loops with C-terminus (with
potential sites for phosphorylation) as shown in Figure 1-1 (Fredriksson et al., 2003;
Perez et al., 2005).
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N-terminu5
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Figure 1-1: General features of GPCR structure. The common features are seven-transmembrane helices,
three extracellular loops with N-terminus and three intracellular loops with C-terminus.
1.1.3 GPCR families
Based on sequence homology and functional similarity, GPCRs can be further separated
into three major families or collections which are Class A (Rhodopsin family), Class B
(Secretin-vasointestinal peptide (VIP) receptor family) and Class C (Metabotropic
I
glutamate receptor family). The Class A family is by far the largest, recognizing a
diverse array of ligands ranging from small biogenic amines (catecholamines and
histamine) to peptides and complex glycoproteins. The Class B family binds several
neuropeptides and peptide hormones. The Class C family binds glutamate, the major
excitatory neurotransmitter as well as GABA, the major inhibitory neurotransmitter
(Kristiansen,2004).
1.1.4 Heterotrimeric G protein families
Heterotrimeric G proteins are considered as important signal transduction molecules
(Kehrl, 1998). G proteins are a diverse class of heterotrimeric proteins composed of
3
three distinct subunits: a, ~, and 'Y. There are at least 20 a, 7 ~ and 12 'Y subtypes in
humans. G proteins can be divided into four main families according to the a-subunit
based on comparison of amino acid sequence and shared intracellular effector molecules:
Gas for stimulatory protein; Gai for inhibitory protein; Gaq for aq containing G protein
and Gal2 for 0.12containing G protein (Downes et al., 1999; Ulloa-Aguirre et al., 1999).
The Gai family, which have ability to inhibit adenylyl cyclase, include members of Gail,
Gai2, and Gai3.The a-subunits can be myristoylated or palmitoylated (Chen et al., 2001).
This facilitates their association with membrane and seven-transmembrane receptors
(Wedegaertner et al., 1995). Each family of a-subunits regulates a diverse cluster of
effector proteins (for example; adenylyl cyclase, ion channels and phosphatidylinositol-
specific phospholipase C), as illustrated in the Section 1.1.6. Moreover, the ~ and 'Y
subunits might be as a dimer and a heterotrimer (Smrcka, 2008). The heterotrimer of
heterotrimeric G proteins can function as a molecular switch for the receptor signalling,
as illustrated in the Section 1.1.5.
1.1.5 G protein cycle
In their basal state, G proteins bind guanosine diphosphate (GDP). When a ligand binds
to a GPCR, this activates the receptor, causing a conformational change in the receptor.
This conformational change enhances its affinity for the G protein. The Gn protein then
combines with the GPCR (the G protein is normally considered to be separate from the
inactive receptor) and the G, subunit is activated. GDP is exchanged for GTP at the a
subunit and, as a result, the Gf3ysubunits dissociate from the GTP-bound a subunit to
allow the activation of downstream effectors, as shown in Figure 1-2 (Rens-Domiano et
al., 1995). G protein signalling is terminated by the hydrolysis of GTP to GDP,
conducted by the intrinsic GTPase activity of the Gn subunit, a step which may be
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enhanced through an interaction with accessory proteins, like RGS (regulators of G
protein signalling) proteins. This leads to re-association of the Ga and G~ysubunits and
the GDP-bound G protein can then rebind a receptor to complete the cycle (Figure 1-2).
Figure 1-2: Schematic diagram showing the basic regulatory cycle of a G-protein, adapted from (Conklin
et al., 1993; Neer, 1995). E: Effector, GAPs: G'TPase-activating proteins, GDP: Guanosine diphosphate,
GTP: Guanosine triphosphate and RGS: Regulators of G protein signaling.
1.1.6 Main signalling mechanisms
The main signalling mechanisms are illustrated in Figure 1-3. Gas stimulates adenylyl
cyclase (AC) activity. This enzyme converts ATP to cAMP. Sufficient cAMP
concentration can activate cAMP effector proteins, such as protein kinase A (PKA) or
the exchange protein activated by cAMP (EPAC) (Qiao et al., 2002). An increase of
cAMP level activates protein kinase A (PKA) allowing the cellular response to take
place. For example, release of adrenaline leads to increased cardiac muscle contractility
through phosphorylation and activation of cardiac calcium channels (an effect mediated
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· through the initial activation of Pl-adrenoceptors) (Ochi et al., 1986; Reuter, 1987),
vasodilation of skeletal muscle vascular smooth muscle through phosphorylation and
inhibition of myosin light chain kinase (an effect mediated through the initial activation
of P2-adrenoceptors) (Walter et a/., 1988) and mobilization of glucose in liver through
glycogen phosphorylation of phosphorylase and glycogen synthase (an effect mediated
through the initial activation of P2-adrenoceptors) (Walter et al., 1988). An increase of
cAMP level also activates EPAC. EPAC can then act through the activation of Rap
proteins (Enserink et al., 2004). In turn, EPAC proteins might have implications in a
number of cellular processes such as cell differentiation, proliferation and cell survival
(Roscioni et al., 2008).
As Gai inhibits AC activity, activation of GPCRs coupled to Gi leads to a decrease in
cAMP levels. This results in decreasing the activity of PKA and the phosphorylation of
proteins. Gni protein-coupled receptors inhibit neurotransmitter release through
stimulating K+ efflux and inhibiting Ca2+ channels in the nervous system (Pierce et al.,
2002). The mechanism behind this was suggested through GJlysubunit. The specific Gpy
subunits from Gni-coupled receptors can directly modulate calcium channel fucntion.
This was supported by the fact that transfection of cell lines expressing P/Q-type
calcium channels with GIlYsubunit was reported to cause modulation such that by the
activation of GPCRs (Herlitze et al., 1996), overexpression of Gpy in rat sympathetic
neurons was also shown to reproduce the transmitter-induced calcium current inhibition
(Ikeda et aI., 1999), and P/Q type and N type channels were shown to be inhibited by
pertussis toxin (PTX)-sensitive G proteins, Gni (Shapiro et al., 1994). Moreover, G-
protein beta gamma complex was reported to directly bind to voltage-dependent
calcium channels (De Waard et al., 1997).
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When a ligand binds to a Gaq-proteincoupled receptor, Gaqactivates phospholipase C
(PLC) ~. The active PLC hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP2) to
produce inositol 1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG). IP3 is water-
soluble, so it is able to migrate through the cytoplasm to the endoplasmic reticulum
(ER). IP3 can then bind to JP3 receptors, which are tetrameric intracellular calcium
channels, on ER. Consequently, IP3 induces the channels (lP3 receptors) to open by
enhancing calcium binding to a stimulatory binding site on IP3 receptors, where it
allows calcium to be released from intracellular stores (Taylor et al., 2002). An increase
of Ca2+ levels affects the activity of many enzymes and ion channels. DAG is
hydrophobic, however, and it stays in the membrane to activate protein kinase C (PKC).
This enzyme phosphorylates many proteins including smooth muscle myosin light chain
kinase (MLCK), which leads to increased smooth muscle contractility, as well as
phosphorylating selected isoforms of phospholipase A2 leading to increased arachidonic
acid production (Fuchs et al., 1972; Gailly et al., 1997).
When a ligand binds to a Gal2 protein-coupled receptor, Rho guanine nucleotide
exchange factors are activated, leading to activation of the small G protein Rho. Rho-
GTP activates many enzymes that regulate phosphorylation. For example, Rho kinases,
JNK (a member of the mitogen-activated protein kinases), phosphatidylinositol 4-
phosphate 5 kinase and phospholipase D. Rho kinase can lead to smooth muscle
contraction through phosphorylation and inhibition of the function of myosin light chain
phosphatase (Mizuno et al., 2008).
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Figure 1-3: Schematic diagram showing the main four families of G-protein signalling mechanisms,
adapted from (Jacoby et al., 2006). P: phosphate, RGS: Regulators of G-protein signalling, ER:
Endoplasmatic reticulum, PKC: protein kinase C, PKA: protein kinase A, and AC: adenylyl cyclase.
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1.2 Obesity and diabetes
1.2.1 Obesity
Obesity can be defined as abnormal excessive fat accumulation (excess adiposity) to an
extent that may impair health (James, 2004). The body mass index (BMI), a ratio of
weight (kg) and height in meters squared, is commonly considered as a measure of
obesity. The World Health Organization (WHO) definition is considered overweight as
BMI 2: 25 or obese as BMI 2: 30. However, BMI is a limited measurement since it does
not take into consideration the distribution of body fat (Baumgartner et al., 1995).
Obesity is a growing health problem worldwide. Indeed, the epidemic of obesity poses a
significant public health problem since it now afflicts millions globally. In fact, an
unprecedented change in caloric availability during the mid zo" century has occurred in
many western and developing countries. As a result, obesity results from the prolonged
imbalance between energy intake and energy expenditure. Furthermore, obesity can be
the result of programmed genetic susceptibility, a decrease in exercise and physical
activity, and an increase in high-energy food in modem society (Astrup et al., 1994;
Astrup et al., 2004). Lifestyle modifications such as diet and exercise have been shown
to be successful for obesity (Hayes et al., 2008; Markovic et al., 1998; Thomas et al.,
2006), although, without pharmacological and surgical intervention, maintaining weight
loss is difficult. In addition, the need to find effective pharmacological therapy is more
essential as costs of health care rise with obesity rates (Wadden et al., 2007).
Obesity leads to a range of secondary health problems including type 2 diabetes mellitus
(Colditz et al., 1995), hypertension (Witteman et al., 1989), cardiovascular disease
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(Rimm et al., 1995), osteoarthritis, steatohepatitis and cancer (Calle et al., 2004a; Calle
et al., 2003; Calle et al., 2004b). In fact, obesity, especially visceral obesity, is a main
independent risk factor for insulin resistance and has adverse metabolic effects for it,
which leads to type 2 diabetes (Adams et al., 2006; Allison et al., 1999; Despres et al.,
2006; Reaven, 2005).
In obese individuals, body fat was found to be positively correlated with the percentage
of type II fibres and negatively correlated with the percentage of type I fibres (Kriketos
et al., 1996; Storlien et al., 1996) whereas endurance-trained male athletes were found
to have a greater proportion of type I fibres (Andersson et al., 2000). The use of
histochemistry-based methods for determining fibre type proportion (Abou Mrad et aI.,
1992; Warmington et al., 2000) is possibly a limitation since such methods might not
accurately identify mixed fibres. Therefore, it is recommended to examine the fibre
composition of skeletal muscles using the single fibre level myosin heavy chain (MHC)
isoform analysis in addition to histochemistry-based methods. Indeed, obesity was
correlated with impaired oxidative metabolism in skeletal muscle (Kelley et al., 1999).
Alterations in skeletal muscle fibre phenotype proportions may arise as a consequence
of both lack of physical activity and obesity (imbalance between energy intake and
energy expenditure). This possibly contributes to the complications associated with
obesity (Berggren et al., 2008; Perez-Martin et al., 2001). This might be due to the fact
that type I fibre-rich muscles have higher capacity for oxidation of fatty acid and
glucose and higher capacity for insulin-stimulated glucose uptake (Daugaard et al.,
2000; Henriksen et al., 1990; Song et al., 1999). Therefore, a number of possible
mechanisms for this effect were suggested, such as insulin resistance, increased stores
of intramyocellular triglycerides and possibly the endocannabinoid system (Jeukendrup,
2002; Kelley, 2005).
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Obesity is accompanied by an increase in plasma and tissue level of endocannabinoids
due to a decrease in catabolism, an increase in production, or both (Engeli et 01.,2005;
Sipe et al., 2005). In addition, energy balance might also be regulated by
endocannabinoids through peripheral effects on CBI receptor in the gastrointestinal tract,
adipose tissue, liver, and skeletal muscle (Cavuoto et al., 2007b; Liu et al., 2005;
Pagotto et 01.,2006).
1.2.2 Diabetes mellitus
Diabetes is a chronic metabolic disease characterized by persistently high blood glucose
concentrations (~7.0 mmol/l) in which either not enough insulin is produced from the
body or insulin-target tissues do not respond to the insulin that is produced. There are
three main categories of diabetes. The first is type 1 diabetes mellitus (also referred to as
early-onset or insulin-dependent diabetes mellitus or juvenile diabetes), the second is
type 2 diabetes mellitus (more rarely called late-onset, or non-insulin-dependent
diabetes), and the third is gestational diabetes (Zimmet et al., 1999).
Type 1 diabetes mellitus is caused by the inability of pancreatic ~-cells to produce
endogenous insulin. Successful treatment of type 1 diabetes requires the person to inject
insulin. Type 2 diabetes mellitus is mainly caused by the failure of insulin to act on
metabolic tissues, known as insulin resistance. In other words, insulin resistance is the
reduced ability of insulin to stimulate glucose transport activity and metabolism
effectively (Ferrannini et al., 1991). As insulin is unable to clear out the high blood
glucose level through GLUT4 in skeletal muscle and adipose tissues (insulin-
dependent), hyperglycemia occurs. Consequently, hyperglycemia leads to many
complications including kidney failure, neuropathy, retinopathy and infection since
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these tissues including kidney, neurons and retina are unable to dispose the high glucose
level, in particular of the glucose uptake in these tissues is controlled through an insulin-
independent manner (Nathan, 1993).
There are multiple mediators suggested to facilitate insulin resistance. These mediators
include an increase of the content of triglyceride in liver, pancreas, cardiac tissue and
skeletal muscle (Despres et al., 2006), visceral adipose tissue (Pan et al., 1997), and an
increase in inflammatory adipokines (interleukin-6 (lL-6) and tumor necrosis factor-
alpha (TNFa» from adipose tissue into circulation (Cote et al., 2005). In addition, it has
been suggested that endocannabinoids might also mediate skeletal muscle insulin
resistance (Watt, 2009).
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1.3 Skeletal muscle
Muscle tissues are divided into three types. These are cardiac, smooth and skeletal
muscle. Cardiac muscle is striated and involuntarily controlled. Smooth muscle is non-
striated and involuntarily controlled while skeletal muscle is striated and voluntarily
controlled. Skeletal muscle has many functions in the body. These include producing
skeletal movement, maintaining posture and body positions, storing nutrient reserves
(proteins), producing heat to maintain body temperature and guarding the entrance and
exit of the gastrointestinal tract (Allen, 2004).
1.3.1 Skeletal muscle contraction
Skeletal muscle is one of the most metabolically active tissues. It utilizes carbohydrate
and fat as a source to generate fuel as adenosine triphosphate (ATP). This chemical
energy can be processed to provide energy for the shortening and relaxation process of
the cross-bridge between actin and myosin filament of striated muscle. This process is
known as contraction.
A nerve action potential (AP) translates into muscle contraction through releasing
acetylcholine (ACh) from the terminal ends of the motor axon to the neuromuscular
junction (NMJ). ACh is released via exocytosis into the synaptic cleft. The nicotinic
cholinergic receptor on the muscle membrane can then bind ACh. ACh actions are
terminated by an enzyme called acetylcholinesterase (ACE) which is expressed in
skeletal muscle (Herman et al., 1985). Binding of ACh to these receptors changes its
conformational shape and allows Na+ to move down its concentration gradient into the
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sarcoplasm. This causes depolarization of the muscle membrane. When another AP is
generated, this signal (depolarization) is propagated to the transverse tubules.
Membrane depolarization activates voltage sensitive L-type Ca2+ channels, also known
as "dihydropyridine receptors", this activates other calcium channels of the
sarcoplasmic reticulum (SR) known as "Ryanodine receptors (RyR)". Indeed, ryanodine
receptors can be activated by depolarisation via dihydropyridine receptors, cytosolic
ATP, calmodulin kinase and PKA (Coronado et al., 1994; Fill et al., 2002). Moreover,
the function of the ryanodine receptors can be influenced by proteins such as
calmodulin (Yamaguchi et al., 2003). Furthermore, inorganic phosphate (Pi),
accumulated during exercise, was found to potentiate the release of calcium from the
ER through ryanodine receptors (Fruen et al., 1994). However, the potential role of
cyclic ADP ribose to activate ryanodine receptors as an endogenous regulator is still
controversial in skeletal muscle (Coronado et al., 1994). The skeletal muscle use of
calcium is essential to mediate regulation of contraction. In response to AP, the SR
triggers release of Ca2+ through RyR. The Ca2+ binds to troponin, which leads to a
change in the position of troponin, pulling the tropomyosin to actin, and exposure of the
active (myosin-binding) sites to actin. When myosin of the thick filaments is bound to
actin of the thin filaments, they form cross-bridges. Consequently, this begins the
contraction cycle.
The actin-myosin complex binds ATP, and then myosin breaks the cross-bridges.
Myosin ATPase hydrolyzes ATP and this causes the myosin to revert to its original
shape and to get ready for the next binding.
When the motor neuron stops sending AP, acetylcholinesterase (AChE) breaks down
previously released ACh in the synaptic cleft and no new ACh is released at the
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synaptic cleft. As a result, this leads to no new Ca2+being released from the SR and
Ca2+ being pumped back into the SR continuously. Then, the troponin-tropomyosin
complex returns to its original state, hiding the myosin-binding sites on the thin
filaments. Consequently, no cross-bridge is formed between actin and myosin. Then, the
muscle stretches again to its resting state. Even with this simplified summary, it is clear
that the contraction process is complicated (Berchtold et al., 2000; Gillis, 1977; Lamb,
2000).
1.3.2 Skeletal muscle metabolism
Skeletal muscle is the largest tissue in the human body and represents -40% of the
human body mass and -35-40% of the total body weight in the rat (Delbono et al., 2007;
James et al., 1985; Pedersen, 2011). Occasionally, skeletal muscle is considered by
some researchers as an endocrine organ, since it releases IL-6, which increases glucose
metabolism in resting human skeletal muscle (Glund et al., 2007). Skeletal muscle plays
a crucial role in maintaining body glucose homeostasis; it clears the majority (70-80%)
of ingested glucose, since it is the main site for insulin-dependent glucose uptake (Toft
et al., 1998). It is generally considered the most important site of insulin resistance.
Indeed, skeletal muscle has the ability to oxidize fatty acid and glucose, and this may
also play a crucial role in metabolic diseases (Cahova et al., 2007). Therefore, it is
generally considered as a main site of fatty acid and glucose metabolism (ZurIo et al.,
1990).
Skeletal muscle is the major site involved in energy balance and -20% of energy
expenditure occurs at rest in this tissue (ZurIo et al., 1990). When skeletal muscle
contraction occurs, AIP supports the energy for skeletal muscle. AIP is the only energy
15
source for contraction. Indeed, the skeletal muscle fuel metabolism needs ATP to be
generated continuously in order to match ATP supply to ATP demand. Consequently,
contractile activities are able to proceed. Skeletal muscle under normal physiological
conditions depends on glucose and fat-based fuels for oxidative metabolism. Randle in
the 1960s hypothesized the interaction, relationship and competition between glucose
and fatty acids for oxidation, termed the glucose-fatty acid, or Randle cycle (Randle et
al., 1963). It described a nutrient-mediated regulation of metabolism and depended
primarily on the free fatty acid (FFA) availability which was the main source to be
oxidized. In Randle's study, biochemically, this occurred by ~-oxidation through the
accumulation of acetyl-CoA and citrate, an inhibitor of pyruvate dehydrogenase (PDH)
and phosphofructokinase (PFK). Therefore, this reduced glycolysis and glucose
oxidation by the accumulation of glucose-6-phosphate (G6P) and the inhibition of
hexokinase (HK) activity. Consequently, according to the Randle cycle, this elevated
the glucose concentration and inhibited glucose uptake. Moreover, the glucose-fatty
acid cycle could also be reversed. When glucose concentrations were high, glycolysis
occurred through metabolizing glucose into pyruvate (Randle et al., 1963). This
activated pyruvate dehydrogenase (PDH) which oxidized pyruvate to acetyl-CoA and
finally led to the production of malonyl-CoA which inhibited carnitine palmitoyl
transferase 1 (CPT-1), thus reducing ~-oxidation rates (Sidossis et al., 1996) (Figure
1-4).
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Figure 1-4: The mechanism of inhibition of fatty oxidation by glucose and inhibition of glucose
metabolism by fatty acids, proposed by (Randle et al., 1963). Pyruvate dehydrogenase (PDH), hexokinase
(HK), phosphofructokinase (PFK), acetyl-CoA carboxylase (ACC), fatty acid translocase (FAT/CD36)
and carnitine palmitoyl transferase 1 (CPT-I).
Skeletal muscle contains a fatty acid transporter, known as fatty acid translocase
(FAT/CD36), and glucose transporters, such as GLUT1 and GLUT4. Once skeletal
muscle is stimulated by hypoxia/contraction or insulin, GLUT4 are translocated to the
plasma membrane to activate glucose uptake (Shepherd et al., 1999).
The insulin receptor (lR) is a heterotetrameric transmembrane protein belonging to the
tyrosine kinase receptor superfamily. The IR consists of four subunits, two extracellular
insulin-binding u-peptides responsible for insulin binding, and two transmembrane p-
peptides that contain intracellular tyrosine kinase domains. Insulin binds to the two a-
chains of the IR on the outer surface of the plasma membrane. This binding leads to a
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conformational change that causes activation of the intracellular kinase domains in ~-
subunits due to autophosphorylation. These kinase domains subsequently trans-
phosphorylate a number of tyrosine residues on the opposite ~-chain.
Through phosphorylated tyrosine residues on the receptor, down-stream signalling
molecules such as Src homology 2 domain containing (She) and the insulin receptor
substrate (IRS) proteins can bind to the activated receptor. IRS 1 and its downstream
signalling pathway are crucial for signal transduction, responsible for most of the
metabolic responses of insulin, whereas She regulates mostly non-metabolic processes
induced by insulin (pessin et al., 2000) (Figure 1-5).
The activated IR phosphorylates IRS 1 and She on multiple tyrosine residues. The
phosphorylated substrates (IRS and She) serve as docking sites for proteins containing
Src homology 2 (SH2) domains such as class lA phosphatidylinositol 3-kinase (PI-3K)
and growth factor receptor-binding protein 2 (Grb2), respectively.
PI 3-kinase is composed of one regulatory subunit (P85) and one catalytic subunit
(p 110). The binding of the p85 subunit via its two SH2 domains to residues on IRS 1
leads to a conformational change and activation of the catalytic p 110 subunit and
recruitment of PI-3K to the plasma membrane. The plIO subunit catalyses the
phosphorylation of specific phospholipids, phosphoinositides, on the 3-position to
produce phosphatidylinositol-3-phosphates. PI3,4P and PI3,4,5P are recognized by
proteins that contain pleckstrin-homology (PH) domains including 3' -phosphoinositide-
dependent kinase 1 (PDKl) and AKT.
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AKT (also known as protein kinase B, PKB) relocates from the cytoplasm to the
membrane to bind with phosphatidylinositol-3-phosphates. This induces a
conformational change in AKT. At the membrane, PDKI mediates phosphorylation of
AKT. The activated AKT may then migrate to the cytosol or nucleus; where it can
phosphorylate downstream targets and regulate a number of multiple intracellular
substrates important for glucose, protein and fat metabolism (Shepherd et al., 1998).
As mentioned above, the activated IR phosphorylates She on multiple tyrosine residues,
which allows it to serve as a docking site for proteins SH2 domains such as Grb2. Grb2
is associated with the nucleotide exchange factor mammalian son-of-sevenless (mSos)
via its Src homology 3 (SH3) domain. Binding of the Grb2-Sos complex induces mSos
to activate Ras by exchanging Ras-bound GDP for GTP. Ras can activate multiple
effectors such as PI-3K and RAF proto-oncogene serine/threonine-protein kinase. The
active Raf kinase then triggers the phosphorylation of mitogen-activated protein (MAP)
kinase kinase (MEK1I2) and subsequently, MEK1I2 activates the MAP kinases
extracellular signal regulated kinase (ERK1I2, also known as p42/44 MAP kinases).
Insulin signalling through this pathway can regulate transcription factors and thus gene
expression and cell growth (Force et al., 1998; Katz et al., 2007).
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Figure 1-5: A scheme of insulin signalling pathways, adapted from (Le Marchand-Brustel et al., 2003).
1.3.3 Skeletal muscle fibres
Skeletal muscle is a heterogeneous tissue, since it contains a variety of fibres that differ
in contractile, functional, metabolic and molecular properties (Greenhaff, 1997).
Human skeletal muscle is a mixed fibre-type composition. This is in contrast to other
species, such as rat, in which some skeletal muscle mainly consists of a single fibre type
(Fuentes et al., 1998; Hamalainen et al., 1995). There are three basic fibre types in both
humans and rats depending on the expression of various isoforms of myosin light chains
and myosin heavy chains; Fast-twitch oxidative-glycolytic (FOG), fast-twitch glycolytic
(FG) and slow-twitch oxidative (SO) as shown in Table 1-1 (Close, 1972; Schiaffino et
al., 1994).
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Table 1-1: Characteristics of human muscle fibre types.
Fibre type Mitochondrial Contractile Metabolic Enzyme activity
density function character Oxidative Glycolytic
I (SO) High Slow Oxidative High Low
IIa (FOG) Medium Fast Intermediate High High
lIb (FG) Low Fast Glycolytic Low High
Currently, there is a wealth of data indicating that skeletal muscle fibres in obesity and
type II diabetes have increased lipid content, increased glycolytic activity, and reduced
oxidative enzyme activity. The lower oxidative enzyme activity in skeletal muscle was
explained by either a reduced mitochondrial content or a reduced mitochondrial
function (He et 01.,2001).
These metabolic characteristics including altered patterns of enzyme activity are related
to insulin resistance of skeletal muscle. In addition, skeletal muscle fibre-type
proportions was observed to have a relation to insulin resistance and obesity,
specifically that the proportion of type lIb fibres was found to be higher and that of type
I fibres was found to be lower (Berchtold et al., 2000; He et al., 2001; Kelley et al.,
2002; Kriketos et al., 1996). Indeed, there is a correlation between insulin sensitivity
and the proportion of type I fibres. Skeletal type I fibres have greater insulin-stimulated
glucose transport (Daugaard et al., 2000; Henriksen et al., 1990; Song et al., 1999).
Type I fibres are known to be rich in mitochondria, so they have a relatively large
capacity for oxidation (a high muscle capacity for fat utilization, higher oxidative
capacity for carbohydrate). In addition, type I fibres have greater insulin sensitivity.
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Little is known about GPCRs in skeletal muscle. One group of researchers mentioned
that CB) receptors might have a role in the myoblast differentiation, proliferation and
fibre phenotype (Hannon, 2010). However, this issue is still not yet well studied.
Moreover, there are findings in the literature to suggest that CB) receptors may playa
vital role in glucose uptake in skeletal muscle (Eckardt et al., 2008b; Lindborg et al.,
2011). In addition, it was reported that P2-adrenoceptorsstimulated glucose uptake in rat
skeletal muscle L6 cells and this uptake was inhibited by PI3K inhibitors; this implied
that Pradrenoceptors stimulation might share insulin signalling pathways (Nevzorova et
al., 2006). Moreover, it was suggested that a)-adrenoceptors might affect key proteins
such as AMPK which potentially might affect glucose uptake (Hutchinson et al., 2006).
In general, GPCRs in skeletal muscle might have a role in glucose uptake in the body,
skeletal muscle differentiation and growth. However, these issues are still under
investigation in skeletal muscle. Overall, there is a knowledge gap about potential
functional impacts of GPCRs, especially for CB) receptors in skeletal muscle.
As obesity can lead to health problems including insulin resistance and type 2 diabetes
mellitus (Colditz et al., 1995), and skeletal muscle plays a crucial role in maintaining
body glucose homeostasis in human body (Toft et al., 1998), it is possible that the
modulation of cannnabinoid receptors might playa role to improve glucose uptake and
obesity. This is supported by the fact that 1) Endocannabinoid levels were found to be
higher in several organs of obese animals, central and peripheral (Di Marzo et al., 2001;
Starowicz et al., 2008). 2) Obese rodents compared to lean controls were found to be
more sensitive to the anti-obesity effects of treatment with CB) receptor antagonists
(Hildebrandt et al., 2003). 3) RIM was found to reduce bodyweight and cause a
clinically significant reduction in HbA)c levels in overweight or obese patients with type
2 diabetes (Scheen et al., 2006). 4) During a glucose tolerance test, CB) receptor
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agonism (AEA 10 mglkg or ACEA3 mglkg) was found to lead to elevated circulating
glucose levels in rats (Bermudez-Siva et al., 2006).
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1.4 Cannabinoids
Cannabinoids have been employed for religious ceremonies, as recreational drugs and
as a medicine for thousands of years (Pacher et al., 2006). Indeed, Cannabis plants are
cultivated throughout the world. One of these plants is Cannabis sativa or hashish,
known as marijuana. Marijuana use as medicine dates back to 2737 B.e; it was used for
asthma, gynaecological disorders and migraines (Baker et al., 2003; Kumar et al., 2001;
Lemberger, 1980).
At the end of the 19th century, cannabinol was first isolated as a phytocannabinoid and
its chemical structure was identified in 1940. Later, ~9 -tetrahydrocannabinol (THe), a
major constituent of Cannabis and the principal psychoactive phytocannabinoid, was
isolated in 1964 (Gaoni Y, 1964)(Figure 1-6).
Figure 1-6: Chemical structure ofTHC.
Growing research in this field suggests medical benefits from exposure to THe; for
example, appetite stimulation, anti-spasmodic activity, anti-nausea and analgesia.
However, medical use has been limited since cannabis has psychological and
physiological effects such as sedation, cognitive dysfunction, tachycardia and
hypotension (Felder et al., 2006).
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25 years after the identification of THC, the first cannabinoid receptor was identified in
rat brain (Devane et al., 1988), and the CBI receptor was cloned in 1990 (Matsuda et al.,
1990). Consequently, this opened the way for researchers to detect the major
endogenous cannabinoids (Devane et al., 1988; Howlett et al., 2002; Mechoulam et al.,
1995; Sugiura et al., 1995) and to clone the CB2 receptor in 1993 (Munro et al., 1993).
The cannabinoid system was investigated for its actions in alteration of mood, feeding
behaviour, vasorelatory effects, pain perception and regulation of metabolic factors in
peripheral tissues (Randall et al., 1996; Stein et al., 1996). Indeed, the discovery of a
selective CBI receptor antagonist (Perio et al., 1996; Rinaldi-Carmona et al., 1994) was
notable for an influence on body metabolism. One of these CBI receptor antagonists is
rimonabant (Acomplia) which was synthesized by Sanofi Recherche in France.
1.5 The endocannabinoid system
The endocannabinoid system is a complex endogenous signalling system, which
consists of (at least) two cannabinoid receptors, their endogenous ligands, and enzymes
for ligand biosynthesis and degradation.
1.5.1 CBI and CB} receptors
The CB I receptor is the major receptor responsible for the effects of the
endocannabinoid system in metabolic functions. CBI receptors are the most common
GPCRs expressed in the brain (Tsou et al., 1998), but are also expressed in peripheral
tissues such as adipose, liver, pancreas and skeletal muscle (Izzo et al., 2010; Starowicz
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et al., 2008). On the other hand, CB2 receptors were found to be predominantly
abundant in immune system. Indeed, CB2 receptors were expressed within the spleen,
tonsils, and thymus (Brown et al., 2002; Klein et al., 2003; Liu et al., 2009).
The CBI receptor is highly conserved among human, rat and mouse while the CB2 is
more diverse. The sequence analysis of rat CBI has 99.8% amino acid identity
compared to mouse and 97% compared to human (Chakrabarti et al., 1995). The
sequence analysis of rat CB2has 93% amino acid identity compared to mouse and 81%
compared to human (Griffin et al., 2000; Reggio, 2003; Shire et al., 1996). The
homology between CBI and CB2 is poor since they share only 44% amino acid identity.
(Klein et al., 1998;Munro et al., 1993)(Figure 1-7).
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Figure 1-7: Representative structure of mouse cannabinoid receptors (Klein et al., 1998).
1.5.2 Agonists and antagonists for CBI receptor
There are diverse groups of ligands for cannabinoid receptors including natural (herbal),
synthetic, and endogenous compounds (Di Marzo et al., 2006). The two major
endocannabinoids are anandamide (AEA) and 2-arachidonoyl glycerol (2-AG), where
AEA is an amide while 2-AG is an ester of arachidonic acid (Figure 1-8).
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Figure \-8: Representative chemical structures of the AEA and 2-AG.
AEA is a partial agonist at CBI and CB2 receptors while 2-AG is a full agonist at CBI
and CB2 receptors (Gonsiorek et al., 2000; Mackie et al., 1993). Rimonabant (RIM)
and AM251 are CB I compounds considered as CB I inverse agonists and antagonists.
RIM was used as a therapy for obesity (Carai et al., 2005). ACEA is a synthetic agonist
which is selective for CBI receptor over CB2 receptor by around 2000 times (Hillard et
al., 1999) (Figure 1-9).
A)
B)
o
C)
Figure 1-9: Structures of A) RIM, B) AM251 and C) ACEA.
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1.5.3 CB. signalling
CB] receptor signalling is mediated through the G proteins of the Gi/ofamily (Munro et
al., 1993). Indeed, the effect of activation of CB] receptor was inhibited by pertussis
toxin (Felder et al., 1998). Gj/o, in tum, inhibits adenylyl cyclase and consequently,
inhibits cAMP accumulation. Gi/ocan directly regulate ion channels, inhibiting calcium
channels (Caulfield et al., 1992; Gebremedhin et al., 1999; Mackie et al., 1993) and
activating potassium channels (Mackie et al., 1995; McAllister et al., 1999; Turu et al.).
Activation of CB] receptor leads to phosphorylation of MAPK (Bosier et al., 2010). A
number of mechanisms may be involved in activation of MAPK such as activation of
Gj/oproteins, modulation with other GPCRs, insulin and growth factor receptors (Figure
1-10).
channels Potassium
channels
Figure 1-10: Main effects ofCBI receptor on signal transduction pathways, adapted from (Pagotto et al.,
2006). CBI receptors couple through Gi/oproteins which inhibit adenylate cyclase mediated conversion of
ATP to cAMP, modulate Ca and K channels and activate MAPK.
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1.5.4 Endocannabinoid synthesis and degradation
AEA and 2-AG were found to be derived from phospholipid in the cellular membranes
incorporating long-chain polyunsaturated fatty acids (Fowler et al., 2002). However, the
exact mechanisms for cannabinoid synthesis have not yet been determined. One
proposed mechanism is that AEA is synthesized from N-arachidonoyl-
phosphatidylethanolamine (NAPE) which is enzymatically converted to AEA and
phosphatidic acid by a specific phospholipase D, NAPE-PLD (Cadas et al., 1996). The
production of AEA is a calcium-dependent process (Di Marzo et al., 1994;Mackie et al.,
2006). Once produced, AEA may be hydrolyzed into ethanolamine and arachidonic acid
by fatty acid amide hydrolase (FAAH) (Eckardt et al., 2008a). The production of2-AG
is also a calcium-dependent mechanism (Bisogno et al., 1997; Di Marzo et al., 1996).
Diacylglycerol is generated by the activation of phosphatidylinositol specific
phospholipase C (PLC) through cleavage of membrane phospholipids. Then, 2-AG is
formed from diacylglycerol by diacylglycerol lipase (DAGL). 2-AG is hydrolyzed into
glycerol and arachidonic acid by monoacylglycerol lipase (MAGL) (Eckardt et al.,
2008a).
30
AEA )~
=.
Ethanolamine
+
Arachidonicacid
A)
r-<[
~
2-AG
Glycerol
+
Arachidonic acid
B)
Figure 1-11: Representative biosynthesis and degradation pathways of AEA and 2-AG. A) AEA and B)
2-AG. N-arachidonoyl-phosphotidylethanolamine (NAPE), phospholipase D (PLD), fatty acid amide
hydrolase (FAAH), phospholipase C (PLC), diacylglycerol lipase (DAGL) and monoacylglycerollipase
(MAGL), adapted from (Eckardt et al., 2008a).
1.5.5 CB2 receptors
CB2 receptors are predominantly expressed in immune tissues and cells such as the
spleen, thymus, monocytes, neutrophils, and B-Iymphocytes (Liu et al., 2009). CB2
receptors were found recently to be expressed in brain also, in the brainstem, cerebellum,
thalamic nuclei and cerebral cortex (Suarez et al., 2009). Generally, the expression of
CB2 receptors in peripheral tissues such as adipose tissue, liver, pancreas and skeletal
muscle is still under investigation.
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CB2receptors modulate inflammation and release of cytokines (Pandey et al., 2009). In
addition, CB2 receptors were suggested to mediate analgesic activity for neuropathic
pain, particularly pain induced by inflammation (Hsieh et al., 2011).
1.6 Non-CB./CB1receptors
1.6.1 GPRI19/GPR55/GPRI8
Three orphan GPCRs have recently been implicated as novel cannabinoid receptors.
These are GPRI19, GPR18 and GPR55; oleoylethanolamide (OEA) was proposed as a
ligand for GPRI19, a phosphoinositol substituent of2-AG was proposed for GPR55 and
N-arachidonoyl glycine (NAGLy) was proposed for GPR18 (Brown. 2007; Kohno et al.,
2006; Ryberg et al., 2007).
There is a suggestion that AM251 or RIM, CBI antagonists, are GPR55 agonists (Kapur
et al., 2009; Oka et al., 2009; Waldeck-Weiermair et al., 2008; Yin et al., 2009).
although it is still controversial whether GPR55 is a true cannabinoid receptor (Oka et
al., 2007). GPR55 shares less than 15% sequence homology with CBI and CB2 (Ross,
2003) and is expressed in adrenal glands, brain, small intestine (Lauckner et al., 2008;
Ryberg et al., 2007; Sawzdargo et al., 1999; Waldeck-Weiermair et al., 2008; Whyte et
al.,2009).
GPRI19, an oleoyl congener receptor, might be considered as free fatty acid (FFA)
receptor or novel cannabinoid receptor since its natural ligands are fatty acid (FA)
derivatives (Overton et al., 2006). Of these, OEA, an analogue of the cannabinoid AEA,
is one of the most active natural ligands. OEA is of particular interest since it was
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observed to reduce food intake and body weight gain in rodents (Overton et 01.,2008).
Since GPR119 is activated by OEA (Overton et al., 2006), it has been suggested to play
a role in obesity (Overton et 01.,2006).
GPR119 mRNA appears to be expressed only in a limited number of tissues, including
pancreatic cells and enteroendocrine cells in the small intestine in man and rodent using
RT-PCR (Lauffer et 01.,2009). GPR119 may raise intracellular cAMP concentrations in
pancreatic ~-cells through a Gs mechanism (Overton et al., 2008). GPR119 mRNA is
also expressed in skeletal muscle from both rat and human (Soga et al., 2005).
GPR18 mRNA was primarily found in leukocytes, thymus, spleen and testis (Alexander,
2012; Gantz et al., 1997). AEA and THC were also reported as full agonists at GPR18
(McHugh et 01.,2012). Indeed, data suggested that GPR18 is a G, mechanism (Kohno et
01.,2006). However, the physiological role ofGPR18 is still unknown.
1.6.2 PPARs
Recent studies indicate that cannabinoids act at a family of nuclear receptors called
peroxisome proliferator-activated receptors (PPARs, with three sub-types a, ~ and y).
This family, which functions as transcription factors, is involved in lipid metabolism,
inflammation and regulation of metabolism (Michalik et al., 2006; O'Sullivan, 2007).
The endocannabinoids and related endogenous molecules such as AEA and OEA were
shown to activate PPARa (Lo Verme et al., 2005; Sun et al., 2007). Briefly, the
activation of PPARa induces the expression of genes required for the transport and ~-
oxidation of fatty acids in skeletal muscle (Ferre, 2004; Zhang et 01.,2004).
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1.7 The endocannabinoid system effects
1.7.1 Central control of metabolic regulation
The CBI receptor was originally located in the central nervous system. The main role of
endocannabinoids in brain is that they act as retrograde messengers (Maejima et aI.,
2001), predominantly at GABAergic or glutamatergic synapses, although their
retrograde signalling can inhibit the release of multiple neurotransmitters including
serotonin, acetylcholine and neuropeptides (Maejima et al., 2001; Straiker et al., 2006).
The physiological effects of endocannabinoids in the brain are to increase appetite and
feeding, anxiety, neuroexcitability and pain perception (Bellocchio et al., 2008; Di
Marzo et al., 2005) (Figure 1-12).
GABAergic I glutamatergic
Figure 1-12: Representative retrograde inhibition of presynaptic neurotransmitter release by the
cannabinoid system (Maejima et al., 2001). Depolarization-induced suppression of inhibition (DSI) and
depolarization-induced suppression of excitation (DSE).
34
The excitation of the neuron leads to depolarization and an influx of calcium ions. Then,
postsynaptic calcium can activate enzymes that are responsible for endocannabinoid
synthesis from lipid precursors in the postsynaptic cell. After that, endocannabinoids
can leave the postsynaptic cell and bind to cannabinoid receptors on the presynaptic
membrane of the neurons leading to an inhibition of presynaptic calcium influx
(Christie et al., 2001; Wilson et al., 2002).
Endocannabinoids (ECs) are produced on demand (Hashimotodani et al., 2007). They
are highly lipophilic compounds and are not stored in vesicles for secretion. Originally,
CBI antagonism was found to mediate a central hypophagic effect leading to weight
loss (Di Marzo et al., 2001; Vickers et al., 2003). Furthermore, CBI knock-out mice
were found to be resistant to diet-induced obesity (Osei-Hyiaman et al., 2005; Ravinet
Trillou et al., 2004).
1.7.2 Peripheral control
The summary of rimonabant actions in obesity and the effects of CBI receptor
activation were represented in Table 1-2 (Christopoulou et al., 2011; Di Marzo et al.,
2005).
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Table 1-2: Tissue-specific effects of RIM in obesity.
~issue Mechanism
Hypothalamus Decrease Appetite
Nucleus accumbens Decrease Motivation
to Eat
Skeletal Muscle Increase Glucose
Uptake
!Adipose Tissue Decrease adipogenesis
Liver Decrease Lipogenesis
01Tract Increase Satiety signals and gastric emptying
As previously stated, the skeletal muscle is the primary tissue for glucose uptake. CBI
receptor mRNA and protein expression has been detected in skeletal muscle myotubes
and tissues of rodents and humans (Cavuoto et al., 2007b; Pagotto et al., 2006). In
addition, in mice fed a high fat diet (HFD), the expression of CBI in skeletal muscle
was found to be up-regulated (Pagotto et al., 2006). Chronic CBI receptor antagonism
during euglycemic hyperinsulinemic clamp increased glucose uptake in diet-induced
obese rats by several skeletal muscle groups (Nogueiras et al., 2008).
Adipose tissue is a highly metabolically active tissue. mRNA expression of CBI
receptors in rodent adipose tissues using RT-PCR (Cota et al., 2003) and human adipose
tissues using western blot (Roche et al., 2006; Spoto et al., 2006) have been described.
It is worth mentioning that the expression of CBI in adipose tissue was up-regulated in
rodent models of obesity (Bensaid et al., 2003; Starowicz et al., 2008; Yan et al., 2007).
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There is a strong indication that endocannabinoid system is present in the liver,
specifically using mouse liver and in situ hybridization (Osei-Hyiaman et al., 2005).
The CBI receptor appears to influence the disease state of liver and whole body
parameters as well. For example, treatment of obese (fa/fa) rats administered orally with
30 mg/kg RIM daily for 8 weeks was found to abolish hepatic steatosis. In parallel, it
was also found to decrease total cholesterol, free fatty acids, and plasma levels of
triglycerides and increase the high/low-density lipoprotein cholesterol (HDLc/LDLc)
ratio (Gary-Bobo et al., 2007).
There is conflicting data about the expression of CBI and CB2 receptors in the pancreas
(Starowicz et al., 2008). CBI receptor mRNA expression was detected in pancreatic
human islets (Bermudez-Silva et al., 2008). However, further investigations found that
CBI receptors were expressed in glucagon- and somatostatin-secreting (1- and ()-cells
and CB2 receptor, not CBI receptor, was found to be colocalized in insulin-secreting ~-
cells and non ~-cells from mouse using QRT-PCR and immunocytochemistry
(Bermudez-Silva et al., 2008; Juan-Pico et al., 2006; Starowicz et al., 2008; Tharp et al.,
2008).
Vagal CBI expression was found to be inhibited by gut peptides such as cholecystokinin
(Burdyga et al., 2004). Regarding CBI functions, activation of CBI receptor leads to
reduce gastrointestinal motility in both rodents and humans (Coutts et al., 1998;
Esfandyari et al., 2006; Izzo et al., 1999). Furthermore, activation of CBI receptor
decreases the rates of gastric emptying for HFD fed Mice (Di Marzo et al., 2008).
These data suggest that the endocannabinoid system can at least play a role regarding
glucose transport in skeletal muscle and abdominal obesity in adipose tissue and affect
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whole body metabolic parameters in the liver (Manat et al., 2011).
1.8 Endocannabinoid system in obesity
AEA was found to increase food intake in rats, while the CBI antagonist RIM was
found to inhibit food intake (Williams et al., 1999). A key component in the
development of diet-induced obesity for the effect of cannabinoids was found to be CBI
receptor stimulation (Ravinet Trillou et al., 2004). CBI receptors were found also to be
involved in peripheral metabolic regulation.
There are several findings which support the belief that endocannabinoids might
contribute to the development of obesity. First of all, a higher CBI receptor expression
was shown in adipocytes of obese rats and elevated levels of endocannabinoids were
found in animal models of diet-induced obesity (Bluher et al., 2006). Secondly, CBI
receptor knockout mice were resistant to diet-induced obesity (Ravinet Trillou et al.,
2004). Thirdly, obese rodents compared to lean controls were found to be more
sensitive to the anti-obesity effects of treatment with CBI receptor antagonists
(Hildebrandt et al., 2003). Fourthly, FAAH activity in subcutaneous adipocytes was
found be positively correlated with BMI in metabolically healthy humans (Cable et al.,
2011).
Finally, endocannabinoid levels were found to be higher in several organs of obese
animals, central and peripheral (Di Marzo et al., 2001; Starowicz et al., 2008). This was
also found in the circulation of obese human subjects (Engeli, 2008). 2-AG plasma
concentration was found to be correlated with visceral adipose tissue mass (intra-
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abdominal obesity) and markers of metabolic syndrome (FFA, TO, cholesterol and
adiponectin) (Engeli, 2008).
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1.9 Possible targets for CB. receptor
1.9.1 AKT
1.9.1.1 Definition and structure
AKT is a family of serine/threonine-specific protein kinases. The AKT family
comprises three different isoforms: AKTI (also called PKB-alpha (PKBa)), AKT2
(PKB-beta (PKB~)) and AKT3 (PKB-gamma (PKBy)) (Manning et al., 2007).
AKT isoforms are members of the AGC kinase family, which have extensive homology
to protein kinases A, G, and C within their kinase domains. Although these AKT
isoforms are coded by three different genes, those proteins are highly homologous,
sharing a common structure which consists of an N-terminal regulatory domain
(pleckstrin homology (PH) domain), a catalytic kinase domain, and a C-terminal region
(Kumar et al., 2005).
1.9.1.2 AKT expression
AKTI is more ubiquitously expressed, compared to AKT2 and AKT3; however, AKT2
is predominantly expressed in insulin-responsive tissues, such as skeletal muscle,
adipose tissue and liver (Masure et al., 1999) and AKT3 is expressed primarily in brain,
lung, kidney and placenta (Masure et al., 1999). Therefore, the main AKT isoforms
which are expressed in the skeletal muscle are AKTI and AKT2 (Cleasby et al., 2007).
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1.9.1.3 AKT targets
AKT2 activation leads to glucose transporter type 4 (GLUT4) translocation to the
plasma membrane. GLUT4 translocation leads to increased glucose uptake in response
to insulin (Calera et al., 1998). However, the mechanism behind this process is still
under investigation. AKT may playa role in glucose and lipid metabolism. In addition,
AKT was shown to stimulate the association of hexokinase isoforms with the
mitochondria. Hexokinases convert glucose to its active form, glucose 6-phosphate.
However, the direct target of AKT responsible for this process is still under
investigation (Majewski et al., 2004). Furthermore, AKT mediates phosphorylation of
the enzyme glycogen synthase kinase 3 (GSK-3) isoforms on a highly conserved N-
terminal regulatory site (GSK-3a-S21, GSK-3P-S9). This inactivates GSK-3, thereby
diminishing the repression of glycogen synthase (GS), which in tum results in
stimulating glycogen synthesis (Brozinick et al., 2003). GSK-3 was shown to induce
degradation of the sterol regulatory element-binding proteins (SREBPs). SREBPs are
transcription factors that switch on the expression of genes involved in cholesterol and
fatty acid biosynthesis. AKT inactivates GSK-3 and helps SREBP stability and, thus,
increases lipid production (Manning et al., 2007).
AKT also regulates the expression of gluconeogenic and lipogenic enzymes by direct
phosphorylation of S570 on peroxisome proliferator-activated receptor-y coactivator-l a
(PGC-Ia) which is a coactivator that can control genes with several members of the
forkhead box (FOXO) family of transcription factors. For example, FOXOI promotes
hepatic glucose production (Matsumoto et al., 2007).
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1.9.2 GSK-3
1.9.2.1 Isoforms
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase. There are two
GSK-3 isoforms (GSK-3a and GSK-3P) encoded by two distinct genes. GSK-3a has a
molecular weight of 51 kDa and GSK-3p has a molecular weight of 47 kDa (Ciaraldi et
al., 2007; Woodgett, 1990).
1.9.2.2 Signalling and importance
Insulin leads to phosphorylation of AKT. Consequently, AKT phosphorylates GSK-3
and inactivates it. However, GSK-3 inhibits IRS 1 protein through phosphorylation. This
leads to attenuated insulin signalling (Eldar-Finkelman, 2002). GSK-3 also diminished
the repression of glycogen synthase through phosphorylation (Cross et al., 1995). GSK-
3 has been implicated in many disorders, such as cancer and diabetes (Eldar-Finkelman,
2002; Martinez et al., 2002).
1.9.3 AMPK
1.9.3.1 AMPK Structure and their functions
AMP-activated protein kinase (AMPK) is an aP1 heterotrimeric serine/threonine protein
kinase composed of a catalytic (al or (2) subunit and regulatory (PI or P2 and 11012 or 13)
subunits encoded by different genes (Hardie, 2004). AMPK is a prime target of
metabolic diseases such as type 2 diabetes, and the AMPK activator AICAR (5-amino-
I-P-D-ribofuranosyl-imidazole-4-carboxamide) reverses many of the metabolic defects
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in mouse models of obesity and insulin resistance (Fogarty et al., 2010). The activation
of AMPK can lead to an increase of fatty acid oxidation and glucose uptake into muscle,
also increasing fatty acid oxidation, decreasing lipogenesis, cholesterol synthesis and
gluconeogenesis in the liver. In addition, it also decreases lipolysis in adipose tissue.
Furthermore, the activation of AMPK can lead to an increase in mitochondrial
biogenesis (Gruzman et al., 2009).
1.9.3.2 Functions in skeletal muscle
Activation of AMPK by AICAR in skeletal muscle enhances glucose uptake. In the rat
skeletal muscle, AMPK activators including AICAR, were found to increase cell
surface GLUT4leveis (Jessen et al., 2003; Ju et al., 2007).
Currently, there is evidence that AMPK activation stimulated glucose uptake in both
contraction and hypoxia (Jessen et al., 2005; Wright et al., 2005). Acute muscle AMPK
activation induces fatty acid oxidation by decreasing malonyl-CnA concentrations
through phosphorylation and inhibition of acetyl-CoA carboxylase (ACC) and
activation of malonyl-CoA decarboxylase (MCD). Malonyl-CoA is an inhibitor of
carnitine palmitoyl transferase 1 (CPTl), the rate-limiting enzyme that transports long-
chain fatty acids into mitochondria for p-oxidation. This effect leads to decreased lipid
accumulation and increased muscle insulin sensitivity (Hardie et al., 1997a; Hardie et
al., 1997b; Zhou et al., 2009). Chronic AMPK activation by AICAR increases GLUT4,
hexokinase activity and glycogen content, (Holmes et al., 1999), as well as also
increasing the levels of uncoupling protein 3 (VCP3) and PGC-ln in skeletal muscle
(Jager et al., 2007).
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1.9.3.3 Mechanism of action for pharmacological AMPK activators
AICAR is a precursor for the monophosphorylated derivative 5-amino-l-~-D-
ribofuranosyl-imidazole-4-carboxamide (ZMP), which mimics the effects of AMP for
activation of AMPK. Consequently, ZMP causes allosteric activation and promotes the
phosphorylation of AMPK by upstream kinases (Corton et al., 1995) (Figure 1-4).
Figure 1-13: ArCAR, a synthetic nucleotide analogue.
Metformin is a drug used for treatment of type 2 diabetes, where AMPK is a candidate
target (Zhou et al., 2001).
1.9.4 MAPKs
1.9.4.1 Definition, function and families
Mitogen-activated protein kinases (MAPKs) are serine/threonine protein kinases that
regulate cellular activities including gene expression, cell proliferation, mitosis,
differentiation, metabolism and programmed cell death. MAPK are divided into
subfamilies which have several isoforms: extracellular signal-regulated kinase; ERK
(ERKI to ERK8), p38 (p38-a, -~, -y), and c-Jun NH2-terminal kinase; JNK (JNKI to
JNK3). MAPKs are targets of a phosphorylation cascade, composed of at least three
components of kinases, including a MAPK kinase kinase (MAP3K), a MAPK kinase
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(MAP2K), and a MAPK. These kinases are activated in series such that MAP3Ks
(MAPK kinase kinase) phosphorylate and activate MAP2Ks (MAPK kinase).
Consequently, MAP2Ks phosphorylate and activate MAPKs (Pearson et al., 2001).
1.9.4.2 Structure of ERK1/2
ERKI and ERK2 are a 43 and 41 kDa protein, respectively. Thr 183 and Tyr 185
residues on ERK1I2 are phosphorylated by the MAP2Ks MAPKIERK kinase 112
(MEK1I2) (Pimienta et al., 2007; Zhang et aI., 1994).
1.9.4.3 Pathways
The MAPKIERK cascade starts when a variety of extracellular agents such as growth
factors, hormones, and neurotransmitters bind to receptors on the cell surface. The best
example for a description of the ERK pathway is the response after activation of
tyrosine kinase family receptors.
As described above for the insulin receptors, signal transduction is initiated by ligand
binding to the tyrosine kinase receptors, leading to phosphorylation of intracellular
tyrosine residues, leading to recruitment of the Grb2-Sos complex which stimulates the
GTPase Ras to exchange GDP for GTP, leading to activation of the Raf pathway. Raf
kinase activates a series of three MAPK kinases, MAP kinase kinase (MEK) then
phosphorylates ERK1I2 at both threonine and tyrosine residues (Force et al., 1998; Katz
et al., 2007).
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GPCR activation of ERK1I2 is complex, but can involve second messenger-dependent
protein kinases (i.e. PKA and PKC). PKA activates the small GTPase, Rapl. Rap! then
interacts with B-Raf. Activated B-Raf then stimulates ERK. PKC directly
phosphorylates Raf-l , and then Raf-l can activate ERK (Force et al., 1998; Katz et al.,
2007).
Another mechanism of GPCR activation of ERK1I2 is ~-arrestin mediation. The
phosphorylation of GPCR, in particular cytoplasmic serine and threonine residues,
increases its affinity and binding to ~-arrestin (Tobin, 2008). ~-arrestin then act as
scaffolding partner or adaptor protein which facilitates its coupling to alternative
downstream signaling pathway such as MAPKs (JNK, ERK1I2 and p38) or facilitates
its binding to endocytic proteins such as clathrin and adapter protein 2 (AP2) for
endocytosis (Shenoy et al., 2006; Shenoy et al., 2003). The latter binding leads to
internalization of GPCR as a mechanism of desensitization (Shenoy et al., 2006;
Shenoy et al., 2003). Indeed, the MAPK is established to have roles in differentiation,
proliferation and growth, although such roles are not yet described in skeletal muscle.
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1.10 Aim of thesis
The field of phannacogenomics has developed to investigate the questions surrounding
the mRNA expression of genes, how a drug works and how a drug response may
contribute to dissolve diseases or condition states. Experimental observation of GPCR
gene expression and signalling pathway analysis offers a powerful way of
understanding the presence of genes and how these genes affect function.
The aim of this thesis is to investigate GPCR gene expression and down-stream
signalling, focussing on CBI receptors. The major themes of this thesis are;
1. To detect GPCR expression in skeletal muscle and their cognate down-stream
signalling genes.
2. To investigate the signalling associated with these receptors, particularly CBI
receptors, in rat primary skeletal muscle cells.
3. To examine cross-talk between cannabinoid and insulin signalling systems.
4. To examine the functionality ofCBI receptor in rat primary skeletal muscle.
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Chapter 2
Materials & Methods
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2 Chapter Two: Materials and Methods
2.1 Reagents
ACEA, AEA, AM251 and AICAR were purchased from Tocris Company. Rimonabant
was taken from the NIMH chemical Synthesis and Drug Supply Program. All other
materials were purchased from Sigma unless otherwise mentioned.
2.2 Microarray
2.2.1 Materials
Whole genome rat 4*44K DNA microarrays were obtained from Agilent Technologies
Inc. Agilent's One-Color Quick Amp Labeling kit, RNA Spike-In kit and Gene
Expression Hybridization Kit were also purchased from Agilent Technologies Inc.
2.2.2 RNA isolation
RNA was extracted from skeletal muscle, liver, adipose tissues and primary rat skeletal
muscle cells by homogenizing biopsy tissue in Trizol Reagent (2 mL for a 50 mg tissue)
using the pro 200 homogenizer (Janke & Kunkel, Ultra- Turrrax T25). The samples were
then incubated at room temperature for 5 minutes. 200 J..lI bromochloropropane (BCP)
was added for each ml of Trizol Reagent used, the samples were then shaken vigorously.
The homogenates were then centrifuged at 10,000 rpm (8960 g) at 4 Co for 15 minutes
in a Beckman Allegra centrifuge. The upper, aqueous phase was transferred to a fresh
tube. 0.7 ml isopropanol and 0.25 ml NaAcetate (2 M, pH 4) per ml of aqueous phase
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were added and mixed well, and then the mixture was put in the freezer at -20 Co for
one hour. The tube was then centrifuged at 10,000 rpm (8960 g) at 4 Co for 10minutes.
The supernatant was discarded and the pellet washed in 1ml of75% ethanol per 1mlof
Trizol Reagent. The supernatant was then discarded and the pellet left to air dry. After
all the ethanol had evaporated, the pellet was dissolved in 50-100 JlI RNase-free water.
2.2.3 RNA clean up
Cleaning up was done using the Qiagen RNeasy kit. This protocol can be used to further
purify RNA. Buffer RLT (Lysis buffer) and ethanol were added to the sample to create
conditions that promote selective binding of RNA to the RNeasy membrane. The
sample was then applied to the RNeasy Mini spin column. Total RNA bound to the
membrane. Contaminants were efficiently washed away and high-quality RNA was
eluted in RNase-free water. RNA quantities and integrity values were determined using
a ND-IOOONanodrop spectrophotometer and Agilent bioanalyzer, respectively.
2.2.4 RNA quantity and quality
2.2.4.1 Spectrophotometric detection of RNA
RNA was quantified using a spectrophotometer. The DV-absorbance at 230, 260 and
280 nm of the RNA samples was measured in a ND-I 000 Nanodrop spectrophotometer.
An OD260/0D280 ratio and OD260/0D230 between 1.8-2.0 were indicative of good
purity RNA.
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2.2.4.2 AgiJent bioanalyzer
RNA quality is critical for microarray experiments. The integrity of the input template
RNA was determined prior, to labelling/amplification, using the Agilent 2100
bioanalyzer. For the assessment of total RNA quality, the Agilent bioanalyzer provides
RNA Integrity Number (RIN). RIN provides a quantitative value for RNA integrity that
facilitates the standardization of quality interpretation. Samples with a RIN below 7.5
were excluded from microarray experiment. Samples below this cut off point were not
expected to give meaningful results (Kiewe et al., 2009).
2.2.5 Agilent microarray
Sample preparation includes four steps: Preparing One-Color Spike-Mix; preparing
labelling reaction; purifying the labelled/amplified RNA and quantifying the cRNA
(Figure 2-1) and (Figure 2-2). One-Color Spike-Mix was prepared according to the
protocol on Agilent One-Color RNA Spike-In Kit. The thawed Agilent One-Color
Spike-Mix was heated at 37 Co for 5 minutes and vortexed again. Labelling was
performed using the Agilent Gene Expression system according to protocol in Agilent
Quick Amp Kit, One-Color. For the synthesis of cDNA, the low RNA input linear
amplification kit (Agilent) was used to produce an initial RNA amplification of at least
100 folds. In brief, this strategy utilizes an adapter T7 primer for first-strand cDNA
synthesis with MMLV reverse transcriptase, followed by in vitro transcription using T7
RNA Polymerase to simultaneously amplify target material and incorporate Cy3
labelled CTP (Perkin Elmer). The labelled/amplified RNA was then purified using
Qiagen's RNeasy mini spin columns. The concentrations of cRNA (ng/ul.) and cyanine
3 (pmol/ul.) were measured using the NanoDrop ND-lOOO spectrophotometer.
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Labelling efficiency was determined using the yield and specific activity of each
reaction. cRNA preparation must be repeated if the yield is less than 1.65 ug and the
specific activity is less than 9.0 pmol Cy3 per ug cRNA.
Of each sample, 1.65 ug labelled cRNA was fragmented and hybridized on the Whole
Rat Genome Expression Array (4x44K, Agilent). The samples were incubated at 60 Co
for exactly 30 minutes in order to fragment RNA. Hybridization on microarrays slides
(Agilent) was then carried out at 65 Co for 17 hours using an Agilent SureHyb chamber
and an Agilent hybridization oven. Then, slides were washed in Gene Expression Wash.
Afterwards, slides were dried and they were assembled into an appropriate slide holder
for scanning. The TIFF images taken from the scanner were processed with Feature
Extraction Software. See Appendix Section 9.1.5.
Template Total with Spike-In
+
cDNA synthesis
f
cRNA synthesis, labelling and amplification
+
cRNA purification
+
Preparation of htbridization sample
17-hour hybridization (650C)
+
Wash
+
Scan
+
Feature extraction
Figure 2-1: Workflow for sample preparation and array processing.
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~-AAAA~3'
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eDNA
1 T7 RNA PolymeraseCy3-CTP, NTPs
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eDNA
3' 5' eRNA
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Figure 2-2: Schematic diagram of amplified and labelled cRNA procedure. Generation of cRNA for one-
color microarray experiment is shown as stated in One-Color Microarray- Based Gene Expression
Analysis (Quick Amp Labelling).
2.2.6 Affymetrix micro array
RNA was isolated from pnmary rat treated myotubes usmg the Trizol Reagent
according to the manufacturer's instructions, The labelling, hybridization and scanning
were performed by staff at the Nottingham Arabidopsis Stock Centre (NASC) (Figure
2-3),
Briefly, the isolated RNA was followed by purification with Qiagen RNeasy Kit. The
synthesis first-strand eDNA was performed from RNA using T7 in vitro transcription
technology. This technology used T7 oligo(dT) primer to synthesize eDNA. The
synthesis second-strand eDNA was performed through converting the single-stranded
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cDNA into a double stranded DNA (dsDNA). This reaction was carried out by
employing DNA polymerase and RNase H to simultaneously degrade the RNA and
synthesize second strand cDNA. The synthesis of biotin-modified aRNA was carried
out from the double stranded cDNA templates using "IVT Labelling Master Mix". This
step was called the amplification step. Then, the purification of biotin-modified aRNA
was followed to improve the stability of the biotin-modified aRNA through removing
unincorporated NTPs, salts, enzymes, and inorganic phosphate. After purification,
aRNA size distribution was examined again using Agilent bioanalyzer. Labelled aRNA
was fragmented to be prepared for hybridization. Hybridization was performed at 45 Co
for 16 hours using the array hybridization oven. After array scanning, data were
obtained. Hybridization and scanning were performed in the same instrument called
GeneTitan. These data were analyzed using Affymetrix Operating Software. Finally, the
output data were analyzed using the gene expression software called GeneSpring GX.
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1.Poly-A RNA Control
Addition
2. First-strand
eDNA Synthesis
3. Second-strand
eDNA Synthesis
4. IVT I Labeling
ofaRNA
S.aRNA Purification
6. Fragmentation
7.Hybridization
Total RNA Sample
Approximate
Time
5' I i I I I I i I I I I AAAAA 3'
/'" Poly-A RNA Controls
T7 - Oligo(dT) Primerd ./ 3' TTTTT-_S'
.. ' 2.25 hours
S' I I I I I I I I I I I AAAAA 3'
3' 0 nOD 0 0 0 0 0 0 0 TTTTT- _S'
~ 15hours
5' 0 0 0 0 0 0 0 0 0 0 0 AAAAA - _ 3'
3' 0 n non nOD n n n TTTTT - _ S'
Biotinylated
./.... Ribonucleotide 4 hours or
, Analog 16hours
3' I I ,II I IIIII6u6u~5'
3' I I I T I I I T I I 16u~u~5'
T I T
'"
3' I I I I I I I IUUUUU S'
0.75 hour
1 hour
16hours
Figure 2-3: Overview of the array plate 3' IVT labelling assay, adapted from GeneChip® 3' IVT Express
legend: I I I I I RNA i 0 0 0 0 0 DNA _ T7 promoter e- Biotin
Kit.
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2.3 Gel electrophoresis
2.3.1 Materials
lOXTBE:
For I liter:
108 gm Tris Base
55 gm Boric acid
40 ml of 0.5 M EDTA (PH 8.0)
6X Gel sample loading dye, blue:
15% (WN) Ficoll 400
0.25% (WN) xylene cyanol
0.25% Bromophenol Blue
2.3.2 Procedure
Agarose gel2% (WN) was made up in IX TBE buffer by heating in a microwave. The
PCR product (10 JlI of a 50 JlI reaction) and 2 JlI 6x loading dye were loaded onto the
gel which was run for around one hour at a constant voltage of 1OOV. DNA marker
(Fermentas; 100 bp DNA ladder) was used for determination ofPCR product size. DNA
was visualized and photographed with the GeneSnap programme using uv
transillumination.
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2.4 QRT-PCR (Taqman)
2.4.1 Materials
RNeasy Mini Total RNA Purification kits were purchased from Qiagen (West Sussex,
UK). Reagents for reverse transcription of RNA to cDNA were purchased from
Invitrogen (Paisley, UK). Taqman reagents were purchased from Applied Biosystems
(CA, USA). Primers and probes were purchased from Eurofins MWG GmBH
(Ebersberg, Germany).
2.4.2 First strand cDNAsynthesis
Total RNA was reverse transcribed into cDNA using Superscript III First-Strand
Synthesis System (Invitrogen). The following were added into 0.2 ml, RNase-free, PCR
tubes: Total (500 ng) RNA, 1 J!1random primers (100 ng/ul), 1 ul dNTPs (10 mM) and
diethylpyrocarbonate (DEPC) water up to 13 J!1. The tubes were vortexed and
centrifuged briefly. Tubes were heated (MWG-Biotech Primus 96 Plus) to 65 Co for 5
minutes then placed on ice. Following brief centrifugation, master mix was prepared
and added to each sample, by mixing 4 ul 5x RT buffer, 1 J!l 0.1 M DTI, 1 J!l
RNaseOUT (40 U/J!l) and 1 J!l Superscript III (200 U/J!I). The samples were vortexed,
centrifuged and then incubated at 50 Co for 60 minutes, and the reaction was terminated
at 70 Co for 15 minutes. Then, the cDNA was stored at - 20 Co until required.
2.4.3 Relative standard curve method QRT-PCR (Taqman)
RNA preparations and quantification: Total RNA was isolated from skeletal muscle,
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liver, adipose tissues and primary rat skeletal muscle cells using Trizol (Invitrogen), and
purified using RNeasy RNA clean up columns (Qiagen). RNA concentration was
determined using a Nanodrop ND-lOOO.
RNA was reverse transcribed into cDNA using Superscript III reverse transcriptase
(Invitrogen). The probes and primers were diluted to 10mM, and 50 IIIof probe and 75
III of each primer were added to a 2.0 ml tubes. 1300 III of Taqman Universal PCR
Master Mix, Applied Biosystems (4304437), 500 III of HPLC H20 were also added.
The master mix was then vortexed and briefly centrifuged. A master mix for each target
gene was produced according to the number of wells required (Table 2-1). 5 III cDNA
was pipetted into each well of the 96-well plates (StarPCR Raised Rim, Starlab), except
for the NTC (no template control) where 5 III of RNase-free H20 was used as a
substitute. The Master Mix was then pipetted into each well giving a total volume of 20
III in each well. An optical transparent adhesive film was then placed onto the plate
(ABI Prism, 4311971) and a compressor pad placed on top. Quantification assays for
each sample were carried out in triplicate. The mRNA levels were quantified using
Real-time quantitative reverse transcriptase - polymerase chain reaction (qRT-PCR),
performed in ABI StepOnePlus Real-Time PCR Systems using PCR thermal cycling
programs as follows: 50 Co for 2 minutes, 95 Co for 10 minutes and 40 cycles of 95 Co
for 15 seconds and 60 Co for one minute. The primers and probe were designed using
Primer Express 3 software (ABI) and analyzed using Blast N (comparing the query
sequence of the gene of interest with the database of sequences) to identify the query
gene would be the primary target for amplification. The standard curve method was
used, with slope between -3.2 and -3.6 and R2values of more than 99%, indicating that
the amplification efficiency is almost 100%.
58
Table 2-1: peR Master Mix components.
Volume per well
Taqman 2X Universal PCR Master 131-11
mix
Forward primer 0.751-11
Reverse primer 0.751-11
Probe 0.51-11
HPLC Water 5.01-11
Total volume 201-11
2.5 Sample preparation using Trizol reagent
2.5.1 Materials
Trizol reagent was purchased from Invitrogen.
2.5.2 Protein extraction
During RNA extraction procedure using Trizol reagent, after removing the aqueous
phase, the protein was precipitated by adding 1.9 ml isopropanol to the organic bottom
layer. Then, the samples were centrifuged at 5000 rpm (g=224) for 10 minutes at 4 Co.
After that, the supernatant was removed and the pellet was then washed with 0.3 M
guanidine HClI 95% ethanol. The tubes were centrifuged at 7200 rpm (g=465) for 5
minutes. The washing step was repeated three times. 2 ml of 100% ethanol was added
and incubated at room temperature for 20 minutes followed by centrifugation at 7500
rpm (g=46S). Finally, the supernatants were discarded; the pellets were dissolved in
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SDS (sodium dodecyl sulfate)-urea sample buffer. To completely dissolve the pellets
(proteins), sonication was performed for 15 seconds three times. The protein extracts
were stored at -20 Countil required.
2.6 Delipidation of foetal bovine serum
Delipidation of foetal bovine serum was performed according to the method of Cham
and Knowles with slight modification (Cham et al., 1976). 125 ml FBS was mixed with
40:60 volume ratio of N-butanol (100 ml) and di-isopropyl ether (150 ml). The
components were mixed thoroughly by end-over-end rotation on a daisy-wheel for 20
minutes followed by incubation on ice for 20 minutes. Centrifugation was done at 2500
rpm (g=56) for 5 minutes to separate the aqueous and organic phase. The aqueous phase
was extracted carefully using a needle and syringe or pipette. Then, the serum was re-
extracted again with 50 ml di-isopropyl ether, mixed, centrifuged and separated as
before. Then, any trace of solvent was removed using a gentle stream of nitrogen gas for
1-2 hours. Delipidated serum was transferred to a wide mouthed beaker and then
lyophilized using freeze dry for 24-48 hours and reconstituted with 50 ml of HPLC
water. The serum was dialyzed overnight against PBS at 4 Co. The serum was filter
sterilized using 0.2 J.1mcrodisk syringe filters.
2.7 Western blot
2.7.1 Materials
30% Bis-acrylamide was purchased from Severn Biotech (Kidderminster, UK).
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PageRuler Prestained Protein Ladder Plus or Seeblue Protein Ladder was purchased
from Fermentas (York, UK). Nitrocellulose membrane was purchased from GE
Healthcare (Amersham, UK).
4x Separation Buffer, pH 8.8:
1.5 M Tris.Cl
0.4% SDS
4x Stacking Buffer, pH 6.8:
0.5 M Tris.Cl
O.4%SDS
SDS PAGE Separation Gel:
30% Acrylamide solution: 8 ml
4x Separation buffer: 5 ml
Water: 6.8 ml
10% APS (ammonium persulphate): 200 J.lI
TEMED (N,N,N',N'- Tetramethylethylenediamine): 20 ul
SDS PAGE Stacking Gel:
30% Acrylamide solution: 1 ml
4x Separation buffer: 2.5 ml
Water: 6.5 ml
10% APS: 120 J.lI
TEMED: 12 J.lI
5x SDS-UREA Buffer (store at 4 CO):
90 mM Tris HCl pH 6.8 4.5 ml (from 1 M)
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4%(WN)SDS
5% (VN) beta-mercaptoethanol
7 M deionized urea
2g
2.5 ml
35 ml (of 10 M)
(Amberlite Monohed resin was used for 30 minutes to dissolve urea in deionised water).
0.1% (WN) bromophenol blue make up with water to 50 ml.
lOx SDS PAGE Running Buffer:
For 500 ml:
Tris base: 15 g (250 mM)
Glycine: 72 g (1.92 M)
SDS: 5 g (or 50 mll0% SDS solution) (1%)
lOx Transfer Buffer (SDS free):
For 500 ml:
Tris base 15 g
Glycine 72 g
Stripping Buffer:
25 mM glycine, (PH 2.0)
2%SDS
Blocking buffer:
3% fish gelatin in TBS-T
lOx TBS (Tri-Buffered saline) (TBS) pH 7.4:
For 500 ml:
NaCI: 4.4 g
KCI: 1.0 g
Trisbase: 15.0 g
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TBS-T:
Dilute 10XTBS 1:10 and add Tween-20 to 0.1% CVN) final concentration.
Ponceau Red:
0.1% (WN) Ponceau S (3-hydroxy-4[2-sulpho-4-(4-sulphophenylazo)-phenyl-azo]-2,7-
napthalenedisulphoric acid) in 5% (VN) acetic acid.
2.7.2 SDS-PAGE
The samples (20 J-lI)were loaded onto a 12% SDS polyacrylamide gel. 5 J-llof seeblue
marker (Invitrogen) was loaded with each gel as a molecular weight marker. The protein
was separated by gel electrophoresis in a Bio-Rad gel apparatus (Mini-PROTEAN)
filled with SDS-PAGE running buffer. A constant current of 150 volt was supplied for
around one hour. The separated proteins from the gel were transferred to pre-soaked
nitrocellulose membrane in transfer buffer. A constant current of 105 volt was supplied
for around one hour. The protein was stained on the membrane with Ponceau S. Non-
specific antibody binding was reduced by blocking the nitrocellulose membrane in
blocking buffer (3% gelatin in 0.1% TBS.T) for one hour at room temperature with
continuous gentle shaking. The nitrocellulose membrane was subsequently incubated
with primary antibody overnight at 4 Co on a roller (Table 2-2). After overnight
incubation, the membrane was washed with lXTBST three times each 20 minutes. The
membrane was then incubated with secondary antibody diluted 1:10,000 for one hour at
room temperature. After washing three times for 5 minutes with lXTBST, the
membrane was rinsed with distilled water. Finally, the membrane was scanned using
The Odyssey® Infrared Imaging System (LI-COR Biosciences, Lincoln, NEIUSA),
which equipped with two infrared channels. Using two detection channels, total and
phosphorylated forms could be visualized and differentiated between on the same gel
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(same expenninet) usmg different secondary antibodies. Band intensities were
quantified by densitometry, using Odyssey software version 3. For details of antibodies
used in this study (Table 2-2).
2.7.3 Antibodies
Primary antibodies are summarized in (Table 2-2). Goat 680 anti-rabbit, goat 680 anti-
mouse, goat 800 anti-rabbit and goat 800 anti-mouse secondary antibodies were
purchased from Li-Cor Biosciences (Cambridge, UK). The secondary antibodies were
raised in goat and they are anti-mouse or anti-rabbit.
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Table 2-2: Details of primary and secondary antibodies used with Odyssey system.
Antibody Company Species Concentration Condition Secondary Approx
(Catalog raised in Weight
number) (Bands)
(kDa)
Monoclonal-- Cell Signaling rabbits 111500 Overnight 1110000 44
phospho- incubation
p44/42MAPK
(ERKII2)-
(#4370)
Monoclonal-- Cell Signaling mouse 1/1500 Overnight 1110000 42
p44/42MAPK incubation
(ERKI/2)-
(#9107)
Polyclonal=- Cell Signaling rabbits 111000 Overnight 1110000 60
Phospho- incubation
AMPKa--
(#2531)
Monoclonal= Cell Signaling rabbits 111000 Overnight 1110000 51 a
phospho-GSK- incubation 46 ~
3a/~-(#9327)
Monoclonal -- Santa Cruz mouse 111000 Overnight 1/10000 51 a
GSK-3a/~-- Biotechnology incubation 47 ~
(sc-7291)
Monoclonal -- Cell Signaling mouse 111000 Overnight 1110000 60
phospho-AKT - incubation-
-(#4051) using bags
Polyclonal - Cell Signaling rabbits 1/500 Overnight 1110000 60
AKT--(#9272) incubation-
using bags
Monoclonal -- Cell Signaling mouse 1/500 Overnight 1110000 40
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P38-(#9107) incubation
Monoclonal -- Cell Signaling rabbits 11500 Overnight 1110000 43
phospho- P3 8-- incubation
(9215)
Monoclonal-- Abeam mouse 111500 Overnight 1110000 21
eyclophilin-- incubation
(ab74173)
2.8 Quantification of protein samples
2.8.1 Materials
Staining solution (Coomassie Blue):
0.2% (WN) Coomassie Brilliant Blue
20% (VN) methanol
10% (VN) acetic acid
Destaining solution:
20% (VN) methanol
10% (VN) acetic acid
Storage solution:
5% (VN) acetic acid
2.8.2 Coomassie blue staining
After dissolving the pellet from protein extraction in SDS-urea buffer, the dissolved
proteins were heated to 99 Co for 5 minutes, followed by centrifugation at 10,000 rpm
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(g=896)for 5 minutes. 20 JlI of SDS-urea samples were loaded onto SDS 12%
polyacrylamide gels for electrophoresis. Coomassie Blue staining procedure was done
to determine the relative quantity of proteins in the samples for western blot.
After electrophoresis, the apparatus was disassembled, and the gel was removed from
the glass plates and transferred to a tray. The gel was soaked in staining solution for one
hour with gentle shaking at room temperature. The staining solution was discarded, and
the gel was destained using two-three changes of destaining solution on shaker
overnight until bands were clearly visible. The blots were scanned using Odyssey
(Infrared fluerescence). The relative quantity of proteins was determined through
estimation of any sharp protein band stained by Coomassie Blue staining solution to
ensure reliable comparisons of the protein quantities in different samples in which these
quantities represent the total amount of protein loaded into each well.
2.9 3T3-Ll cell culture
2.9.1 Materials
3T3-Ll preadipocytes were obtained from American Type Collection (ATCC). FCS
(foetal calf serum) was purchased from PAA Laboratories (Somerset, UK). NCS
(newborn calf serum) was purchased from PAA Laboratories (Somerset, UK). Oil red 0
stain was purchased from British Drug Houses Ltd (Poole, England).
Medium 1
- Dulbecco's Modified Eagle Medium (DMEM) high glucose with 10% NCS
-2 mM glutamine
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-1% of (10,000 units penicillin and 10 mg streptomycin/ml)
Medium 2
- DMEM high glucose with 10% FCS
-2 mM glutamine
-1% of(10,000 units penicillin and 10 mg streptomycin/ml)
-0.5 mM 1-methyl-3-isobutylxanthine
-0.25 ~M dexamethasone
-166 nM insulin
Medium 3
- DMEM high glucose with 10% FCS
- 2 mM glutamine
- 1% of (10,000 units penicillin and 10 mg streptomycin/ml)
- 166 nM insulin
Medium 4
- DMEM high glucose with 10% FCS
- 2 mM glutamine
- 1% of (10,000 units penicillin and 10 mg streptomycin/ml)
2.9.2 3T3-Ll cell culture
2.9.2.1 Thawing cells
The cryotube containing frozen cells in the 6th passage was taken out of -80 Co freezer.
Those cells were defrosted very quickly in 37 Co water bath for 1-2 minutes. Afterwards,
the cryotube was removed from the water bath and the cells were quickly resuspended
in 50 ml sterile conical tube with 10 ml of medium 1. The cells were incubated in 75
cm2 tissue culture flasks at 37 Co, 5% C02 and 5% humidity with a media change every
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48 hours.
2.9.2.2 Trypsinizing and passaging the cells
Once cells reached 75-80% confluency in 75 cm2 flasks, the medium 1 was removed
from the flasks and the cells were washed with PBS. After that, the cells were treated
with the proteolytic enzyme trypsin (3 ml) to detach adherent cells from the surface of
the flasks. After around 30 seconds-one minute, the trypsin was aspirated and the cells
were then suspended in medium 1. Those cells from one culture flask were divided into
2-4 new culture flasks. The cells were incubated in 75 cm2 tissue culture flasks at 37 Co
and 5% C02, with a media change every 48 hours.
2.9.2.3 3T3-Ll cell culture
The cells were seeded at -1 x lOs cells in 35 mm dishes or 6 well plates. The cells were
cultured until 100% confluent. After 2 days from reaching confluence, cells were
induced to differentiate with medium 2. The cells were maintained in this media for 3
days. Then, the cells were incubated with medium 3 for 2 days. Differentiated cells
were incubated with medium 4 for 2 days.
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2.9.2.4 Oil-Red 0 staining
This method was used to visualize lipid droplets after differentiation to adipocytes.
After removing the media, cells were washed with PBS for three times. Then, the cells
were fixed in 10% formalin at room temperature for 10 minutes. The cells were washed
again with PBS for three times and then incubated for one hour at room temperature
with Oil Red 0 stain. After that, the cells were washed again with PBS for three times
and PBS was added to prevent dehydration. Images were taken for the cells using a
digital camera connected to microscope (Nikon) at X40 magnification.
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F)
Figure 2-4: Representative photographs of3T3-Ll-fibroblast cells differentiating into 3T3-Ll-adipocytes.
A) 3T3-Ll-fibroblast cells, B) confluent fibroblast fixed and stained with Oil Red 0, C) fibroblast
incubated in media 2, D) fibroblast incubated in media 3 and F) 3T3-Ll adipocytes were fixed and
stained with Oil Red O.
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2.10 Primary rat skeletal muscle cell culture
2.10.1Materials
Ham-F 10 and FBS were purchased from PAA Laboratories (Somerset, UK). Horse
serum was purchased from Invitrogen.
1.1.1 Primary cell culture
Muscle culture was performed as Blau and Webster method with slight modification
(Blau et al., 1981). Hindlimb muscles from Wistar rats were removed and immersed in
phosphate buffered saline (PBS), washed to remove the remnants of blood, and minced
finely with scissors and scalpel blades on a Petri dish. The tissue was transferred to a 50
ml flask for trypsinization: 5-10 ml of 0.25% (WN) trypsinlEDTA OX) was added
with stirring at 37 Co. Cells were collected after serial trypsinization (successive 15
minutes periods; until all tissue was dispersed), and then neutralized with an equal
volume of medium. The collected cells were filtered through 100 J.1mnylon mesh ("cell
strainers") to purify the cells from the debris, and centrifuged for 10 minutes at 17,000
rpm (g=26) at room temperature. The supernatant layer was removed and the cell pellet
(satellite cells) was re-suspended in Ham's FlO growth medium, pre-plated on uncoated
flasks for 10 minutes at 37 Co to purify these satellite cells from fibroblasts present in
the extract, and then transferred to culture flasks coated with 0.2% (WN) gelatin. The
satellite cells were then grown to confluent myoblasts and differentiated into myotubes
in growth medium. 20% CVN) fetal bovine serum (FBS) and 5 ml of penicillin and
streptomycin (10,000 units penicillin and 10 mg streptomycin/ml in 0.9% NaCl) were
added to Ham's FlO.
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After one day, the cells were fed with fresh medium, cells require fresh medium every
48 hours. The cells were fed with 20% (VN) FBS fresh medium for three weeks, then
reduced to 10% (VN) FBS fresh medium for two weeks and then changed to 6% horse
serum and 10 mM glucose Ham's F for two to three days.
A)
B)
Figure 2-5: Representative myoblasts and myotubes derived from Wistar rat skeletal muscle. A)
myoblasts taken during the third week of tissue culture and B) myotubes taken during sixth week of tissue
culture.
2.11 cAMP assay
2.11.1 Materials
cAMP Kit was obtained from Cayman Chemical (Europe).
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2.11.2 cAMP assay! cAMP EIA
Accumulated cAMP in the myotube cells was measured by a competitive enzyme
immunoassay (EIA) kit (Cayman Chemical). Cells were cultured in 6-well cell culture
dishes and then cells were pretreated. At the end of the exposure period, 40 ul S M HCl
was added to each well (2 ml media 6% horse serum). The plates were stored at -20 Co
until assayed in duplicate for cAMP using an EIA kit according to the manufacturer's
instructions for cAMP measurement with acetylation (Cayman Chemical).
Then, the experimental well plates were thawed in 0.1 M HCl and media (6% horse
serum) at room temperature for 20 minutes and scraped to ensure total cell lysis and
release of cAMP into the HC!. The lysates of the samples were collected into 1.S ml
microcentrifuge tubes and centrifuged under 10,000 g for 10 minutes at 4 Co. The
supernatants were transferred to new tubes. SODul of the supernatants were transferred
to new tubes for acetylation process. Standards and samples were acetylated in 1.Stubes.
O.OSml of samples or standard solutions was added in duplicate to mouse monoclonal
anti-rabbit IgG coated wells of a 96-well plate. cAMP linked to acetylcholinesterase
(Tracer) and cAMP antiserum were added to the appropriate wells. Then, the plate was
incubated 18-24 hours at 4 Co.
After washing S times using a plate washer (Skatron Instruments), the plate was
incubated with 200 J-llEllman's solution (the acetylcholinesterase (AChE) substrate) for
90-120 minutes at room temperature with gentle shaking (400-600 rpm). The plate was
read at a wavelength of 40S nm to measure the intensity of the colour (yellow) that
developed. The measurement was inversely proportional to the amount of free cAMP
present. The concentration was calculated by the 4-parameter logistic equation obtained
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from the standard curve using GraphPad Prism, version 5.03 (GraphPad Software Inc).
The cAMP concentration of samples was determined and given as pmol/well. Each
sample was performed in duplicate.
2.12 Calcium imaging
2.12.1 Materials
Fura-2AM (L-[2-( carboxyloxazol-2-yl)-6-amino-benzofuran-5-oxy ]-2-(2' -amino-
5'methyl phenoxy)ethane-N,N,N,N-tetraacetic acid pentaacetoxymethyl ester)) was
bought from Calbiochem company.
2.12.2 Glass coverslip preparation
Satellite cells were grown on 19 mm glass coverslips and differentiated into myoblasts
over around 14-21 days as described in the methods (Section 2.8.2).
2.12.3 Fura-2AM cell loading
The intracellular [Ca2+]j was quantified in single cells within myoblast clusters with the
Ca2+-sensitive fluorescent dye fura-2AM using Andors IQ imaging system.
Cells were washed with Ca2+ buffer, then were incubated with 5 J.111 mM fura 2-
acetoxymethyl ester (fura-2 AM) dissolved in 895J.11buffer (NaCI, 145 mM; KCI, 5 mM;
CaCl2, 2 mM; MgS04.7H20, 1 mM; HEPES, 10 mM; glucose, 10 mM) with 100 J.11
FCS for one hour and 15 minutes at 37 Co.
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After loading with the fluorescent calcium indicator fura-2 AM, the cells were washed
three times with buffer to remove the extracellular fura-2AM and incubated in the Ca2+
buffer for 15 minutes before using cells in imaging (Figure 2-6 and Figure 4-14).
When fura2-AM enters the cell membrane, it is then cleaved by cytoplasmic esterases
into impermeable fura2 and AM component. Indeed, fura2 is a UV light excitable dye
which binds to free intracellular Ca2+ more selectively over other cations such as Mg2+
(Grynkiewicz et al., 1985). Fura2 is excited at 340nm and 380nm wavelengths of light.
The excitation spectrum of fura2 peaks at 380nm in the absence of Ca2+, while the peak
shifts to 340nm without a significant change in the emission peak when Ca2+ is bound to
fura2, for example after Ca2+ release from the sarcoplasmic reticulum.
Figure 2-6: Myoblasts after loading with fura-2AM. For colour image, see (Figure 4-14).
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2.12.4 Calcium imaging studies of myoblasts
Covers lips were fixed to a Perspex chamber using vacuum grease. A coverslip with
adherent cells was positioned on the stage of a inverted fluorescence microscope and
examined using Retiga chilled digital intensified charge-coupled device (CCD) camera.
Cells were suprafused with Ca2+ buffer. Changes in [Ca2li were measured as the ratio of
peak. fluorescence emission intensities (measured at 500 nm) at excitation wavelengths
of 340nm and 380nm, respectively. [Ca2li was calculated from fluorescence emission,
monitored by Retiga chilled digital intensified charge-coupled device (CCD) camera,
using a standard curve created with solutions containing known concentrations ofCa2+.
After around one minute of measuring basal responses, a standard protocol was
followed in which myoblast cells were exposed to 10 J.1MofUTP for around one minute
then 20 minutes as a washout period. After that cells were exposed to ATP (1 mM) for
one minute followed by 20 minutes washout period. Finally, cells were exposed to 4
J.1Mof ionomycin for one minute.
Images were taken at a rate of one image per 5 seconds. UTP and ATP produce a robust
calcium signal which reach the peak after approximately 30 seconds and take about 3
minutes to go back to basal. So, one image per 5 seconds interval is sufficient to trace
the calcium signal in primary rat skeletal muscle cells. Besides that, there are technical
limitations in the Andors IQ imaging system which could not capture images in a rate
faster than one image per 5 seconds. The intensity measurements were then collected in
Microsoft Excel. Excel and Prism software was used to calculate each cell's intensity
change and the mean intensity of all cells over time.
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Increases in [Ca2+]i were measured by subtracting mean basal [Ca2+]i from the peak
[Ca2+]j measurement. The percentage of cells that responded to drug was also
determined. Cells were also identified by responsiveness to drug. Myoblasts displaying
an increase in ratio (from basal) < -0.08 (standard deviation of basal period) following
suprafusion with the buffer were considered as non-responsive and therefore excluded
from the study.
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2.13 Glucose uptake assays
2.13.1 Materials
3H 2-Deoxy-D-glucose (2-DOG) (specific activity 0.74 TBq/mmole) was purchased
from PerkinElmer. DMEM zero glucose and 1 gIL glucose was purchased from
Invitrogen.
Reaction buffer:
-138 mM NaCI,
-1.85 mM CaCh,
-1.3 mM MgS04,
-4.8 mMKCI,
-0.2% (WN) BSA,
-50 mM HEPES pH 7.4
2.13.2 Glucose uptake in 3T3-Ll cells
24 hours before the experiment, the differentiated 3T3-Ll adipocytes in 6 well plates
were serum-starved using 12.5 mM glucose, serum free DMEM. After the starving
period, the cells were washed three times with PBS at 37 Co and incubated with 2 ml
reaction buffer for 45 minutes at 37 Co. Then, the cells were treated with insulin (200
nM) in reaction buffer for 10 minutes, followed by the addition of 250 III of 27.8kBq
3H 2-DOG and 1.5 mM of cold 2-DOG for 10 minutes. Glucose uptake was terminated
by washing the cells with ice cold PBS containing 10 mM glucose three times. Then,
the cells were solubilised in 500 III 0.5 M NaOH and 0.1% SDS. 300 III of lysate was
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transferred to a scintillation vial and 5 ml liquid scintillant was added. Radioactivity
was measured using a scintillation counter (LKB Instruments, Maryland, USA).
Samples were assayed for 2-DOG uptake as disintegrations/minute/well.
2.13.3 Glucose uptake in skeletal muscle myotubes
The procedure is identical to that described for 3T3-Ll cells with the exception that the
myotubes were starved for 2-5 hours in Ham-F containing 6 mM glucose. In order to
examine whether the glucose uptake could be changed in primary rat skeletal muscle
myotubes, insulin dose-response curve was examined first.
2.13.4 Glucose uptake in 3T3-L1 cells/skeletal muscle myotubes (adjusted
protocol).
The procedure is identical to that described for original protocol with the exception that
DMEM «0% serum and 6 mM glucose) or (0% serum and 0% glucose» were used
instead of Ham-F 10.
2.14 Immunocytochemistry
2.14.1 Materials
0.1 M PBS
Triton X-lOO
SerumlBSA
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Primary antibody (rabbit polyclonal to glucose transporter GLUT4 (ab33780))
TTBS (Triton + Tris buffered saline)
Secondary antibody (Alexa Flouro® 488 goat anti-rabbit IgG (H+L)*2mg/ml)
Shaker table
Dark box
2.14.2 Proced ure
The myotube cells on glass covers lips were fixed in 4% PFA (paraformaldehyde) for
thirty minutes at room temperature. After PFA was aspirated, the cells were incubated at
room temperature with ice-cold 0.1 M PBS for 10 minutes. Then, the cells were washed
with 0.1 M PBS three times. The coverslips were blocked with 50 ul goat serum, 6 I.d
Triton 100%, 1 ml 0.1 M PBS for one hour at room temperature. Then, the coverslips
were incubated with the indicated primary antibody, raised in rabbit, (GLUT4; 1:1000
dilution) overnight at 4 Co, followed by washing for five times with 0.1 M PBS for 10
minutes. After that, secondary antibody (Alexa Flouro® 488 goat anti-rabbit IgG
(H+L)*2mg/ml; 1:500 (2 J.lIper ml TTBS)) was added for one hour and followed by
washing with 0.1 M PBS for five times for 10 minutes. Then, the coverslips were kept
dry overnight, the coverslips were then mounted onto microscope slides using mounting
medium with DAPI. Cells were viewed and photographed with fluorescent microscope
lX40. Image on fluorescent microscope on green channel for antibody and blue for
DAPI (nuclear stain) were used. Cells were taken with an oil immersion lens at 40x
magnification.
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Chapter 3
GPCRs Expression
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3 Chapter Three: mRNA expression of GPCRs and
associated signalling partners in skeletal muscle tissues
3.1 Introduction
G protein coupled receptors (GPCRs) are the largest family of proteins in the human
genome. Indeed, GPCRs are the richest targets for pharmaceutical drugs on the market
today; it is estimated that they are the targets of 30-50% of all medications due to their
vast and varied roles in regulating the body processes, metabolism and signal
transduction and their involvement in key biological functions (Kobilka, 2007;
Tilakaratne et al., 2005). GPCRs are expressed in every tissue and play a major role in
many diseases.
G proteins are a diverse class of heterotrimeric proteins composed of three distinct
subunits: c, ~, and 'Y. G proteins can be divided into four main families: Gas; Gai; Gaq
and Ga12 (Downes et al., 1999; Ulloa-Aguirre et al., 1999). The main signalling
mechanisms are illustrated in Chapter One (Figure 1-3).
Gasstimulates adenylyl cyclase (AC) activity. This enzyme converts ATP to cAMP. An
increase of cAMP level activates protein kinase A (PKA). As Gai inhibits AC activity,
activation of GPCRs coupled to G, leads to a decrease in cAMP levels. This results in
decreasing the activity of PKA. When an agonist binds to a Gaq protein-coupled
receptor, Gaq activates phospholipase C (PLC). The active PLC hydrolyses
phosphatidylinositol 4,5-bisphosphate (P1P2) to produce inositol 1,4,5-trisphosphate (lP3)
and 1,2-diacylglycerol (DAG). IP3 is water-soluble, so it is able to diffuse through the
cytoplasm to the endoplasmic reticulum, where it allows Ca2+ to be released from
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enzymes and ion channels. DAG is hydrophobic, however, and it stays in the membrane
to activate protein kinase C (PKC). This enzyme phosphorylates many proteins such as
the insulin receptor substrate-I in skeletal muscle (Schmitz-Peiffer et 01.,2008; Waraich
et al., 2008). When a ligand binds to a G«12protein-coupled receptor, Rho guanine
nucleotide exchange factors are activated, leading to activation of the small G protein
Rho. Rho-GTP activates many enzymes, such as Rho kinases that regulate
phosphorylation.
Skeletal muscle is a heterogeneous tissue since it contains a variety of fibres that differ
in contractile, functional, metabolic and molecular characteristics (Pette et al., 1997;
Staron et al., 1999). Moreover, skeletal muscle is the largest organ in the human body
and represents -40% of the human body mass and 35-40% of the total body weight in
the rat (Del bono et al., 2007; Pedersen, 2011). Indeed, skeletal muscle utilizes the
majority (70-80%) of ingested glucose since it is the main site for insulin-dependent
glucose uptake (Toft et al., 1998). Therefore, it is generally considered the most
important site of insulin resistance.
By virtue of their large number, widespread expression and important mechanistic and
regulatory roles in cell physiology and biochemistry, GPCRs play multiple well-
recognized roles in clinical medicine. Therefore, GPCRs might be important In
maintaining homeostasis in skeletal muscle though mediating responses to
neurotransmitters and hormones. Finding the most highly expressed GPCRs will be
hopefully helpful to define and characterize vital potential in terms of identifying novel
targets related to clinical disorders. For most of those targets, it remains an open
question whether the expression of these GPCRs in skeletal muscle is an important
contributor to potential functional and metabolic roles in this tissue.
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Identifying those receptors could be performed by assessing the binding of radioligands
(Le. radiolabelled agonists or antagonists), antisense approaches, expression studies
(protein and mRNA level) and signalling pathways responses to such GPCRs. However,
there are several challenges for some of these techniques. Indeed, the expression of
receptor at protein level and radioligand binding assays can be difficult as limited
validated antibodies to detect receptor protein and limited radioligands to bind to
particular receptors are commercially available. Moreover, the availability of such
agonists and antagonists to examine the signalling of GPCRs, in particular for orphan
GPCRs, may be limited.
There are, however, very few studies about the expression of GPCRs and their
signalling and the diversity and roles of these receptors in skeletal muscle. There has yet
been no comprehensive analysis carried out of GPCRs and GPCRs signalling pathways
in skeletal muscle published in the literature. This study utilized microarray technology
to identify the identity and relative levels of GPCRs expressed in skeletal muscle.
3.2 Aims
The purpose of the investigations in this chapter was to characterize the mRNA
expression of GPCRs and their ancillary signalling proteins in rat mixed fibre-type
skeletal muscles using DNA microarray and QRT- PCR (Taqman) techniques.
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3.3 Experiment design and methods
3.3.1 Tissue collection
Two male adolescent Wistar rats (180-200 g, 4-6 weeks old) were killed by cervical
dislocation without anesthesia. This method was approved by the University of
Nottingham Ethics Committee and the Animals Scientific Procedures Act (ASPA).
Liver, adipose (mixed from subcutaneous, epididymal and omental) and skeletal muscle
were obtained. Skeletal muscle (mixed fibre-type from hindlimb) tissues were separated
bilaterally: tissue was immediately frozen in liquid nitrogen and stored at -80°C with
liver and adipose tissue, muscle tissue was cultured after the isolation of satellite cells in
gelatine-coated flasks. The fibre type distributions for rat skeletal muscle used in this
study was represented in Table 3-1 (Staron et al., 1999).
Table 3-1: Fibre type expression (%) in different muscles from the rat, adapted from (Staron et al., 1999).
Muscle Fibre type (%)
I IIA lIB IC (IIC,IIAD,
IIDBand
lID)
Soleus 82 9.3 - 1.8 6.9
Tibialis Anterior 2.4 12.2 49 0.2 36.2
Extensor 4.0 15.5 30 0.8 49.7
Digitorum
Longus
White 0.1 0.8 77 - 22.1
Gastrocnemius
Red 22 18 5.1 1.9 53
Gastrocnemius
Due to the cost implications, the microarray experiments were performed from two rats
in this chapter. However, it is recommended to perform more repeats to support the
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results deduced in this chapter, in particular it is hard to depend on 2 repeats due to
variations in species or technical work. Indeed, more repeats will solidate the data
statistically.
3.3.2 Tissue culture
Tissue culture was performed as described in Chapter 2, Section 2.8.
3.3.3 Microarray procedure
Agilent 4*44K DNA one color whole genome microarrays were used to measure the
expression of 41090 genes in liver, adipose tissue and mixed fibre-type of skeletal
muscle from rat hindlimb. The microarray experiment was carried out as described in
the Methods; Chapter 2, Section 2.2.5.
After assessing the quality control criteria (Appendix 9.1.6) generated from feature
extraction software, extracted data were further processed with GeneSpring GX 11.
3.3.4 Normalization
Normalization is necessary in micro array experiments since the absolute amounts of
RNA cannot be determined, due to variations in labelling and hybridization. Expression
intensities resulting from the same amount of RNA can differ when comparing two
microarrays. Therefore, comparison of data from multiple arrays or multiple samples on
a single array requires the data to be normalized. Data values below 1.0 were omitted
and then set to 1.0. The raw data were then transformed by taking the log to base 2.
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Then, the 75th percentile value was subtracted from each measurement in that array.
Summary:
Step 1: Log, transformation.
Step2: Percentile Shift. 75th percentile was calculated for each array and this value was
subtracted from each value on the array. 75th percentile value was determined after
ranking the values from the highest to lowest relative intensity values.
Calculations:
Figure 3-4-A was taken as an example to explain how the data were arrived at.
Skeletal muscle:
Glut4 has a raw data (relative intensity value) =32326 and the 75th percentile of this
array=252.
Stepl:
LOg2for the raw data of Glut4=14.9 and Log, for the raw date of 75th percentile=7.9.
Step2:
LOg2 for the raw data of Glut4 - Logj for the raw data of 75th percentile=14.9-7.9=7
(Table 3-2 ).
Table 3-2: Explanation of normalization calculations for Glut4 in skeletal muscle, liver and adipose
tissues.
Raw/Glut4 Raw (75th Log2Glut4 Log- (75th Difference
percentile) percentile)
Skeletal 32326 252 14.9 7.9 7
muscle
Liver 11.76 220.95 3.5 7.8 -4.3
Adipose 21858 294.94 14.4 8.2 5.2
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3.3.5 Reproducibility
The reproducibility of microarray was determined by calculating Pearson correlations
using Graphpad Prism, version 5.03 (GraphPad Software Inc) on normalized data for all
pair combinations of microarrays among biological replicate tissues (two animals, with
3 technical sites for skeletal muscle and one technical site for adipose and liver) (Table
3-3).
Table 3-3: The two biological skeletal muscle, liver and adipose replicates. Site A is a mixture of extensor
digitorum longus and tibialis anterior, site B is a mixture of soleus and plantaris, and site C is a mixture of
red and white gastronemius muscle with roughly equal amounts of each muscle.
RatA RatB
Skeletal muscle-Site A Skeletal muscle-Site A
Skeletal muscle-Site B Skeletal muscle-Site B
Skeletal muscle-Site C Skeletal muscle-Site C
Liver Liver
Adipose Adipose
3.3.6 Concordance
Concordance is defined as an agreement in the types of data (entities) that occurs among
the pairs (biological or technical replicates) which reflects their degree of similarity in
terms of entity expression.
Concordance was calculated by dividing entities classified as "present" in all replicates
by entities classified as "present" in at least one of them (Figure 3-1).
Concordance=B/(A +B+C).
A: number of entities available only in first repeat.
B: number of entities available in both first and second repeat.
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C: number of entities available only in second repeat.
Figure 3-1: A Venn diagram for calculating concordance.
The term entities "genes" were used throughout this study to designate the transcripts
that are identified by these probes "features".
Entities were considered "present" only if the output was uniform, not saturated and
above the background. Entities were also considered "marginal" only if the output was
not above or equal to background. However, entities were considered "absent" only if
the output was not uniform and saturated.
A feature is non-uniform if the pixel noise of the feature exceeds a threshold established
for a "uniform" feature. A feature is saturated if 50% of the pixels in a feature are above
the saturation threshold which equal 65000.
"Present", "marginal" or "absent" are terms defining the nature of the hybridization
(binding of probe to gene) signals on each microarray. However, the terms "expressed
transcripts", "weakly transcripts" and "not expressed transcripts" are different. The
latter are terms defined by comparing the results obtained among different conditions
(disease vs normal) and should not be confused with "present", "marginal" and "absent"
(Rimbault et al., 2009). Therefore, not all GPCR entities classified as "present" are
expressed and some GPCR entities classified as "marginal" might be expressed.
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The use of the threshold (present detection) will eliminate the entities that are likely to
be unreliable and will keep the entities classified as "present". These entities, which are
classified as "present", might be expressed or not. Consequently, the use of the
threshold will increase true positive to false negative.
Filtering by signal will remove the entities with a signal close to background. However,
the choice of how to determine the background is arbitrary (Background subtraction
method was applied through identifying the position of the probe on the microarray and
calculating the background signal and subtracting it from the hybridization signal of the
probe (Figure 3-2». However, many systematic sources may still remain to contribute
to the background signal component, including any non-specifically-bound fluorescent
signal or contaminants on the glass, fluorescent signal that is non- specifically
associated with the DNA probes themselves and any artifacts from washing,
hybridization and labelling.
Probe
Exclusion Zone
Local Background
Figure 3-2: Background substraction method.
This method (Agilent micro array) was used in this study to eliminate the entities that
are likely to be unreliable (entities are not classified as "present" in all replicates).
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3.3.7 QRT-PCR (Taqman)
Myoblast and myotube cells were grown and differentiated as described in Chapter 2.
The cells were collected in TriReagent, and processed as described in Chapter 2,
Section 2.2.2. RNA was reverse transcribed into cDNA using Superscript III reverse
transcriptase (Invitrogen). Then, QRT-PCR (Taqman) was performed as described in
Chapter 2, Section 2.4.
Gene expression levels (in arbitrary units) were determined from the mean of triplicate
determinants of each sample. As stated in Chapter 2, Section 2.4, data from Taqman
were only used if the slope of the standard curve for each plate was between -3.2 and -
3.6 and R2 values of more than 0.99. In addition, Ct values of triplicate readings for an
individual sample, which were more than 0.5 Ct apart, were excluded. The following
primers and probes (Eurofins) were used (Table 3-4).
QRT-PCR (Taqman) measures the amount of accumulated PCR product. PCR
amplification is characterized by three phases of the amplification reaction; lag,
exponential (log-linear) and plateau phases. Indeed, there is a quantitative relationship
between starting material and PCR product during the exponential phase of PCR. When
fluorescence signal, which is proportional to the amount of accumulated PCR product,
increases during PCR cycles, it reaches the threshold cycle (Ct value) at which the
fluorescent signal is first recorded during the exponential phase. The threshold is
usually detected when 1011_1012 PCR product molecules are present. This enables an
accurate quantification of starting material using QRT-PCR (Taqman). The fewer the
number of cycles required to reach the log amplification phase for a particular gene, the
greater the amount of the target gene detected. The standard curve was then performed
by plotting the Ct values against the logarithm of the initial cDNA serial dilution.
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Usually, reference genes were used as the non-variant normalizing genes.
The mRNA expression levels of specific genes were not normalized to the mean of the
mRNA expression level of p-actin and 18S in this study. The reason behind that was
explained by variant cycles in different stage of differentiation in skeletal muscle
(myoblast, myotube and tissue) for p-actin and 18S.
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Table 3-4: Oligonucleotide sequences for probes and primers.
Sequences (5' ? 3') Amplicon Gene Bank
size (bp) Accession No.
Gene
18s FWD CGGCTACCACATCCAAGGAA 188 M10098
PROBETGCTGGCACCAGACTTGCCCTC
REV GCTGGAATTACCGCGGCT
Acth FWD GAGCGTGGCTACTCCTTCGT 72 NM_OO1100
PROBEACCACAGCTGAGCGCGAGATCGT
REVGTAGCACAGCTTCTCCTTGATGTC
enr1 FWDCCAAAAGTGGAGAGCGACAAC 68 NM_012784.4
PROBE ATCCAGATCACCATGCCGTTCACA
REV CGTCTCGAAGGTCCCAA TGT
Gpr40 FWDCCTGCCCGACTCAGTTTCTC 80 NM_153304.1
REV CGGAGGCAGCCCACATAG
PROBETTCTGCTCTTCTTTCTGCCCTTGGTTATCA
Adra2a FWD GGCCTCAGCGGACATCCT 64 NM_012739.3
PROBE TGGCCACGCTGGTCATTCCCTT
REV CATAACCTCGTTGGCCAAAGA
Gpr1l9 FWD TCCATATTCCAGCAGACCACCTA 70 NM_181770.1
PROBECATGGGCCCTGCACCTTCTTTGC
REV GCACAAACCTTGGGTGAAACA
3.4 Statistical analysis
Analysis was performed using GraphPad Prism, version 5.03 (GraphPad Software Inc).
Data were represented as means ± standard error of mean (SEM).
3.5 Results
3.5.1 Reproducibility
In order to examine the reproducibility between replicates, Pearson correlation was
performed. Correlations on normalized data among skeletal muscles and among liver
replicates were above 0.97 (Pearson correlation), indicating high reproducibility.
Similarly, correlation between adipose replicates was slightly lower at - 0.96. Adipose
tissue samples were taken from three different parts with different proportions of
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subcutaneous, epididymal and omental adipose tissue (Figure 3-3 and Table 3-5).
Adipose correlations
11
Liver correlations Skeletal correlations
10 15
Figure 3-3: The correlation between two biological replicates; from liver (0.97) (Pearson score), adipose
tissue (0.95) and mixed fibre-type skeletal muscle (0.97) taken from hindlimb from two rats. The axes
represent the relative intensity values for gene expressions.
Table 3-5: Correlation between two biological replicates from mixed fibre-type hindlimb skeletal muscle
(0.97) taken from two rats. Site A was a mixture of extensor digitorum longus and tibialis anterior, site B
was a mixture of soleus and plantaris, and site C was a mixture of red and white gastrocnemius muscle
with roughly equal amount of each muscle.
Correlation RatA RatB
Site Site
A B C A B C
RatA Site A 0.98 0.95 0.97 0.98 0.97
B 0.98 0.95 0.96 0.97 0.96
C 0.95 0.95 0.96 0.96 0.95
RatB Site A 0.97 0.96 0.96 0.98 0.98
B 0.98 0.97 0.96 0.98 0.98
C 0.97 0.96 0.95 0.98 0.98
3.5.2 Concordance
In order to examine the similarity of relative expression among entities classified as
"present", concordance was calculated.
Entities (22839, 26199,28466, 29476,24574 and 23610) classified as "present" were
observed in six mixed fibre-type skeletal muscles (Table 3-6). The concordance among
skeletal muscle replicates was 79-90% for these entities. The concordance for all
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skeletal muscle replicates is 79% for the entities classified as "present".
GPCR entities (133, 119,215, 161, 191 and 115) classified as "present" were observed
in six mixed fibre-type skeletal muscles (Table 3-6). The concordance among the
skeletal muscle replicates was 51-82% for the GPCR entities classified as "present".
The concordance for all skeletal muscle replicates is 51% for the GPCR entities
classified as "present".
Table 3-6: The number of whole genome entities and GPCR entities classified as "present" in each
individual muscle tissue from two biological replicates-.
whole genome entities GPCR entities
RatA Site A 22839 133
B 28466 215
C 24574 161
RatB Site A 26199 119
B 29476 191
C 23610 115
The differences in concordance among replicates might be ascribed to differences in
biological or technical issues, labelling, hybridization or washing issues. The
concordance rate for entities classified as "present" for all skeletal muscle replicates
(79%) from rat whole genome microarray was higher than the concordance rate for
GPCR entities (51%). The possible reasons for this observation are that a large
percentage of GPCRs may be detected at marginal levels relative to the background of
those entities on the microarray slides (background level). Another reason is that the
expression levels for GPCR entities possibly are usually lower than overall genome
entities that contain structural proteins. In other words, the variation in the numbers of
GPCR entities classified as "present" among different replicates is explained by GPCR
entities might be located in low ranking as "present" and high ranking as "marginal".
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3.5.3 Confirmatory expression
Glut4, Jabp3, ppara and pparg were selected as confirmatory genes to define skeletal
muscle, liver and adipose tissue for the microarray experiments in order to reflect the
microarray reliable data in a tissue specific manner.
The present study revealed that the glut4Imusc1e-fat glucose transporter was highly
expressed in skeletal muscle and adipose tissue while low expression was observed in
liver tissue (Figure 3-3A). Fatty acid binding protein 3 (fabp3) was also highly
expressed in skeletal muscle while low expression was observed in liver and adipose
tissues (Figure 3-3B). Ppara was highly expressed in liver and skeletal muscle tissue
while low expression was observed in adipose tissue (Figure 3-3C). Pparg was highly
expressed in adipose tissue while low expression was observed in liver and skeletal
muscle tissues (Figure 3-4D).
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Figure 3-4: RNA transcript levels for (A) glut4, (B) Jabp3, (C) ppara and (D) pparg in mixed skeletal
performed).
muscle, liver and adipose from two male Wistar rats. (As number per group is not equal, statistics was not
3.5.4 Skeletal muscle type definition
In order to determine the type of skeletal muscle fibres, the relative intensity values of
the rat fast and slow fibre type specific structural subunits were determined (Figure
3-5); Troponin I (tnnil), troponin T 1 (tnntI), tropomyosin 3 (tpm3), myosin light chain
2 (myI2), and, myosin heavy chain 7 (myh7) are markers for slow twitch muscle (Barton
et al., 1999; Gahlmann et al., 1988; Pieples et al., 2000; Smerdu et al., 1994;
Tajsharghi, 2008). Troponin I 2 (tnni2), troponin T 3 (tnnt3), troponin C 2 (tnnc2)
tropomyosin 1 (tpmI), myosin light chain 1 (myll) and myosin light chain 3 (myl3)
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myosin heavy chain 1 (myhl) myosin heavy chain 2 (myh2) are markers for fast twitch
muscle (Periasamy et aI., 1984; Pieples et al., 2000; Schreier et al., 1990; Smerdu et al.,
1994; Tajsharghi, 2008). Slow twitch muscle structural subunits (tnnil, tnntl, tpm3,
myl2 and myh7) and fast twitch muscle structural subunits (tnni2, tnnt3, tnne2, tpml,
myll, myl3, myhl and myh2) were detected (419 ranking out of 41090).
Skeletal muscle structural subunits
Tpm3
Tpm1
Myl3
Myl3
Myl2
Myl1
Myh7
Myh2
Myh1
Tnnc2
Tnnt3
Tnnt1
Tnni2
Tnni1
0
1111111111111 IT
'////////77I////////Ai
:--"""",,-,,,,,,,,,-,,,,,,
IlTmT
2 4 6 8 10 12
Normalized intensity values
Figure 3-5: RNA transcript levels for muscle structural subunits classified as "present" in mixed skeletal
muscle tissue for three replicates from two independent repeats (male Wi star rats).
3.5.5 mRNA expression for skeletal muscle-defining receptors
In order to define skeletal muscle, the relative expression of ryanodine receptors was
investigated. Ryr1 and ryr 3 were classified as "present". However, ryr2 was classified
as "marginal" in all skeletal muscle replicates (38038 ranking out of 41090). Ryr1 was
highly detected compared to ryr3 in skeletal muscle (269 and 20718, respectively
ranking out of 41090) and above reference gene (TATA box binding protein (Tbp))
(Figure 3-6). In other words, ryr 1 was highly expressed in skeletal muscle compared to
others (Figure 3-6).
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Ryanodine receptors in all skeletal muscle
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Figure 3-6: RNA transcript levels for ryanodine receptors classified as "present" in mixed skeletal muscle
tissue for three replicates from two independent repeats (male Wistar rats).
Neuromuscular junctions (NMJs) consists of presynaptic (the axon terminal of a motor
neuron), synaptic cleft and postsynaptic (the motor end plate of a muscle fibre) elements.
Acetylcholine (ACh), the major excitatory neurotransmitter at neuromuscular junctions,
is synthesized by "choline acetyltransferase" (ChAT), and ACh is loaded into synaptic
vesicles by "the vesicular acetylcholine transporter" (VAChT) (de Castro et al., 2009).
ACh diffuses into the synaptic cleft and activates the nicotinic acetylcholine receptors
which are expressed in skeletal muscle (Kues et al., 1995). ACh actions are terminated
by acetylcholinesterase (AChE) which is also expressed in skeletal muscle (Herman et
al., 1985). It is worth noting that there are synaptic-vesicle-associated proteins such as
synaptophysin and synaptotagmin (Fox et al., 2007; Juzans et al., 1996), and axonal
proteins (neurofilaments) to support normal axonal growth, are expressed in neurons
(Hoffman et al., 1987).
In order to define skeletal muscle and also to examine any contamination from the nerve
terminal, the relative mRNA expression of nicotinic acetylcholine receptor subunits u, p,
E, 0 and j genes (chrno; chrrft, chrny, chrno, chrney; acetylcholinesterase gene (ache),
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choline acetyltransferase (chat) and vesicular acetylcholine transporter (slcJSa3),
neurofilaments (light (nejl), medium (ne/m) and heavy (nefh», synaptotagmin I and II
(sytl and syt2) and synatophysin (syp) were investigated using the microarray.
Nicotinic acetylcholine receptor subunits ul , ~1, E, 0 and 'Y genes were detected (high
intensity values (ranking - 8000 out of 41090» compared to muscarinic receptor 3 gene
(chrm3) (ranking for chnn3 was - 14547 out of 41090). Other muscarinic receptors
were classified as "marginal" in all skeletal muscle repilcates (ranking - 30000 out of
41090). Acetylcholinesterase (ache) was detected (high intensity values) compared to
synaptotagmin I and II (sytl and syt2). Moreover, choline acetyltransferase (chat) and
vesicular acetylcholine transporter (slclSa3), neurofilaments (light (nejl), medium (nejh)
and heavy (nefh» were not detected in skeletal muscle tissues (Figure 3-7).
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Figure 3-7: RNA transcript levels for nicotinic receptor subunits, muscarinic receptor 3 and
independent repeats (male Wistar rats).
acetylcholinesterase classified as "present" in mixed skeletal muscle tissue for 3 replicates from two
3.5.6 mRNA expression of GPCRs
The mRNA relative intensity values of GPCR entities classified as "present" in all
skeletal muscle replicates using microarray is shown in Table 9-12 in Appendix.
88 GPCRs out of 329 (taken from "The International Union of Basic and Clinical
Pharmacology") in all skeletal muscle samples were classified as "present" using
Agilent microarray. From 88 GPCRs, a number of different receptors coupled to
different G proteins were selected for further investigation in the next chapters based on
the following criteria:
1) Any of the signals for the GPCR entities is above the lowest signal of reference
gene (tbp) of any skeletal muscle replicates (-0.2) or above the lowest signal
from any of the nicotinic cholinergic subunits (chmal) of any skeletal muscle
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replicates (-0.72=--1). Tbp is used as a reference gene to normalize the gene
expression in tissues that display structural reorganization and architectural
changes (Yuzbasioglu et al., 2010). Moreover, it is well-known that nicotinic
cholinergic receptors are expressed in skeletal muscle (Kues et al., 1995).
2) Known and available ligands, local expertise and cost.
38 GPCR entities were detected in skeletal muscle tissue (ranked higher (higher relative
intensity values) than either nicotinic cholinergic alpha subunit (chrnal) or reference
gene (tbp) (12526 and 10220 ranking out of 41090, respectively)), see (Table 9-12) in
Appendix. From these 38 GPCR entities, ~radrenoceptors, P2Y., P2Y2 and P2Y6
receptors, A, and A2A-adenosine receptors, NPY YI receptor and u2-adrenoceptors were
selected as shown in Table 3-7. These GPCR entities include three main families that
coupled to different G proteins (Gs, Gj and Gq) in this study. Examples of Gs-GPCRs are
~2-adrenoceptor, A2A-adenosine receptor, Gj-GPCRs are Al adenosine receptor and
NPY YI receptor, and Gq-GPCRs are P2Y., P2Y2 and P2Y6 receptors. These examples
of detected GPCR entities will be investigated in the next chapter to examine the
possible different signalling in skeletal muscle cells. Indeed, investigation of the
different families (Gs, G, and Gq) of GPCRs might help to confirm the expression and
understand the expected signalling and functional role of these receptors and to
investigate the possible cross-talk between GPCRs signalling and their signalling
partners' genes.
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3.5.7 mRNA expression oCGPCRs using QRT-PCR (Taqman)
Some entities were selected to be examined by QRT-PCR (Taqman). The criteria was to
cover different ranking areas from the microarray entities list and to select OPCR
entities that possibly have some expected roles in skeletal muscle glucose metabolism
(Eckardt et al., 2008b; Lindborg et al., 2011; Overton et al., 2008; Ravinet Trillou et al.,
2004; Swaminath, 2008).
Examining mRNA expression of these receptors (CBI receptor, OPRl19, Ur
adrenoceptors and OPR40) in skeletal muscle will be helpful in this study for further
investigation. This is due to the fact that CBI receptors have been implicated to possibly
playa role in the development of insulin resistance in obese as well as diabetic patients
with elevated levels of endocannabinoids (Ravinet Trillou et al., 2004). Moreover, a
relationship between GPR40 or GPRl19 and diabetes has been suggested. However, the
mechanisms behind these issues are still unclear (Overton et al., 2008; Swaminath,
2008). In order to examine the expression of these receptors and validate the mRNA
expression ofOPCRs, QRT-PCR (Taqrnan) was performed.
mRNA of actb and 18S were detected in QRT-PCR (Taqrnan) at Ct values of..., 19 and
22, respectively (ranking in the microarray; 8 and 275, respectively, out of 41090).
mRNA for adra2a and cnr1 were detected in rat skeletal muscle tissues at Ct ...,32 and
27, respectively (ranking in the microarray; 14208 and 34463/35034 out of 41090,
respectively). There was no significant difference in the expression of adra2a and cnr1
between skeletal muscle and adipose tissues using QRT-PCR (Taqrnan). Gpr40 was not
detected using QRT-PCR (Taqrnan) (ranking in the microarray; 40809 out of 41090).
Gpr 119 was detected at Ct ...,33 (ranking in the microarray; 25255 out of 41090-
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marginal in 4 skeletal muscle replicates out of 6 replicates) (Figure 3-6)). Overall, actb,
18S, cnr1, gpr 119 and adra2a were detected in skeletal muscle tissues.
Table 3-8: Ct values for QRT-PCR (Taqman) for GPCR entities and reference genes for skeletal muscle
cells and tissues and for liver and adipose tissues from two replicates from two rat repeats.
Gene/Ct value Skeletal Myotube Myoblast Liver Adipose
Actb 19.5 16.5-17.5 16.5-17.9 20.0 17.6
18S 21.5-23.0 21.5 22.5 22.5 22.5
Gpr40 Undetermined Undetermined Undetermined Undetermined Undetermined
Cnrl 26.5-27.0 27.5 27.5 31.0 27.5
Adra2a 31.0-32.0 30.0 28.0 37.0 30.0
Gprl19 32.0-33.0 35.0-36.0 35.0 31.0 31.5
3.5.8 mRNA expression of GPCR protein signalling partners
To measure the mRNA levels of a comprehensive profile of GPCR signalling-related
gene products, microarray was used.
mRNA of four main G protein a subunits (gnas, gnai (gnai2 and 3), gnaq, gnall and
gna12) were classified as "present" in all skeletal muscle replicates. However, gnas was
found be highly detected (553 ranking out of 41090) compared to others and above tbp
reference gene (Figure 3-8-A).
The mRNA sequence for the gnai2 isoform was validated compared to the provisional
mRNA sequence of gnail and gnai3 in rat. All G-protein P and y isoforms were
classified as "present" in all skeletal muscle replicates. Gnbl, gnb2, gnb5, gng5, gngl0
and gng12 were highly detected compared to the others (3351, 2562, 6308 and 8247
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ranking out of 41090) and above (bp reference gene (Figure 3-8-B,-C).
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Figure 3-8: RNA transcript intensity values for G protein-a CA), G protein-B CB) and G protein-y (C)
subunits classified as "present" in mixed skeletal muscle generated from two male Wistar rats.
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GPCR signalling pathways are modulated by ancillary proteins including regulator of G
protein signalling (RGS). RGS are proteins that act as GTPase accelerating proteins for
alpha subunit (De Vries et al., 2000; Sierra et al., 2000). To investigate the relative
expression of these genes, microarray was used.
mRNA encoding rgs2, rgs3, rgs4, rgs5, rgslO, rgsll, rgs14, rgs19 and Axinl were
classified as "present" in all skeletal muscle replicates. Rgs2, rgs5 and Axinl were
highly detected compared to the others (3366,4414 and 3094 ranking out of 41090) and
above tbp reference gene (Figure 3-9).
RGS
Axin1
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Rgs1 r--r~r-~-'--+-~--~~~
-5 -4 -3 -2 -1 023 4
Relative Intensity Values
Figure 3-9: RNA transcript intensity values for RGS classified as "present" in mixed skeletal muscle
generated from two male Wistar rats.
3.5.8.1 Gs and Gj-GPCR-associated signalling proteins
Gas and Gai modulate adenylyl cyclase (AC) activity. This enzyme converts ATP to
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cAMP. Phosphodiesterase (PDE) is an enzyme that terminates cAMP signalling. The
cAMP level modulates protein kinase A (PKA) activity. There are different isoforms of
AC, PKA and PDE. To investigate the relative expression of these genes, microarray
was used.
mRNA encoding adcy2, adcy4, adcy5, adcy6, adcy7 and adcyl0 were classified as
"present" in all skeletal muscle replicates. Adcy2 and adcy6 were highly detected
compared to the others (1061 and 2631, respectively ranking out of 41090) and above
tbp reference gene (Figure 3-10-A).
mRNA encoding pdelb, pde2a, pde4a, pde4b, pdedd, pde7a, pde7b, pde8a, pde9a,
pde 1Oaand pde 11a were classified as "present" in all skeletal muscle replicates. Pde4a,
pde4b and pde4d were highly detected compared to others (8480 ranking out of 410990)
and above tbp reference gene (Figure 3-10-B).
mRNA encoding PKA regulatory subunit al and a2 (Prkarla and Prkar2a) as well as
catalytic (a and p) subunits were classified as "present" in all skeletal muscle replicates.
Prkarla was highly detected compared to the others (6759 ranking out of 41090) and
above tbp reference gene (Figure 3-10-C).
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Figure 3-10: RNA transcript intensity values for AC (A), PDE (B) and PKA subunits (C) and classified as
"present" in mixed skeletal muscle generated from two male Wistar rats.
3.5.8.2 Gq-protein-associated signalling
Gaq activates phospholipase C (PLC). The active PLC hydrolyses phosphatidylinositol
4,5-bisphosphate (P1P2) to produce inositol 1,4,5-trisphosphate (IP3) and 1,2-
diacylglycerol (DAG). DAG can activate protein kinase C (PKC), and IP3 can also
activate 1P3 receptors on the endoplasmic reticulum. Regarding DAG, DAG can be
hydrolyzed into a free fatty acid and monoacylglycerol by diacylglycerol lipase.
Moreover, DAG can be phosphorylated to phosphatidic acid by DAG kinase. Regarding
IP3, 1P3 can be phosphorylated to IP4 by inositol-trisphosphate kinase (itpk) while
inositol phosphate can be dephosphorylated to inositol by inositol monophosphatase
(impa). To investigate the relative expression of these genes, microarray was used.
mRNA encoding pleb3, pleb4, pledl, pled3, pled4, pleel and plcll were classified as
"present" in all skeletal muscle replicates. Pledl and pled4 were highly detected
compared to the others (7286 ranking out of 41090) and above tbp reference gene
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(Figure 3-11-A). mRNA encoding dagla, daglb, dgka, dgkg and dgkz were classified as
"present" in all skeletal muscle replicates. Daglb and dgkz were highly detected
compared to the others (7018 ranking out of 41090) and above tbp reference gene
(Figure 3-11-B). mRNA encodingprkca, prkcb, prkcd, prkce, prkcg, prkch, prkcq and
prkcz were classified as "present" in all skeletal muscle replicates. Prkcd and prkcq
were highly detected compared to the others and above tbp reference gene (10220
ranking out of 41090) (Figure 3-11-C). mRNA encoding IP3 receptors (itprl, itpr2 and
itprJ), IP3 kinase b and c (itpkc and itpkb), impal and impa2 were classified as "present"
in all skeletal muscle replicates. Impal and impa2 were detected in skeletal muscle
compared to tbp reference gene (Figure 3-11-D).
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Figure 3-11: RNA transcript intensity values for PLC (A), OAG related genes (B), PKC (C), and IP3-
related genes (0) classified as "present" in mixed skeletal muscle generated from two male Wi star rats.
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3.5.8.3 G12-protein signalling
Gal2 activates Rho guanine nucleotide exchange factors for the small G protein Rho.
Consequently, Rho-GTP activates many enzymes such as Rho kinases. To investigate
the relative expression of these genes, microarray was used.
mRNA encoding rhoa, rhob, rhod, rhog, rhoq and rock], rock2 were classified as
"present" in all skeletal muscle replicates. Rock] was highly detected compared to the
other (3412 ranking out of 41090) and above tbp reference gene. Rhoa and rhoq were
highly detected compared to others (3188 ranking out of 41090) and above tbp
reference gene.
Rho family and Rho kinase
Rock2
Rock1
Rhoq
Rhog
Rhod_predicted
Rhob
Rhoa
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Figure 3-12: RNA transcript intensity values for low molecular weight G protein (Rho) and Rho-kinase
classified as "present" in mixed skeletal muscle generated from two male Wistar rats.
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3.6 Discussion
Traditional methods for the quantification of gene expression, such as RT-PCR or
Northern blot analysis, focus on a single gene at a time. Therefore, these techniques are
not suitable to determine the relative mRNA expression of GPCRs, G proteins and their
target enzymes in skeletal muscle. Microarrays can be used to study simultaneously the
relative expression of many genes.
3.6.1 Validation of the microarray
The two biological replicates were found to be reproducible since the Pearson
correlations for normalized data for all pair combinations among biological replicate
tissues were above 0.96.
Glut4, Jabp3, ppara and pparg expressions were selected as confirmatory
measurements since their relative expression levels in different tissues have been well
documented in the literature. Glut4 is highly expressed in skeletal muscle and adipose
tissues (James et al., 1989), however, it is not detected in liver (Liu et al., 1992; Rayner
et al., 1994). Fabp3 is not detected in liver and adipose but is highly expressed in
skeletal muscle (Heuckeroth et al., 1987). Ppara is highly expressed in liver and
skeletal muscle with low expression in adipose tissue (Braissant et al., 1996; Lemberger
et al., 1996). Pparg is expressed predominantly in adipose tissue with low expression
seen in liver and muscle (Kiec-Wilk et al., 2005; Vidal-Puig et al., 1997). The findings
of the present study confirmed that: a) glut4 is highly expressed in skeletal muscle and
adipose tissue relative to liver; b) Jabp3 is highly expressed in skeletal muscle and
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negligibly expressed in liver and adipose; c) ppara is highly expressed in liver and
skeletal muscle; and d) pparg is highly expressed in adipose tissue with low expression
seen in liver and skeletal muscle tissue. This gave the microarray data to be valid and
reliable to detect relative mRNA expression of genes in a tissue specific manner.
Slow and fast twitch muscle structural subunit genes mRNA were expressed in skeletal
muscle. This reflects that the dissection has been covered both fast and slow skeletal
muscle fibres. This also indicates that the detected GPCR entities will cover different
types of fibres.
Contraction is one of the primary functions of skeletal muscle, involving cell-surface
acetylcholine receptors and intracellular ryanodine receptors. Release of acetylcholine
at the neuromuscular junction activates nicotinic acetylcholine receptors to cause
skeletal muscle depolarization and contraction. Indeed, ryanodine receptors induce Ca2+
release into the cytoplasm to prolong the contraction.
Nicotinic acetylcholine receptor subunits c l , ~, e, 0 and y genes and ache were detected
in skeletal muscle tissue compared to choline acetyltransferase (chat), vesicular
acetylcholine transporter (slcJ8a3), synaptotagmin I and II (sytl and syt2),
synatophysin (syp) and neurofilaments (light (nejl), medium (ne/m) and heavy (nefh».
This gave evidence for skeletal muscle specific receptor expression and also gave
evidence that less contamination occurred to skeletal muscle from the nerve terminal
during the dissection itself.
In this study, ryrl was highly expressed in skeletal muscle (269 ranking out of 41090)
(Table 3-8). This is in line with what was shown in human and murine skeletal muscle
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(Giannini et al., 1995; Lanner et al., 2010; Sei et al., 1999). Moreover, ryr2 was
predominantely expressed in murine heart muscle and almost all over in the brain
(Giannini et al., 1995). Ryr3 was universally expressed in murine tissues (Giannini et
al., 1995).
It was shown that RyRI is responsible for sarcoplasmic reticulum (SR) depolarization-
induced calcium release. This is supported by the fact that when RyRI deficient skeletal
muscle cells were used, calcium release was mostly eliminated in skinned skeletal
muscle fibres of mice (Ikemoto et al., 1997). However, RyR3 gave a weak SR
depolarization-induced calcium release in skinned skeletal muscle fibres of RyRl
knock-out mice (Endo, 2009; Ikemoto et al., 1997). Therefore, targeting RyRI
selectively might have implications for the contraction of skeletal muscle. The
implication of this is that RyRI might have a role in skeletal muscle contraction,
consequently, it should be recommended to be also investigated as a therapeutic target
for glucose uptake in skeletal muscle.
3.6.2 GPCR expression in skeletal muscle
GPCRs expression was examined in this study using two different techniques, Agilent
microarrayand QRT-PCR (Taqman). Using Agilent microarray, 38 GPCR entities were
found to be expressed in skeletal muscle in this study. These include LPAI
lysophosphatidic acid receptors (endothelial differentiation, lysophosphatidic acid G
protein-coupled receptor, 2 (Edg2», chemokine receptors 4 (CXCR4), glucagon
receptor 2, platelet-activating factor receptors, GABAsl receptors, S1P2 sphingosine-l-
phosphate receptors (endothelial differentiation, sphingolipid G protein-coupled
receptor, 5 (Edg5», parathyroid hormone receptors, mGlu2 and mGlu3 metabotropic
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glutamate receptors, dopamine D, receptors, neurotensin receptor 2, opioid receptor
delta 1, calcitonin receptors 1, arginine vasopressin receptors 1A, bradykinin B2
receptors and C5al complement peptide receptors. However, other GPCR entities can
not be excluded for being expressed in skeletal muscle.
These GPCRs are somewhat less well-known in terms of their activity in the skeletal
muscle system. Relatively little information in the literature is reported in both normal
and disease state about the role of these GPCRs in functional activities and in signal
transduction of skeletal muscle tissues.
The importance of such GPCR patterns detected in skeletal muscle tissue might be
approved in the regulation of several intracellular functions. These functions in skeletal
muscle might include contractile responses, glucose uptake, regulation of metabolism
and skeletal muscle proliferation, differentiation and growth. To date, virtually no
information is available regarding physiological functions, pathophysiological roles,
regulation and gene expression patterns of such GPCRs in skeletal muscle tissues.
As a large number of GPCR entities were discussed in this study, these GPCR entities
were divided in their groups (class A, class B and class C) as described in Chapter One:
G PROTEIN-COUPLED RECEPTORS CLASS A
LPAl lysophosphatidic acid receptors gene mRNA was found to be expressed in a wide
range of different human and mouse tissues including skeletal muscle, heart, brain,
stomach, kidney, spleen, thymus, testis and lung (An et al., 1998; Choi et al., 2010; Ye,
2008). LPAr lysophosphatidic acid receptors were also shown to couple to Gai, Gaq, and
Gal2l13 (Fukushima et al., 1998; Ishii et al., 2000). As skeletal muscle expressed Ipar1in
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this study, it is possible that the activation of LPAI lysophosphatidic acid receptors
affect proliferation and differentiation in skeletal muscle. Therefore, LPAI
lysophosphatidic acid receptor agonists might be considered as a therapeutic target to
improve skeletal muscle mass. This is supported by the fact that I) The activation of
LPAI lysophosphatidic acid receptors by LPA was shown to stimulate proliferation,
migration, and invasion in human colon cancer cell lines (DLD1) which expressed
IparI (Shida et al., 2003).2) Lparl-/- mice were also found to have a higher adiposity
than wild-type mice (Simon et al., 2005). 3) LPAI lysophosphatidic acid receptor
activation reduced the differentiation of mouse 3T3F442A preadipocytes (Simon et al.,
2005). Apart from that potential role, LPAI lysophosphatidic acid receptors might have
a role in glucose uptake. As skeletal muscle expressed lpar 1 in this study, it is also
possible that LPAI lysophosphatidic acid receptors play a role in glucose uptake in
skeletal muscle, and it might be, therefore, considered as a therapeutic option for
diabetes. The implication of this is that LPAI lysophosphatidic acid receptor agonists
should be recommended to be investigated as a therapy to treat diabetes. This is
probably due to the fact that LPA was shown to stimulate GLUT4 translocation and
glucose uptake in 3T3-Ll adipocytes and L6 GLUT4myc myotubes which expressed
LPAI lysophosphatidic acid receptors (Yea et al., 2008), and acute administration of
LPA in mice was also shown to cause a fall in blood glucose level (Yea et al., 2008).
Regarding another GPCR, GPCR activators such as chemokines, a large family of 8 to
10-kd cytokines or proteins, act as chemoattractants (Luster, 1998). The activation of
chemokine receptors by chemokines lead to activation of phospholipases through G
proteins which yield to an increase in IP3, the release of calcium and the activation of
protein kinase C (Luster, 1998). Moreover, chemokines were also shown to activate the
Ras and Rho families (Laudanna et al., 1996). Chemokines such as SDFla, stromal
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cell-derived factor-l alpha, can bind to specific GPCRs such as CXCR4 (Gi or Gq
coupled). Indeed, cxcr4 was detected in skeletal muscle in this study. This is consistent
with cxcr4 was expressed in skeletal muscle satellite cell lines (Ratajczak et al., 2003).
As skeletal muscle expressed cxcr4 and sdfla (1277 ranking out of 41090) in this study,
it is possible that CXCR4 in skeletal muscle plays a role in migration during
myogenesis which is essential for skeletal muscle growth and regeneration. This is
suggested due to the fact that it was shown that SDFla enhances migration and
proliferation of the immortalized C2C12 muscle cell line (Odemis et al., 2007), and
chemokines were also suggested to be important for muscle precursor cells in the
migration during myogenesis (Vasyutina et al., 2005). Therefore, CXCR4 agonists
might be recommended to be examined as a therapeutic option to improve skeletal
muscle myogenesis, growth and to treat skeletal muscle regeneration disorders.
Platelet activating factor (PAF) receptors are thought to couple via Gq protein and
activate PLC which leads to calcium release and increase in DAG (Deo et al., 2004;
Izumi et al., 1995; Shimizu et al., 1992). PAF is a phospholipid activator with several
physiological functions such as being a mediator of inflammation. Moreover, PAF is
released from cells such as macrophages, basophils, monocytes and polymorphonuclear
neutrophils. PAF response might be mediated through PAF receptors. As it was
suggested that binding of PAF to its PAF receptors will be involved in its biological
function such as inflammation, and PAF receptors gene mRNA was expressed in
skeletal muscle in this study, it is possible that PAF receptors might have an
inflammatory role in skeletal muscle. Therefore, therapeutic intervention by PAF
receptor antagonists might be useful to decrease inflammation in skeletal muscle.
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Apart from that potential role, PAF receptors might have a role in proliferation. As
skeletal muscle expressed ptafr in this study, it is possible that PAF receptors might
have a role in proliferation and differentiation in skeletal muscle through modulation
mitogen-activated protein (MAP) kinase activity. This is supported by the fact that it
was shown that stably transfected cells (Chinese Hamster Ovary Cells) with PAF
receptors activate MAP kinase and MAP kinase kinase when these cells were exposed
to PAF (Honda et al., 1994), and it was also shown that PAF induced growth
stimulation and inhibition in a dual manner in rat fibroblasts over-expressing PAF
receptors (Kume et al., 1997). The implication of this is that PAF receptors should be
recommended to be investigated as a therapeutic option for skeletal muscle growth.
SIP2 sphingosine-l-phosphate receptors (sJpr2 (edg5)) gene mRNA was expressed in
C2CI2 myoblast and myotubes (Meacci et al., 2003). SIP2 sphingosine-l-phosphate
receptors were also shown to couple to Gai, Gaq, and GaJ2IJ3(Jiang et al., 2007). As
skeletal muscle expressed sJpr2 in this study, and SIP was also shown to inhibit C2CI2
proliferation and stimulate myogenic differentiation through activation of ERKIIERK2
and p38 MAPK via SIP2 sphingosine-l-phosphate receptors (Donati et al., 2005), it is
possible that SI P2 sphingosine-l-phosphate receptors affect proliferation and
differentiation in skeletal muscle. The implication of this is that SI P2 sphingosine-l-
phosphate receptor agonists should be examined as a potential therapeutic option to
stimulate skeletal muscle growth and lean weight gain.
Another GPCR that needs attention is dopamine D, receptor (drd5). Dopamine
receptors are classified into two groups, namely Dr-like and Drlike receptors; the DJ
receptor/Ds receptor group (Dj-like) and the D2 receptor/D, receptorID4 receptor group
(Dj-Iike) are based on their molecular structures, physiological functions and
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pharmacological activities. Dr-like receptors are positively coupled to adenylyl cyclase
via heterotrimeric Gs protein activation and the formation of cAMP while the D2-like
receptors are mainly coupled to Gj which negatively modulates cAMP generation by
inhibiting the activity of adenylyl cyclase (Herve et al., 1993; Strange, 1993). Indeed, it
was shown that the dopamine Dl and dopamine D, receptors mediate the anti-atrophy
.effects of the dopamine 115 receptor after the treatment of skeletal muscle with selective
dopamine D dDs receptor agonist, SKF 81297, through an increase in skeletal muscle
cAMP (Reichart et al., 2011). Moreover, levodopa with carbidopa «L-3,4-
dihydroxyphenylalanine (L-DOPA), the precursor to the dopamine)), was also shown to
diminish glycogen synthase activity, glycogen concentration and insulin-stimulated
glucose transport in rat skeletal muscle, possibly through intervening insulin-stimulated
tyrosine phosphorylation of insulin receptor substrate (IRS)-1 (Smith et al., 2004).
Furthermore, drd5 was detected in skeletal muscle in this study. In sum, it is possible
that dopamine Ds receptor might have multiple roles in skeletal muscle including
glucose uptake and skeletal muscle growth. Further investigation should be
recommended to examine dopamine D, receptor agonists as a therapeutic target to treat
skeletal muscle regeneration disorders and to examine dopamine D, receptor
antagonists as a therapeutic target to treat diabetes.
Neurotensin (nts) receptor 2 (Ntsr2) gene mRNA was expressed in mouse and rat brain
(Chalon et al., 1996; Sarret et al., 1998; Walker et al., 1998). Nts-stimulated ERK1I2
was shown in rat cultured cerebellar granule cells expressing nts receptor 2 (Gendron et
al., 2004; Sarret et al., 2002). Neurotensin is a 13 amino acid neuropeptide released
from the brain. The activation of nts receptors 2 with SR48692 and SR142948A, nts
receptor 1 antagonist and nts receptor 2 agonist respectively, was found to stimulate the
MAP kinase activity and trigger inositol phosphate accumulation and calcium
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mobilization in Chinese hamster ovary cells (CHO) expressing human nts receptor 2
(Vita et al., 1998). Indeed, skeletal muscle expressed ntsr2 in skeletal muscle in this
study. It is possible that nts receptors 2 might playa role in proliferation, differentiation
and contraction in skeletal muscle. Therefore, it is recommended to investigate the nts
receptor 2 agonists as a pharmacological option to stimulate lean weight gain and
skeletal muscle growth.
Opioid receptors couple to Gj protein (Law et al., 2000). Activation of opioid receptors
delta 1 was also shown to increase intracellular calcium levels in neuroblastoma x
glioma hybrid NG108-15 cells (Jin et al., 1992), and to stimulate ERK1I2 activity in rat
fibroblasts and human embryonic kidney (HEK) cells, expressing opioid receptors delta
1 (Burt et al., 1996; Schulz et al., 2004; Tso et al., 2000). Indeed, skeletal muscle
expressed opioid receptors delta 1 (oprdJ) in this study. It was also reported that the
density of opioid receptors delta 1 was found to be higher in muscles from obese
diabetic mice compared to normal mice using autoradiography (Evans et al., 1995;
Evans et al., 1996). It was also shown that beta-endorphin, a non-selective endogenous
opioid receptors ligand, increased the glucose uptake in soleus muscles taken from lean
male mice via opioid receptor delta 1 (Evans et al., 2001), and increased glucose uptake
in resting and contracting skeletal muscle (Evans et al., 1997). Indeed, beta-endorphin
was found to be released into the circulation during exercise (Carr et al., 1981; Goldfarb
et al., 1997). Taken together, it is possible, therefore, that these opioid receptors delta 1
might be important for maintaining muscle function during exercise through beta-
endorphin, and might also be involved in glucose uptake, differentiation and growth in
skeletal muscle. Therefore, it is possible that the opioid receptors delta 1 agonists might
be considered as a therapeutic option for diabetes and skeletal muscle regeneration
disorders.
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Arginine vasopressin (AVP) receptor lA (avprla) gene mRNA was expressed in
skeletal muscle in this study. This is consistent with avprla was shown to be expressed
in human skeletal muscle tissue, and was also shown to be expressed significantly
higher in proliferating myoblasts than in differentiated myotubes in rat L6C5 myogenic
cells (Alvisi et al., 2008; Thibonnier et al., 1996).
AVP was shown to induce myogenic differentiation of rat L6 cells and mouse satellite
cells (Nervi et al., 1995). Moreover, the effects of AVP could be mediated through the
Arginine vasopressin receptors lA which were found to couple to Gq in CHO cells
(Briley et al., 1994). Arginine vasopressin receptors 1A overexpressed in mouse
skeletal muscle in mice was also shown to exhibit significantly increased expression of
differentiation markers such as Pax7, embryonic-MHC and myogenin and to accelerate
the activation of satellite cells compared to mock-transfected mice (Toschi et al., 2011).
Taken together, these data suggest a potential role of this receptor in induction of
myogenic differentiation and that could be involved in the regulation of myogenesis in
skeletal muscle. Therefore, further investigation is recommended to examine this
receptor as a potential therapeutic target for diseases characterized by altered muscle
regeneration.
Another GPCR that needs attention is bradykinin B2 receptor, bradykinin exerts its
effect on two subtypes of Gq-GPCR, namely bradykinin B1 and B2 receptors (Leeb-
Lundberg et al., 2005). Bradykinin B2receptor (bdkrb2) mRNA was detected in skeletal
muscle in this study. This is consistent with the bradykinin B2 receptor was found to be
detected on the plasma membrane of skeletal muscle cells of the rat hindlimb (Figueroa
et al., 1996), and it was also reported that bradykinin B2 receptors were expressed in
guinea pig skeletal muscle tissue (Rabito et al., 1996).
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As bdkrb2 was detected in skeletal muscle in this study, it is possible that bradykinin B2
receptors might playa role of insulin resistance and glucose uptake in skeletal muscle,
and therefore bradykinin B2 receptor agonists be recommended to be investigated as a
therapeutic target for diabetic patients. This is supported by the fact that chronic in vivo
administration of bradykinin was shown to significantly improve whole body glucose
tolerance in the severely insulin resistant obese Zucker rat which was suggested to be a
result of the enhanced insulin-stimulated skeletal muscle glucose uptake (Henriksen et
al., 1998), and bradykinin B2receptor knockout mice was also shown to have impaired
insulin-dependent glucose transport (Duka et al., 2001). Apart from that potential role,
bradykinin B2receptor might have an inflammatory role. Bradykinin, a nine amino acid
polypeptide, is one of various inflammatory mediators released from inflamed tissues
after tissue injury to mediate the inflammatory process (Dray et al., 1993). As
inflammatory muscle pain was shown to be associated with the up-regulation of both
bradykinin Bland B2 receptors which contributed to mechanical hyperalgesia in
inflammatory muscle pain in male Swiss mice (Meotti et al., 2012), and bdkrb2 was
also detected in skeletal muscle in this study, it is possible that bradykinin B2 receptors
might play a role in inflammatory skeletal muscle pain. Therefore, antagonizing
bradykinin B2receptors in skeletal muscle might be considered as a therapeutic target
for pain management.
With regard to another GPCR, C5al complement peptide receptors gene mRNA was
reported to be expressed in monocytes, neutrophils, esinophils and basophils, and it was
also shown that c5ar 1 was expressed in human liver and HepG2, lung cells, astrocytes
and microglia cells (Haviland et al., 1995; Lacy et al., 1995). It was also shown that
c5arl was up-regulated in injured human skin and rat burn injury (Greco et al., 2010;
Yang et al., 2007) and up-regulated in casting and tenotomy-induced muscle atrophy in
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male mice (Bialek et al., 2011). Indeed, skeletal muscle expressed c5ar} in this study.
Taken together, it is possible, therefore, that the C5al complement peptide receptors
playa role in skeletal muscle injury, wound pathophysiology and growth. However,
little information in the literature was reported about the role of C5al complement
peptide receptors in skeletal muscle. Apart from that potential role, C5al complement
peptide receptors might have a role in obesity. It was also reported that c5ar} was up-
regulated from omental adipose in obese human being compared to normal human
being using gene expression micro array (Gomez-Ambrosi et al., 2004). It is possible,
therefore, that C5al complement peptide receptors in skeletal muscle might be
investigated as a therapeutic target for obesity. The implication of this is that C5al
complement peptide receptor antagonists should be investigated to decrease weight, to
improve skeletal muscle growth and wound healing.
G PROTEIN-COUPLED RECEPTORS CLASS B
Glucagon receptor (Gcgr) gene mRNA were expressed in multiple tissues at relatively
high levels such as liver, kidney, heart, adipose tissue and at relatively low level in rat
skeletal muscle tissue (Hansen et al., 1995). Glucagon, which is secreted from the alpha
cells of the pancreas, exerts its effects by binding to the glucagon receptors. Glucagon
receptors are known to couple to Gs, Gj and Gq (Jiang et al., 2003a; Mayo et al., 2003).
Coupling to G, will activate AC and increase cAMP level, and then the elevation of
cAMP level will activate PKA which lead to the phosphorylation of many proteins in
the liver involved in glycogenolysis (such as glycogen phosphorylase kinase, glucose-e-
phosphatase and glycogen synthase), gluconeogenesis (such as phosphoenolpyruvate
carboxykinase (PEPCK) and glucose-e-phosphatase) and glycolysis (such as pyruvate
kinase) (Jiang et al., 2003a). The two splice variant glucagon receptor transcripts has
been reported in rat tissues, however the physiological significance of these transcripts
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remain unclear. Little is known about the glucagon receptors in skeletal muscle.
However, antagonizing glucagon action through the glucagon receptors, which was
expressed in skeletal muscle in this study, might provide avenue for a therapeutic option
for diabetes.
Apart from that potential role, glucagon receptors might activate ERK in skeletal
muscle. As Gcgr was expressed in skeletal muscle in this study, it is possible, therefore,
that glucagon receptors might affect proliferation and differentiation through ERK
activation or contraction through calcium release in skeletal muscle. This is probably
due to the fact that glucagon was also shown to activate ERK1I2 in Human Embryonic
Kidney (HEK) cells expressing human glucagon receptor (Jiang et al., 2001) and
glucagon was also shown to mediate calcium rise in baby hamster kidney cells (BHK)
expressing human glucagon receptor (Hansen et al., 1998). The implication of this is
that glucagon receptors might be recommended to be investigated as a therapeutic target
for skeletal muscle growth and contraction.
It is worth noting that glucagon receptor might preferentially couple to Gus, but it also
couples to other G-proteins. Although most GPCRs can activate more than one Ga-
subtype, each GPCR shows preferential coupling to one subtype over another such as
Gs, G, and Gq• Consequently, the defined Ga-subtype activates specific downstream
signalling pathway (Alexander et al., 2012). This phenomenon might be defined by
ligands under experimental or physiological conditions since the ligands induce
conformational changes in the receptor. However, there is no evidence in the literature
weather the overexpression is related to this phenomenon.
Parathyroid hormone (PTH) receptors 1 (pthr 1) gene mRNA was abundantly expressed
in rat kidney and bone tissues, and it was also expressed in many other rat tissues
128
including skeletal muscle, ovary, placenta, aorta, adrenal gland, bladder, brain,
cerebellum, breast, heart, ileum, liver, lung, placenta, skin, spleen, stomach, uterus, and
testes (Lee et al., 1996; Tian et al., 1993; Urena et al., 1993). Moreover, PTH receptors
1 are thought to couple to Gs, Gq, G, and GI2 (Mahon et al., 2006; Plati et al., 2007;
Singh et al., 2005). Indeed, skeletal muscle expressed Pthrl in this study. Overall, it is
possible that PTH receptors 1 modulate cAMP and calcium release in skeletal muscle
tissue which might be important for muscle growth and contraction as discussed
previously. The implication of this is that PTH receptors 1might be recommended to be
investigated to improve contraction-stimulated glucose uptake, consequently the PTH
receptors 1 agonist might be used to treat diabetes.
Calcitonin receptor (Caler) was shown to be linked to adenylyl cyclase and
phospholipase C (Poyner et al., 2002). Calcitonin is released from the parathyroid
glands and its inhibitory effect on bone resorption is caused by the activation of
calcitonin receptors in mature osteoclasts (Poyner et al., 2002). Caler was shown to be
expressed in mature rat and human osteoclasts (Chen et al., 2004; Nicholson et al.,
1986). However, this receptor was not detected in osteoclast progenitor cells, but the
expression of this receptor increased during mouse and rat osteoclast differentiation
(Quinn et al., 1999). Caler was also found to be expressed in mice and human satellite
cells (Fukada et al., 2007; Gnocchi et al., 2009; Yamaguchi et al., 2012). As caler was
expressed in skeletal muscle in this study, it is possible that calcitonin receptor might
play a role in proliferation in skeletal muscle which might be important for skeletal
muscle growth. This is supported by the fact that the activation of the calcitonin
receptors was shown to increase ERK1I2 activity in HEK cells expressing calcitonin
receptors (Chen et al., 1998), and it was also reported that calcitonin receptor protein
expression was down-regulated on activated satellite cells (Fukada et al., 2007).
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Therefore, calcitonin receptor agonists should be recommended to be investigated as a
therapeutic option to improve skeletal muscle growth.
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G PROTEIN-COUPLED RECEPTORS CLASS C
With regards to another GPCR, GABAB1 receptors (Gabbrl) gene mRNA was
expressed in human and rat brain (Berthele et al., 2001; Bischoff et al., 1999). It was
also reported to be expressed in peripheral rat tissues including testis, ovary, urinary
bladder, heart, spleen, liver, small intestine, large intestine, lung, kidney and stomach
(Castelli et al., 1999). Indeed, GABABI reeceptors were found to inhibit and activate
adenylyl cyclase activity via the G, and Gpysubunits (Hashimoto et al., 1997). Moreover,
Gabbrl was also expressed in skeletal muscle in this study. Taken together, it is
possible that GABABI reeceptors decrease cAMP level which might be important for
skeletal muscle growth. This is supported by the fact that it was demonstrated that
modulation of skeletal muscle cAMP levels by inhibition of phosphodiesterases (PDEs)
or activation of P2-adrenoceptors increase rodent skeletal muscle mass (Hinkle et al.,
2005; Hinkle et al., 2002). However, the mechanism behind this is still unclear.
Therefore, GABABI receptor agonists might be considered to be investigated to improve
skeletal muscle growth in rats.
Metabotropic glutamate receptors are classified into group I (mfllu, and mfllu,
metabotropic glutamate receptors), group II (mGlu2 and mGlu3 metabotropic glutamate
receptors) and group III (mGIll4, mGlll6, nrGlu» and mGlu8 metabotropic glutamate
receptors) based on signal transduction and sequence homology. mGlu2 and mGlu,
metabotropic glutamate receptors (grml and grm3) gene mRNA was expressed in rat
neurons (Parmentier et al., 1996; Tanabe et al., 1992; Tanabe et al., 1993). The action
of glutamate can also exert through mGlu2 and mGlu3 metabotropic glutamate receptors.
As skeletal muscle expressed grm2 and grm2 in this study, and mGlu2 and mGluJ
metabotropic glutamate receptors were also found to couple predominantly to G,
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proteins (Niswender et al., 2010; Parmentier et al., 1996), and mGlu2 metabotropic
glutamate receptors was also found to inhibit adenylyl cyclase in CHO cells, it is
possible that mGlu2 and nrGlu, metabotropic glutamate receptor decrease cAMP level
in skeletal muscle which might be important, as discussed previously, for skeletal
muscle growth.
Regarding 38 CPCRs detected in skeletal muscle in this study, three main families of
GPCRs (Gs, Gj and Gq) were detected in skeletal muscle tissue using the microarray.
Examples include Gs-GPCR (~-adrenoceptor, A2Aadenosine receptors), Gj-GPCR (AI
adenosine receptor and NPY YI receptor) and Gq-GPCR (P2YI and P2Y2 receptors).
These GPCRs will be investigated in this study for further signalling and functional
roles in skeletal muscle. The discussion of these receptors will be found in the next
chapter.
Regarding the other GPCRs which were detected in skeletal muscle using QRT-PCR,
adra2a mRNA were detected in QRT-PCR (Taqman) and these agreed with the
microarray. GPR40 mRNA was not detected in QRT-PCR (Taqman) and this agreed
with the microarray. CBI mRNA was also detected using QRT-PCR (Taqman).
However, it was classified as "marginal" in the microarray. This did not contradict with
the reliability of the microarray data since it was reported that the validation did not
often result in agreement between microarray and QRT-PCR data (Morey et al., 2006).
Moreover, GPR119 was detected using QRT-PCR (Taqman) at high Ct values (Ct-32-
35, low expression). It also agreed with the microarray that detected GPR119 at ranking
-25000. So, in general, the intensity values from the microarray agreed with Ct values
from QRT-PCR (Taqman) except with cnrl. Finally, cnrl, gpr119 and adra2a were
detected in skeletal muscle tissue and will be investigated in this study for further
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signalling and functional roles in skeletal muscle. The discussion of these receptors will
be also found in the next chapters.
With the recognition of detected GPCRs mRNA relative expression and their
downstream associated signalling partner genes, it is possible to understand the
signalling of GPCRs in skeletal muscle tissues. GPCRs, in general, can be linked to
ubiquitous downstream effectors. Such receptor signalling systems can also offer
alternative therapeutic approaches. Therefore, the expression of these GPCR signaling
partners will be discussed in the following section.
3.6.3 GPCR signalling partners
GPCR responses can be controlled through signalling proteins such as 0 proteins,
protein kinases, phospholipases, etc. When ligands bind to GPCRs, GPCRs transduce a
specific signal through a second messenger inside the cells. This raises the question of
how the specific signal can be produced.
One possible way to raise the specificity of the response is by determining specific
isoforms of signalling protein expressed in that tissue. GPCR signalling partner protein
gene expression was examined in skeletal muscle. Little has been reported about mRNA
expression of GPCR signalling partner genes in skeletal muscle.
All of the main G protein alpha subunits (gnas, gnai and gnaq) genes were classified as
"present" in skeletal muscle at different intensity values in this study. Gnas was found
to be high expressed compared to gnai, gnaq, gnall and gna12. However, the
microarray data can not exclude or include the mRNA expression of OJ, Oq, Gil and GI2
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genes, as described in Section 1.3.6. Indeed, this is in line with another study that
showed that mouse skeletal muscle expressed gnas, gnai2 and gnai3 (Suzuki et al.,
1998).
As gnas was expressed in skeletal muscle in this study (Figure 3-8-A), it is possible that
the Gs signalling cascade affects skeletal muscle phenotypes. This is suggested due to
the fact that Gai2 overexpression was shown to cause a switch to slow fibre phenotypes
(Minetti et al.), and G, knockout mice were found to have more slow-twitch fibres than
littermate controls (Chen et al., 2009). However, the mechanism is still unclear. The
implication of this is that antagonizing Gs protein should be recommended to be
investigated to increase slow fibre phenotype which is useful in insulin resistance in
skeletal muscle as described previously in Chapter one.
Gnbl, gnb2, gnb5, gng5, gnglO and gngl2 were expressed in skeletal muscle in this
study (Figure 3-8-B, C). mRNA encoding beta and gamma G protein subunits including
gnbl, gnb2, gnb5, gngJO and gngJ2 were expressed in different areas in rat brain (Betty
et al., 1998). Indeed, it is possible that different isoforms expressions might bind to G
alpha subunit which might give a specificity of G protein signalling, G protein-receptor
interaction or different cross-talk with other signalling. However, little in the literature
is reported about the roles of these specific isoforms.
GPCR signalling can be regulated by a further class of proteins, RGS proteins. RGS are
proteins that act as GTPase accelerating proteins for G alpha subunit (De Vries et al.,
2000; Sierra et al., 2000). One mechanism through which RGS control the signalling of
G protein is substrate specificity. The specificity for RGS could also regulate certain
GPCRs pathways. For example, RGS2 seems to act on Gq over Gi preferentially
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(Hubbard et al., 2006). Indeed, the recognition of tissue-specific distribution for ROS is
of great importance.
Rgs2, rgs5 and axinl were expressed in skeletal muscle in this study (Figure 3-9). Rgs5
agrees with studies in the literature in human skeletal muscle and heart using northern
blot (Chen et al., 1997a; Seki et al., 1998). This is in line with a previous study that
reported that rgs2 mRNA was detected in rat skeletal muscle, liver, kidney, heart,
spleen and testis (Miles et al., 2000). Axinl was also reported to be expressed in mouse
tissues including testis, lung, heart, kidney, brain, ovary, spleen and liver (Zeng et al.,
1997). Moreover, it was reported that rgs3, rgs5, rgs9, rgsll, rgsl2 and rgsl6 were
detected in human skeletal muscle (Lanninie et al., 2004).
As rgs2 was expressed in skeletal muscle in this study (Figure 3-9), and the specificity
for ROS2 seems to act on Oq over Oi preferentially (Hubbard et al., 2006; Ingi et al.,
1998), it is possible that ROS2 affect OPCR (Oqprotein family), such as P2Y receptors
which were expressed in skeletal muscle (Table 3-7), and consequently, the signalling
of Oq-OPCRs might affect IP3 concentration, calcium level in the skeletal muscle and
finally affect contraction.
G! and Gj-GPCRs associated signalling partner genes
Major signalling genes for G, and OJ-OPCRs were detected at different intensity values.
G, and G, modulate adenylyl cyclase, which are important in catalyzing the conversion
of ATP to cAMP. Adey2 and adey6 were expressed in skeletal muscle (Figure 3-1O-A).
This is in line with that adey2 and adey6 mRNA expression were detected in mouse
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skeletal muscle (Suzuki et al., 1998). Deletion of AC6 was performed in mouse,
nothing was reported about obvious skeletal muscle phenotypes (Tang et al., 2008).
As adcy2 and adcy6 were expressed in skeletal muscle (Figure 3-1O-A), it is possible
that AC2 and AC6 were activated by OPCRs signalling pathways from Os, OJ, and Oq
through uncoventional mechanism. Furthermore, the response for OPCRs might also be
determined by specific isofonns of AC expressed in skeletal muscle. This is supported
by the fact that 1) Purification of recombinant AC2 from Sf9 cell membranes was
activated by OPr (Taussig et al., 1993) and AC2 was also activated by PKC in HEK-
293 cells transfected with recombinant AC2 (Lustig et al., 1993).2) Recombinant AC6
expressed in insect cells (Hi-5 cells) was inhibited by PKA (Chen et al., 1997c), and
recombinant AC6 expressed in S121 cells was also inhibited by PKC (Lai et al., 1999).
3) Of3ysubunit increased AC2 activity while it decreased ACI activity in membranes
from Sf9 cells infected with ACI or AC2 (Tang et al., 1991).
cAMP production can be stopped through inhibition of AC or activation of the OTPase
function of the Os protein. Termination of cyclic nucleotide signalling is mediated by a
family of enzymes, called PDEs. This family can hydrolyze 3'5'-cyclic guanosine
monophosphate (cOMP) and/or cAMP, depending on the particular subfamily.
Knowing the isofonn expression in skeletal muscle could allow selective enhancement
of cyclic nucleotide levels through the use of PDE isoforrn-selective inhibitors. PDE2,
PDE4, PDE7 and PDE8 selectively hydrolyze cAMP, PDE9 selectively hydrolyzes
cOMP and PDEI hydrolyzes both cOMP and cAMP (Lewis et al., 2006). Pde4a, Pde4b
and Pde4dwere expressed in skeletal muscle in this study (Figure 3-10-B). Indeed, high
mRNA expression of PDE4B was found in human skeletal muscle using microarray
(Bingham et al., 2006). It was also reported that PDE4 subtypes were all inhibited by
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rolipram, PDE4 inhibitors (Wang et al., 1997).
As pde4 is expressed in skeletal muscle in this study (Figure 3-10-B), and PDE4
inhibitors such as roflumilast have recently been approved for chronic obstructive
pulmonary disorder, it is possible that PDE4 inhibitors may reduce skeletal muscle
atrophy in a manner similar to Gsprotein-coupled receptor activation (Pradrenoceptor).
Indeed, PDE4 might have implications in muscular disorders such as muscular
dystrophy (Hinkle et al., 2005). Indeed, rolipram, a selective PDE4 inhibitor, was found
to prevent the mouse skeletal muscle weakness and wasting with limb casting and
sciatic nerve resection (Hinkle et al., 2005). Furthermore, PDE activity was observed to
be higher in skeletal muscle of dystrophic mice (Bloom, 2005; Lin et al., 1976). Indeed,
PDE4 was reported to contribute to the major cAMP hydrolyzing activity in mouse
skeletal muscle (Bloom, 2002). Overall, this suggests that imbalance between cAMP
degradation and production in skeletal muscle might cause harmful effects on the
signalling cascades related to skeletal muscle fibre atrophy. Therefore, PDE4 should be
recommended as a therapeutic option for skeletal muscle growth. The implication of
this is that PDE4 inhibitors should be investigated to treat skeletal muscle dystrophy.
cAMP exerts the majority of its effects through the protein kinase PKA, which is made
up of regulatory and catalytic subunits. Regulatory subunits include RIa, RIp, RIIa and
RIIP subunits, while catalytic subunits comprise Co, Cp, and Cy. Each subunit is
encoded by a unique gene. In this study, PKA regulatory (subunit al) subunit is
expressed in skeletal muscle (Figure 3-9-B).
The expression of regulatory subunit al and a2 agrees with the literature regarding the
expression of these genes in rat and mouse skeletal muscle (Burton et al., 1997; Morita
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et al., 1995). The beta and gamma isoforms were also reported to be expressed in brain,
testis and adipose (Brandon et al., 1997). Moreover, mRNA and protein expression of
both RIa and Ca were found to be detected in mouse embryonic skeletal muscle
(Imaizumi-Scherrer et al., 1996) and RIa mRNA was also expressed in soleus muscle
(Hoover et al., 2001).
RIa was suggested to functionally compensate the RIIa in mouse skeletal muscle
deficient RIIa through the analysis of L-type calcium channel regulation (Burton et al.,
1997). There is no PKA subunit knockout reported in animals. However, mutant
Prkar Ia in embryonic stem cells and in liver tissue was shown to produce a dominant
negative RIa regulatory subunit (RIa) which leads to decrease in PKA activity (Willis et
al., 2011). Indeed, further investigation should be recommended to examine whether
Prkarla is the main subunit responsible for the PKA activity in skeletal muscle.
Since pde4 and adcy6 were expressed in skeletal muscle, it is possible that PKA might
be an important regulator of cAMP concentration in this tissue. This is supported by the
fact that PKA was found to phosphorylate and activate human PDE4D in COSI-cells
(Hoffmann et al., 1998; Houslay et al., 2003), and recombinant AC6 expressed was
inhibited by PKA (Chen et al., 1997c). Therefore, PKA might be considered as a
therapeutic option to modulate cAMP in skeletal muscle, consequently PKA should be
recommended to be investigated as a therapeutic option for skeletal muscle growth as
discussed previously.
Qg-GPCRs associated signalling partner genes
Major signalling genes associated with Gq-GPCRs were expressed at different relative
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intensity values. PLC isozymes, depending on the structure, are classified into six
families (~, 'Y, a, E,~, T), where the ~ family are the primary targets for Gq•
Pled1 and pled4 were expressed in skeletal muscle (Figure 3-10-A). Regarding pled1
expression, this is in line with pled1 was expressed in mouse, rat and human skeletal
muscle tissue (Cheng et al., 1995; Homma et al., 1989; Lee et al., 1999). Moreover, the
nuclear accumulation of PLCa 1was reported to be affected by calcium in Madin Darby
canine kidney (MDCK) cells stably expressing OFP-PLCal (Fujii et al., 1999; Okada et
al., 2005; Yagisawa, 2006). However, the mechanism behind this issue is not known yet.
PLCal activity, purified from the cytosolic fraction of bovine brain, was also shown to
be stimulated by bovine brain GJ3y(Park et al., 1993). Therefore, Pl.Cddl might cross-
talk to other conventional GPCR signallings. Pled4 was expressed in skeletal muscle in
this study. This is consistent with that pled4 was detected in normal human tissues,
including skeletal muscle and kidney tissues using northern blot analysis (Leung et al.,
2004). Pled1 and pled4 were also shown to be expressed in proliferating hepatoma cells
(Santi et al., 2003). As pled4 was expressed in skeletal muscle (Figure 3-10-A), and
overexpression of PLCa4 was shown to activate ERK112 in breast cancer cell line
(MCF-7 cells) (Leung et al., 2004), it is possible that PLCa4 in skeletal muscle will
activate ERK which possibly affects proliferation in skeletal muscle cells. Therefore,
the implication of this is that PLCo4 should be recommended to be investigated as a
therapeutic option for skeletal muscle regeneration. To examine this issue, knockout
mice should be recommended to investigate the effects of PICol and PICa4. Overall,
major regulation of OPCRs might be directed depending on PLC isoforms expressed in
tissues. Little in the literature is reported about the role of these isoforms.
Regarding PLC signalling, the active PLC hydrolyzes phosphatidylinositol 4,5-
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bisphosphate (PIP2) to produce inositol 1,4,5-trisphosphate (lp)) and 1,2-diacylglycerol
(DAG). Indeed, DAG activates protein kinase C (PKC).
DAG levels can be regulated by phosphorylating DAG by Diacylglycerol kinase (DGK)
to form phosphatidic acid, then allowing the recycling of phosphatidic acid into
membrane phospholipid. It was suggested that DGK isoforms might have substrate
specificity in vivo through subcellular location (van Blitterswijk et 01.,2000). Dgkz was
expressed in skeletal muscle (Figure 3-10-B). This agrees with the literature regarding
dgkz mRNA expression in mouse skeletal muscle (Chibalin et al., 2008). Indeed,
endogenous and green fluorescent protein-tagged overexpressed DGK~was found to be
localized mostly to the nucleus compared to overexpressed DGKa, DGKp, and DGKI
in mouse C2Cl2 cells (Evangelisti et 01.,2006). Down-regulation of Dgkz by siRNA in
C2Cl2 was shown to markedly impair differentiation (Evangelisti et 01.,2006). Taken
together, this isoform (DGK~) might have a different signalling pathway and substrate
specificity from the other isoforms in skeletal muscle. Moreover, it is possible that
DGK~ might play a role in skeletal muscle growth. Further work is recommended to
investigate subcellular location of DGK~ in skeletal muscle using tagged overexpressed
protein and immunofluorescent imaging and to investigate its role in differentiation and
proliferation process.
DAG can be hydrolyzed into a free fatty acid and monoacylglycerol by diacylglycerol
lipase. Indeed, diacylglycerol (DAG) lipase is a key enzyme in the biosynthesis of the
endocannabinoid, 2-AG. It is worth noting that two DAG lipase isozymes were cloned;
DAGLa and DAGLp (Bisogno et al., 2003). Daglb was expressed in skeletal muscle
(Figure 3-10-B). Moreover, protein expression of DAGLa and DAGLp have been
reported to be expressed in mouse brain (Bisogno et al., 2003). However, little in the
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literature is reported about the roles of these proteins. .
Regarding PKC, mRNA expression for each gene isoform usually differs among tissues.
Prkcd and prkcq were expressed in skeletal muscle (Figure 3-10-B). This is consistent
with Prkcd was expressed in rat primary skeletal muscle and differentiated rat L6 cells
at the level of RNA and protein (Horovitz-Fried et al., 2006). Moreover, prkcq was
reported to be the most abundantly expressed PKC isoform in mouse skeletal muscle
(Osada et al., 1992).
As prkcq was expressed in skeletal muscle (Figure 3-11-C), it is possible that activation
of PKCe by GPCR expressed in skeletal muscle plays a role in insulin resistance and
glucose metabolism. This is probably due to the fact that PKCe protein expression was
shown to be higher in insulin-resistant fast muscle fibres than slow muscle fibres
(Donnelly et al., 1994) and transgenic mice with dominant negative PKCe in skeletal
muscle were found to have hyperglycemia, hyperinsulinemia and gain weight (Serra et
al., 2003). The implication of this is that PKCe might be investigated as a therapeutic
option for diabetes and obesity.
Regarding Gq-GPCR signalling, inositol phosphate can be dephosphorylated to inositol
by an enzyme called inositol monophosphatase (IMPA). IP) receptors (itprl, Upr2 and
itpr3), IP) kinase band c (itpkc and itpkb), impal and impa2 were classified as "present"
in all skeletal muscle replicates. However, no obvious differential relative expression
was observed among different types of IP) receptors, IP) kinases and IMPA isoforms. It
is worth mentioning that IP3 receptors sequences are provisional in rats. Further
investigation should be recommended to examine these IP) receptors using DNA
sequencing, QRT-PCR (Taqman) and immunoblotting. ImapJ and imap2 were
expressed in skeletal muscle in this study (Figure 3-10-D). mRNA and protein
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expressions of both IMPAI and IMPA2 were shown at different levels in different areas
in mouse brain (Sjoholt et al., 2000; Willsky et al., 2006). However, little in the
literature was reported about the different roles of these isoforms.
G12-GPCRs associated signalling partner genes
Major signalling genes for G12-GPCRs were detected at different intensity values in this
study. Rockl, rhoa and rhoq were expressed (Figure 3-11). This is consistent with
rockl was reported to be expressed in rat tissue such as skeletal muscle, liver, heart,
lung, kidney and pancreas while rock2 was reported to be expressed mainly in the brain
(Amano et al., 2000; Ishizaki et al., 1996; Matsui et al., 1996; Meyer et al., 2006).
mRNA expression of rhoa and rhob was reported to be expressed in CNS and the
peripheral nervous system of chicken embryos (Malosio et al., 1997). ROCKI deficient
mice were shown to induce insulin resistance by impairing insulin signalling in skeletal
muscle (Lee et al., 2009). Therefore, the activation of ROCKI in skeletal muscle might
be recommended to be investigated as a therapeutic option for treatment of diabetes.
In summary, this chapter showed that LPA1 lysophosphatidic acid receptors
(endothelial differentiation, lysophosphatidic acid G protein-coupled receptor, 2 (Edg2)),
CXCR4, glucagon receptor 2, platelet-activating factors receptors, GABAB1 receptors,
SI P2 sphingosine-I-phosphate receptors (endothelial differentiation, sphingolipid G-
protein-coupled receptor, 5 (Edg5)), parathyroid hormone receptors, mGlu2 and mGlu3
glutamate receptors, dopamine D, receptors, neurotensin receptor 2, opioid receptor
delta 1, calcitonin receptors 1, arginine vasopressin receptor l A, bradykinin B2
receptors, C5aI complement peptide receptors, CBI receptor, GPRII9, <l2-adrenoceptor,
~2-adrenoceptor, Al and A2A-adenosine receptors, NPY YI receptor, P2Y .. P2Y2 and
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P2Y6 receptors genes mRNA were detected in skeletal muscle. Moreover, Os, O~" 0~2'
G~s,OyIO,Oy12,RGS2, ROSS, Axinl, AC2, AC6, PDE4a, PDE4d, PKA RIa, PLC34,
PLC31, DAGlp, DGK~, DGKa, PKC3, PKCe, IMPA1, IMPA2, ROCK1, RhoA and
RhoQ genes mRNA were also highly detected in skeletal muscle tissue compared to
other isoforms. However, the other GPCR entities cannot be excluded. These entities
which are expressed in skeletal muscle in this study might be therapeutic options to
improve contraction, glucose uptake, proliferation, differentiation, myogenesis and
growth in skeletal muscle. The implication of this is that these targets should be
recommended to be investigated for diabetes, obesity and muscle regeneration disorders.
This chapter gave a picture and guide for the some GPCRs detected in skeletal muscle,
their signaling protein genes in skeletal muscle, which has not previously been reported,
in order to be investigated in this study. In the next chapter, signalling will be
investigated for these GPCRs representative of the different families.
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Chapter 4
GPCR Signalling
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4 Chapter Four: GPCR Signalling in Skeletal Muscle Cells
in vitro
4.1 Introduction
GPCRs expressed in adult skeletal muscle would be anticipated to mediate the effect of
a variety of endogenous substances on physiological roles on skeletal muscle, such as
muscle contraction, glucose uptake, control of muscle mass and expression of synaptic
proteins. However, there have been very few studies directly focusing on the function of
GPCRs in skeletal muscle.
Myotubes are primary skeletal muscle cells sharing the morphological, metabolic and
biomedical characteristics and properties of adult skeletal muscle (Henry et al., 1995;
Raymond et al., 2010). Our study showed that mRNA for many GPCRs were expressed
in skeletal muscle tissues; notably AI and A2Aadenosine receptors, P2-adrenoceptors,
NPY YI receptor, GPRII9 receptor, CBI receptor, P2Y., P2Y2 and P2Y6 receptors,
a2A-adrenoceptors (see Chapter 3). Since there has been little evaluation of GPCR
signalling in myotubes, and it was not possible to investigate all the GPCR apparently
expressed in skeletal muscle, some examples were chosen. This selection was based on
an attempt to examine signalling through the three main groups of G protein, Gs, Gi and
Gq, as well as receptor targets previously examined in the laboratories at Nottingham.
From the top 38 highly ranked GPCRs list detected using the microarray and GPCRs
detected using the QRT-PCR (Taqman) in skeletal muscle, A2Aadenosine receptors,
GPR119 and pz-adrenoceptors were selected as Gs-coupled, while a2A-adrenoceptors
and AI adenosine, NPY YI and CBI cannabinoid receptors were selected as Gi-coupled.
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This group (G, and OJ-OPCRs)were tested by quantifying levels of cAMP. However,
P2Y), P2Y2 and P2Y6 receptor were selected as Oq-coupled and were tested by
assessment of levels of intracellular calcium ions.
4.2 Aims
To assess the downstream signalling of OPCRs in rat primary skeletal muscle cells
using cAMP assay, calcium imaging and immunoblotting.
4.3 Experimental design and methods
4.3.1 cAMP assay
Accumulated cAMP in the myotube cells was measured by a competitive Enzyme
Immunoassay (EIA) kit (Cayman Chemical). Cells were prepared as discussed in
Chapter 2, Section 2.10. Where indicated, cells were pre-incubated with the
phosphodiesterase inhibitor, 3-isobutyl-l-methylxanthine (IBMX) (30 IlM) 20 minutes
prior to agonist addition. Similarly, where indicated, antagonists were added 20
minutes prior to agonist addition. In some instances, cells were co-exposed to the
adenylyl cyclase activator forskolin simultaneously with agonists. At the end of the
exposure period for the drugs, 40 III 5 M HCI was added to each well (2 m! media
(Ham-Fl O), 6% horse serum), before assessment of cAMP levels as described in the
Methods (Section 2.11).
146
4.3.2 Calcium imaging
Cells were assessed by imaging for intracellular calcium ion levels as described above
(see Chapter 2, Section 2.12). Myoblast cells on the covers lips were exposed to VTP,
ATP and ionomycin, as indicated, for one minute. In some instances, MRS2179 was
perfused over the cells for 3 minutes prior to agonist addition. Peak ratios were
calculated by subtracting the baseline fluorescence ratio (excitation at 340/380 and
emission at 500 nm) from the fluorescence ratio obtained during drug superfusion
(~FR). The results are presented as means ± standard error of mean (SEM) in change in
fluorescence ratio units (~FR) and mean ± SEM of the area under the curve (AVC) in
arbitrary units.
4.3.3 Western blot of ERK activation
Wistar rat (5 weeks old) primary vastus lateralis 90% myotubes in 6 well plates were
serum-starved (Ham-F 10 medium in the absence of further additives) for 3 hours.
Antagonists were applied for 30 minutes before agonists (incubated for the indicated
periods). After treatment, cells were washed with ice-cold PBS, and then scraped with
Trizol (800 J,llper well). After separation on SDS-PAGE gels and blotting, each blot
was analyzed for p-ERK to ERK ratios to assess ERK activation.
4.4 Statistical analysis
Data were analyzed using one way ANOV A and Bonferroni post-hoc test. Analysis was
performed using GraphPad Prism, version 5.03 (GraphPad Software Inc). Differences
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were considered significant at P< 0.05. Data are reported as means ± SEM of triplicate
or quadruplicate wells generated from two animals (n=2), except where indicated.
Statistics was performed from low number of repeats (n=2 rats) (no statistical difference
was observed among the replicates within the same treatment) for cAMP and western
blot experiments in this chapter due to cost implications. Indeed, it is recommended to
perform more repeats to support the results deduced in this chapter, in particular it is
hard to depend on statistical analysis from 2 repeats due to variations in species or
technical work. Indeed, more repeats will solidate the data statistically.
Due to the limitations of time and cost, a complete concentration response curve or time
response curve were not performed for every drug. Instead, a single concentration and a
single time point were used based on the previous literature. Different concentrations
and time points are required to have a clear comprehensive image about the nature of
the response.
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4.5 Results
4.5.1 Effect of GPR119 agonists on cAMP levels
Treatment ofmyotube cells with the endogenous GPRII9 agonist OEA (10 ~M) for 10
minutes did not result in a significant increase in cAMP compared to vehicle (0.01%
DMSO). Treatment of myotube cells with forskolin (100 nM) and OEA (10 ~M) in
combination also did not lead to any increase in cAMP levels (Figure 4-1).
Figure 4-1: Effect of OEA on cAMP accumulation in myotubes (n=2 rats). cAMP production was
measured following incubation of cells for 10 minutes with vehicle (0.01% DMSO), forskolin (lOO nM, I
JlM), OEA (10 JlM) and forskolin after 10 minutes incubation. (***) p < 0.001 versus vehicle. Data were
analyzed using one way ANOV A test followed by Bonferroni post-hoc.
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Treatment of myotube cells with the synthetic GPR119 agonist AZ359 (25 and 100 nM)
for 10 minutes failed to evoke a significant increase in cAMP levels compared to
vehicle (0.01% DMSO). Similarly, treatment of myotube cells in the presence of either
100 nM forskolin or 30 IlM IBMX, a nonselective phosphodiesterease inhibitor, did not
increase cAMP levels compared with IBMX or forskolin alone (Figure 4-2).
15 Ex-1 Ex-2 Ex-3
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Figure 4-2: Effect of AZ359 on cAMP accumulation in myotubes in three different experiments (three
different rats) (n=2 rats). cAMP production was measured following incubation of cells for 10 minutes
with vehicle (0.01% DMSO), AZ359 (25 nM and 100 nM), forskolin, AZ359+IBMX and IBMX, Ext;
experiment 1; Ex2; experiment 2; Ex3; experiment 3. (***) P < 0.001 versus vehicle or AZ359. Data
were analyzed using one way ANOV A test followed by Bonferroni post-hoc.
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In order to confirm the activity of the novel GPRl19 agonist, its effect on cAMP levels
in 3T3-Ll mouse adipocytes was examined. Treatment of cells with AZ359 (100 nM)
for 10 minutes did not show a significant increase in cAMP compared to vehicle (0.01%
DMSO). Interestingly, treatment of 3T3-Ll adipocyte cells with forskolin (100 nM) and
AZ359 (lOO nM) resulted in a significant inhibition of cAMP accumulation compared
to forskolin alone (p < 0.01) (Figure 4-3).
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Figure 4-3: Effect of AZ359 on cAMP accumulation in 3T3-Ll adipocytes (n=2 experiments). cAMP
production was measured following incubation of cells for 10 minutes with vehicle (0.01% DMSO),
AZ359 (100 nM) and forskolin (lOO oM). (**) P < 0.01; ** forskolin ± AZ359, (+++) P < 0.001; +++
forskolin versus vehicle. Data were analyzed using one way ANOV A test followed by Bonferroni post-
hoc.
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4.5.2 Effect of the GPRl19 agonist AZ359 on ERK phosphorylation
Treatment ofmyotube cells with AZ359 (25 nM) failed to show a significant increase in
P-ERK1/ERK1 and P-ERK2/ERK2 ratios at 5, 10 and 15 minutes compared to vehicle
(0.01 % DMSO) (Figure 4-4). The molecular weight of the bands for P-ERKlIERKl
and P-ERK2/ERK2 was detected at 44 kDa and 42 kDa, respectively, as expected.
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Figure 4-4: Effect of AZ359 on phosphorylation ofERK in rat primary skeletal muscle cells (n=2 rats). A)
Myotubes were treated with vehicle (0.01 % DMSO), AZ359 (25 nM) for 5 and 10 minutes. B) Myotubes
were treated with vehicle (0.01 % DMSO), AZ359 (25 nM) for 10 and 15 minutes. C) Representative
blots showing myotubes treated with vehicle (0.0 1% DMSO), AZ359 (25 nM) for 5 and 10 minutes,
phospho-ERK 112(green bands), ERK 112(red bands). D) Representative blots showing myotubes treated
with vehicle (0.01% DMSO), AZ359 (25 nM) for 10 and 15 minutes, phospho-ERK 112 (green bands),
ERK 1/2 (red bands). Data were analyzed using one way ANOV A test followed by Bonferroni post-hoc.
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4.5.3 Effect of a NPV VI receptor ligand on cAMP levels
As mRNA encoding the NPY Yl receptor was detected in skeletal muscle in this study,
the potential inhibitory effect of NPY on cAMP levels was assessed. Neither basal
levels of cAMP nor forskolin (1 IlM)-stimulated cAMP were altered in the presence of
NPY (300 nM) (Figure 4-5).
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Figure 4-5: Effect of NPY on cAMP accumulation in myotubes (n=2 rats). cAMP production was
measured foIlowing incubation of cells for 10 minutes with vehicle (0.01% DMSO), [Leu31, Pr034]
Neuropeptide Y (NPY) (300 nM) and forskolin (1 J.l.M).(***) P < 0.001 versus vehicle or NPY. Data
were analyzed using one way ANOV A test foIlowed by Bonferroni post-hoc.
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4.5.4 Effect of cannabinoid receptor ligands on cAMP levels
Since CBI receptor mRNA was detected using QRT-PCR (Taqman) in this study, the
potential inhibitory effect of CB I agonists on cAMP levels was assessed.
In myotubes, neither basal nor forskolin (1 I1M)-evoked elevation of cAMP was altered
significantly in the presence of ACEA, the selective CBI receptor agonist (Hillard et al.,
1999), (10 nM), AEA, endogenous cannabinoid receptor agonist (Lin et al., 1998), (10
11M)or RIM, CBI antagonist/inverse agonist (Rinaldi-Carmona et al., 1994), (100 nM)
for 10 minutes compared to vehicle (0.01% DMSO) (Figure 4-6).
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Figure 4-6: Effect of ACEA, AEA and RIM on cAMP accumulation in myotubes (n=2 rats). cAMP
production was measured following incubation of cells for 10 minutes with vehicle (0.01% DMSO),
cannabinoids and forskolin, ACEA (10 nM), AEA (10 JlM), forskolin (1 JlM) or RIM (100 nM) 30
minutes prior. (***) p < 0.001 versus vehicle, ACEA, AEA or RIM. Data were analyzed using one way
ANOVA test followed by Bonferroni post-hoc.
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4.5.5 Effect of adenosine receptor ligands on cAMP levels
mRNA encoding A2Aand AI adenosine receptors was detected in skeletal muscle in this
study, where A2Aadenosine receptors were anticipated to elevate cAMP levels and AI
adenosine receptors would likely inhibit cAMP production.
Treatment of myotube cells with the non-selective adenosine receptor agonist NECA
(Castanon et aI., 1994; Klotz et aI., 1998) at concentrations anticipated to activate A2A
and A2Badenosine receptors (100 nM and 10 ~M, respectively) for 10 minutes showed
significant increases in cAMP compared to vehicle (0.01% DMSO). Treatment of
myotube cells with the selective A2A adenosine receptor agonist CGS21680 (100 nM)
(Ongini et al., 1999), however, did not induce any increase in cAMP. The stimulatory
effect of NECA was significantly inhibited by the selective A2B adenosine receptor
antagonist PSB603 (10 ~M) (Borrmann et al., 2009), p < 0.001 (Figure 4-7).
Figure 4-7: Effect ofNECA, CGS2l680 and PSB603 on cAMP accumulation in myotubes (n=2 rats).
cAMP production was measured following incubation of cells for 10 minutes with vehicle (0.0 I%
DMSO), NECA (100 nM and to IlM), PSB603 (10 IlM), CGS2t680 (lOO nM) and forskolin. (***) p <
0.001 versus vehicle or NECA+PSB603. Data were analyzed using one way ANOVA test followed by
Bonferroni post-hoc.
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The potential coupling of AI adenosine receptors to inhibition of cAMP was
investigated using the AI receptor-selective agonist S-ENBA (Haynes et al., 1998;
Hussain et al., 1995). However, neither basal nor forskolin (1 JlM)-evoked elevation of
cAMP in myotube cells was altered in the presence of S-ENBA (100 nM) (Figure 4-8).
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Figure 4-8: Effect of S-ENBA on cAMP accumulation in myotubes (n=2 rats). cAMP production was
measured following incubation of cells for 10 minutes vehicle (0.01% DMSO), S-ENBA (lOO nM) and
forskolin. (U"') P < 0.001 versus vehicle or S-ENBA. Data were analyzed using one way ANOVA test
followed by Bonferroni post-hoc.
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In order to investigate the presence of other components of the adenosine system
(Figure 4-9), the expression for the enzymes and transporters required for adenosine
cycling was assessed.
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Figure 4-9: Schematic summary of the regulation of extra- and intracellular adenosine and inosine
concentrations. ATP: adenosine tri-(di-, mono-) phosphate; ADP; adenosine diphosphate; AMP;
adenosine monophosphate. IMP; inosine monophosphate (Marshall, 2000; Spielman et al..• 1991).
Adenosine deaminase, adenosine kinase and S-adenosylhomocysteine hydrolase mRNA
expression were detected in the skeletal muscle tissue in this study. In addition, ecto-5'
nucleotidase and ectonucleotide pyrophosphatase/phosphodiesterase 1, 2 and 3 mRNA
were also detected in the skeletal muscle. Nucleoside transporters mRNA were detected
as well (Table 4-1).
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Table 4-1: RNA transcript intensity values for genes related to adenosine machinery in mixed skeletal
muscle from 3 replicates generated from two male Wistar rats. The number represents the relative
intensity values for these genes which are all above tbp (TATA box binding protein) reference gene.
RatA RatB
Gene Gene name A B C A B C
Ada Adenosine deaminase 2.1 1.7 1.8 1.6 1.7 2.0
Adk Adenosine kinase 2.7 3.8 3.1 3.3 3.4 3.1
S-adenosylhomocysteine
Ahcy hydrolase 3 2.8 2.3 4.1 3.7 4.1
Solute carrier family 28
Slc28aI (nucleoside transporters) 1
-1 -1.2 -1.2 -2.7 -3.1 -2.5
Solute carrier family 28
Slc28a2 (nucleoside transporters) 2 3.2 3 3.5 0.5 0.2 0.8
Solute carrier family 29
Slc29al (nucleoside transporters) 1 5 4.2 5.4 4.9 5 4.9
Nt5e 5' nucleotidase, ecto
-0.7 -0.7 -0.9 -0.5 -0.3 -0.7
Ectonucleotide
pyrophosphatase/phosphodiestera
Enppi se 1 1.7 1.2 1.2 1.7 1.7 2
Ectonucleotide
pyrophosphatase/phosphodiestera
Enpp2 se2 0.6 0.3 0.7 0.6 1.1 0.9
Ectonucleotide
pyrophosphatase/phosphodiestera
Enpp3 se 3 1.4 1.2 2.1 1.6 2.3 2.3
158
4.5.6 Effect of uradrenoceptor ligands on cAMP levels
Adra2a expression was detected using QRT-PCR (Taqman) and microarray in this
study. Functional expression of the o,2A-adrenoceptoras a Gr-coupled receptor was
assessed by quantifying cAMP levels. Treatment of myotube cells with UK14304, an
o,2-adrenenoceptor agonist (Jasper et al., 1998), inhibited forskolin (1 J.lM)-evoked
elevation of cAMP significantly. However, rauwolscine, the selective o,2-adrenoceptor
antagonist (Convents et al., 1989;Uhlen et al., 1994), did not prevent this effect (Figure
4-10).
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Figure 4-10: Effect ofUKl4304 and rauwolscine on cAMP accumulation in myotubes (n=2 rats). cAMP
production was measured following incubation of cells for 10 minutes with vehicle (0.01% ethanol),
UKl4304 (100 nM) and rauwolscine (100 nM). * vs basal. + vs forskolin. Data were analyzed using one
way ANOV A test followed by Bonferroni post-hoc.
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4.5.7 Effect of uradrenoceptor ligands on ERK phosphorylation
u2-adrenoceptor coupling to ERK phosphorylation was investigated as an alternative
coupling mechanism. Treatment of myotube cells with UK14304 for io minutes
showed a significant increase in P-ERKlIERKl and P-ERK2/ERK2 ratios compared to
vehicle (0.01% ethanol). The molecular weight of the bands for P-ERKI/ERKI and P-
ERK2/ERK2 was detected at 44 kDa and 42 kDa, respectively as expected.
Interestingly, treatment of myotube cells with rauwolscine (100 nM), 30 minutes prior
to the addition of UK14304 inhibited the effect of UK14304 significantly for both P-
ERKI/ERKI and P-ERK2/ERK2 ratio. However, rauwolscine showed a significant
inhibition of basal levels of ERK phosphorylation as well (Figure 4-11).
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Figure 4-11: Effect of UK14304 and rauwolscine on phosphorylation of ERK in rat primary skeletal
muscle cells (n=2 rats). A) Myotubes were treated with vehicle (0.01% ethanol), UK14304 (100 nM) for
10 minutes, UK14304 for 10 minutes + rauwolscine (100 nM) 30 minutes prior. * ± UK14304. + ±
rauwolscine. B) Representative blots showing myotubes treated with vehicle (0.01 % ethanol), UK14304
(100 nM) for 10 minutes + rauwolscine (100 nM) 30 minutes prior, phospho-ERK 1/2 (green bands),
ERK 1/2 (red bands). Data were analyzed using one way ANOVA test followed by Bonferroni post-hoc.
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4.5.8 Effect of IJ-adrenoceptor ligands on cAMP levels
The potential coupling of ~2-adrenoceptors to elevation of cAMP levels was assessed,
since mRNA encoding ~2-adrenoceptor was detected using microarray in this study.
Isoprenaline, a non-selective ~-adrenoceptor agonist (Bylund et al., 1994), failed to
increase cAMP levels in myotube cells, as did the ~2-adrenoceptor-selective antagonist
ICI118551 (Bilski et al., 1983) (Figure 4-12-A). In contrast, isoprenaline evoked a
significant elevation of cAMP levels in 3T3-Ll adipocytes (Figure 4-12-B).
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Figure 4-12: Effect of isoprenaline on cAMP accumulation in myotubes and 3T3-Ll adipocytes (n=2 rats
and n=2 experimets, respectively). A) Effect of isoprenaline on cAMP accumulation in myotubes. cAMP
production was measured following incubation of cells for 10 minutes with vehicle (0.01% DMSO),
isoprenaline (10 JlM), ICIl1855l (100 nM) and forskolin (I JlM). Ex-I; experiment 1, Ex-2; experiment
2 (***) P < 0.001 versus vehicle. B) Effect of isoprenaline on cAMP accumulation in 3T3-LI adipocytes.
cAMP production was measured following incubation of cells for 10 minutes with vehicle (0.01%
DMSO), isoprenaline (10 JlM) and forskolin (100 nM). (**) P < 0.01 versus vehicle. Data were analyzed
using one way ANOV A test followed by Bonferroni post-hoc.
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4.5.9 Elevation of intracellular calcium ion levels in myotubes
mRNA encoding P2Y), P2Y2 and P2Y6 receptors was detected using the microarray in
this study. As the majority of P2Y receptors are Gq-coupled, Ca2+-imaging techniques
were employed to investigate their functional coupling.
748 myoblast cells were imaged from four animals. ATP (1 mM) elevated intracellular
calcium ion levels in all 748 myoblast cells (imaged from four animals; 150-250
cells/animal), with a peak increase in fluorescence ratio (L\FR; Fura-2 340/380 nm
excitation) of 0.33 ± 0.06 after approximately one minute, while 575 cells responded to
10 JlM UTP (0.18 ± 0.08 L\FR). Thus, around 77% and 100% of cells responded to UTP
and ATP, respectively (Figure 4-13) and (Figure 4-14).
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Figure 4-13: A representative trace showing changes in 340:380 run excitation wavelength ratios in
myoblast cells, in response to UTP, ATP and ionomycin. Recording of 340:380 ratio were made at
various time points, where at point A, the cells were exposed to UTP (10 J.1M)for one minute, twenty
minutes later, at point B, the cells were exposed to ATP (1 mM), twenty minutes later, at point C, the
cells were exposed to ionomycin (4 J.1M);(imaged from four animals; 150-250 celis/animal).
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Figure 4-14: Ratiometric pseudocolour images of myoblast cells. A; basal, B, myoblast cells following
exposure to 10 IlM UTP; C, myoblast cells following exposure to 1 mM ATP; D, myoblast cells
following 4 IlM ionomycin; E, colour scale, arbitrary numbers representing 340:380 ratios.
lonomycin
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Two sets of myoblast cells were imaged from 4 different rats. One set (713 cells) were
investigated for responses to ATP alone, while ATP responses in the other set (815 cells)
were assessed after 3 minutes exposure to MRS2179, a selective P2YI receptor
antagonist (Boyer et al., 1998). There was no significant difference in the response
between the two sets either in AVC or in Peak (Figure 4-15).
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Figure 4-15: Pre-exposure of myoblast cel1s to the P2Y1 receptor antagonist (MRS2179) (IO ~M, for 3
minutes) on the effects of ATP (1 mM)-evoked peak response (A) and AUC (in arbitrary units) (B) in the
whole population of cel1s. Myoblast cells showed an elevation in intracellular calcium levels in response
to 1 mM ATP; imaged from four animals; 150-250 cells/animal.Data were analyzed using Paired t test.
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4.6 Discussion
A number of GPCRs were observed to be expressed in skeletal muscle tissue using the
microarray and QRT-PCR (Taqman), as mentioned in Chapter Three. The signalling
(functionality) associated with these receptors has not previously been investigated in
detail in skeletal muscle. Therefore, conventional second messenger studies
(investigating cAMP, Ca2+ and ERK activation) were conducted to assess their
functionality.
cAMP is an important second messenger in skeletal muscle. It was found to increase the
expression of members of the orphan family of nuclear receptors, subfamily 4 (NR4A),
compared to other nuclear receptors in skeletal muscle (Maxwell et al., 2005). These
transcription factors regulate the gene expression of proteins responsible for fat and
glucose metabolism through up-regulating the mRNA expression of pyruvate
dehydrogenase kinase 4 (PDK4), forkhead box protein 01 (FOX01), peroxisome
proliferator-activated receptor-s coactivator (PGC-l a), phosphatidate phosphatase
LPINI (lipin-Iu), GLUT4 and muscle phosphofructokinase (Pfkrn) (Chao et al., 2007;
Kanzleiter et al., 2010; Lessard et al., 2009). The implication of this is that activation of
NR4A receptors might improve glucose glycolysis, glucose transport and lipid
oxidation in skeletal muscle, and consequently NR4A receptors might be a therapeutic
target for diabetes and obesity. Another critical second messenger is calcium, which
transduces extracellular signals into numerous intracellular events in many cell types.
Indeed, the functions of calcium range from short-term responses, such as contraction
and activation of some enzymes (such as adenylyl cyclase), to longer-term responses
such as gene expression (Berridge, 1997). In skeletal muscle, calcium has a crucial role
for contraction (Berchtold et al., 2000). When calcium is released from sarcoplasmic
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reticulum, it binds to troponin and pulls tropomyosin allowing the myosin to bind to the
actin, consequently, contraction occurs (Berchtold et al., 2000). Calcium might also
improve contraction-stimulated glucose uptake through activating GLUT4 translocation,
calmodulin-dependent protein kinases, calmodulin and protein kinase Cs (lhlemann et
al., 1999; Jessen et al., 2005; Wright et al., 2004; Youn et al., 1991). However, the
mechanism is still unclear.
One family of GPCRs, called adrenoceptors, was investigated using the cAMP assay.
The adrenoceptors are divided into two major types: a and p-adrenoceptors.
In terms of a:z-adrenoceptors, adra2a expression was found in rat skeletal muscle using
northern blot analysis (Lorenz et al., 1990). Consistent with this report, a2A-
adrenoceptors were also detected using the microarray and QRT-PCR (Taqrnan) in this
study. The accepted roles for a2A-adrenoceptors include acting as the major feedback
regulator of noradrenaline release at nerve terminals and the regulation of insulin
secretion through noradrenaline in pancreatic islets through reducing the cAMP
formation (Ahren, 2000; Nakaki et al., 1981). It is noteworthy that a mutation of a2A-
adrenoceptors has been shown to be associated with obesity and metabolic alterations
(Lima et al., 2007). However, there is a lack of possible roles of the a2A-adrenoceptors
in skeletal muscle in the literature. Therefore, a cAMP assay was performed to test the
functionality of this receptor.
UK14304 was found to inhibit cAMP elevation evoked by forskolin. However,
rauwolscine did not prevent this effect. The concentration which was used in this study
for UK14304 is in line with that (100 nM) shown to inhibit forskolin-evoked cAMP
level in rat primary superior cervical ganglionic (SCG) cells (Shivachar et aI., 1999),
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and the concentration which was used in this study for rauwolscine is also in line with
that (100 nM) shown to reverse the effect ofUK14304 inhibition of secretin-stimulated
cAMP level in purified rat bile duct-ligated (BDL) cholangiocytes via a2-adrenoceptors
(Francis et al., 2007). This suggests that the effect ofUK14304 regarding cAMP might
not function through a2A-adrenoceptors since this effect was not blocked by rauwolscine
or it is also possible that the concentration used for rauwolscine did not block the effect
of UK14304 in these primary skeletal muscle cells. In other words, the concentration
used for rauwolscine might not overcome the effect of UK14304 regarding the cAMP,
in particular of the similar relative affinities for UK14304 and rauwolscine to a2A-
adrenoceptors (Kd=lO nM and Ki=3.5 nM, respectively) (Neubig et al., 1988;
Wainscott et al., 1998). Different concentration points of rauwolscine and
concentration-response curve for UK14304 are required to have a clear comprehensive
image of the response in these primary skeletal muscle cells regarding cAMP.
Interestingly, UK14304 evoked a significant elevation of phosphorylated ERK1I2; an
effect blocked by rauwolscine. Furthermore, the inhibitory effect of rauwolscine on
basal levels of cAMP could be interpreted to mean that u2-adrenoceptors in this tissue
exhibit constitutive activity. Rauwolscine has been reported to be an inverse agonist in
stable Chinese hamster ovary cell lines expressing constitutively activated porcine a2A-
adrenoceptors in which the suppression of cAMP production in these cells is reversed
by rauwolscine (Wade et al., 2001). However, nothing in the literature is reported about
constitutively activated rat a2A-adrenoceptors. It is also possible that the influence of
rauwolscine on ERK activation, but not for cAMP inhibition in this study, might be
ascribed to an antagonist bias (i.e. affecting one pathway and not affecting another)
(Kenakin, 2010; Urban et al., 2007). It is also possible that aradrenoceptors mediate
the ERK phosphorylation through an adenylyl cyclase-independent cascade in this study.
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ERKphosphorylation might be mediated through Gp.,subunit. This is in line with that
overexpressed Gpysubunit in CHO cells was shown to activate MAP kinase (van Biesen
et al., 1995). As activation of u2-adrenoceptors was shown in this study to stimulate
ERK, and ERK signal transduction was traditionally suggested to growth related
process (Bennett et al., 1997; Jones et al., 2001; Lopez-Ilasaca, 1998), it is possible that
u2-adrenoceptors have a role in skeletal muscle growth. The implication of this is that
long-term treatment of rats with u2-adrenoceptor agonists should stimulate skeletal
muscle growth and lean weight gain.
For P2-adrenoceptors, in this study, the microarray experiment showed that the mRNA
encoding Pradrenoceptors was detected. This agrees with reports of the expression of
j3-adrenoceptor mRNA in rat skeletal muscle tissues and with expression of P2-
adrenoceptors in rat L6 cells using RT-PCR (Nagase et al., 2001; Sato et al., 2010).
However, treatment ofmyotube cells with isoprenaline, a non selective j3-adrenoceptor
agonist (Bylund et al., 1994), did not increase cAMP levels. The concentration which
was used in this study for isoprenaline is in line with that (10 J.lM)shown to increase
cAMP production in rat L6 cell membranes (Coppock et al., 1996). Moreover, the
concentration which was used in this study for ICI118551 is also in line with that (100
nM) shown to inhibit the isoprenaline-evoked cAMP level in rat primary SCG cells
(Shivachar et al., 1999). However, it is worth noting that the concentration used for
ICI118551 might not block the effect of isoprenaline (10 J.lM).In other words, the high
concentration of isoprenaline might not be antagonized by the concentration used for
ICI118551. Therefore, it is suggested to try another concentration for ICI118551 and
isoprenaline. Indeed, the concentration ratio between the isoprenaline and ICI118551 is
an important issue to consider in this case as the relative affinity of ICI118551 and
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isoprenaline to the receptor, Ki=1.2 oM and Ki=904 oM, respectively (Kikkawa et al.,
1997; Kostka et al., 1989).
The explanation behind the lack of response to isoprenaline in myotubes may be due to
the fact that mRNA expression levels might not reflect protein expression levels in rat
primary skeletal muscle cells. Moreover, skeletal muscle tissue contains multiple cell
types (satellites, myoblasts and myotubes) and receptor expression might be restricted
to a specific cell type. Further investigations should focus on ~2-adrenoceptor protein
expression using immunoblotting, immunocytochemistry or radioligand binding and
should examine any possible potentiation of the effect of isoprenaline in the presence of
cholera toxin in skeletal muscle cells indicating that ~2-adrenoceptor is Os-coupled.
Indeed, it should be expected to increase cAMP level in response to isoprenaline and
cholera toxin. The rationale behind the use of cholera toxin is also to potentiate the
cAMP in myotubes, in particular the cholera toxin induces irreversible potentiation to
adenylyl cyclase through ADP-ribosylation for Os-subunit (Kahn et al., 1984).
Another family, which was investigated, was adenosine receptors, which are divided
into AI. A2A,A2Band A3 adenosine receptors based on pharmacology and coupling to
cAMP production. A, and A3 adenosine receptors are coupled to inhibitory Gi-proteins,
whereas the A2Aand A2Badenosine receptors are coupled to stimulatory G, proteins.
In this study, Al and A2A adenosine receptor mRNA was detected in skeletal muscle
tissue using the microarray. This is consistent with a previous study that showed that
mRNA encoding for adenosine A, and A2A receptors was detected in rat primary
skeletal muscle cells and tissues using northern blot (Lynge et al., 2003).
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In order to examine the signalling of adenosine receptors and particularly to investigate
the Os-coupling OPCRs, we examined cAMP accumulation in primary rat skeletal
muscle cells. NECA, a non-selective adenosine receptor agonist (Castanon et al., 1994;
Klotz et 'al., 1998), was used to examine activation of the A2Aor A2Badenosine receptor,
while S-ENBA was used to examine activation of the Al adenosine receptor. S-ENBA
did not show any inhibition of cAMP, although the concentration of S-ENBA chosen is
consistent with that (100 nM) shown to increase whole cell currents of both inner-wall
and cannula-derived human Schlemm's canal cells through A] adenosine receptors
(Karl et al., 2005). However, little in the literature is reported about rats. The lack of
response to AI adenosine receptor stimulation in this study is in line with a previous
study that showed forskolin-evoked cAMP was not suppressed by the AI adenosine
receptor agonist, R-PIA in rat primary skeletal muscle (Lynge et al., 2003).
However, NECA, a non-selective agonist for adenosine receptors (Castanon et al., 1994;
Klotz et al., 1998), stimulated cAMP accumulation at both 100 nM and 10 J.lM. The
concentration of NECA which was used in this study is in line with that (100 nM)
shown to increase cAMP levels in rat coronary endothelial cells (Bindewald et al.,
2004). To examine which adenosine receptor (A2Aor A2B) leads to increases in cAMP
levels, CGS21680, an A2Aadenosine receptor-selective agonist (Ongini et al., 1999) and
PSB603, an A2B adenosine receptor-selective antagonist (Borrmann et al., 2009), were
employed. CGS21680 did not alter cAMP levels. However, PSB603 blocked the effect
ofNECA. This is consistent with a previous study which showed that the stimulation of
A2B adenosine receptors by NECA activates adenylyl cyclase and increased cAMP
selectively, and not the A2A adenosine receptors which were not stimulated by
CGS21680 in rat primary skeletal muscle cells (Lynge et al., 2003). The concentration
which was used in this study for PSB603 is in line with that (10 IlM) shown to inhibit
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adenosine-induced bicarbonate ion secretion in duodenal rats through A2Badenosine
receptors (Ham et al., 2010). Similarly, the concentration of CGS21680 used in this
study is also in line with that (100 nM) shown to elevate rabbit carotid body cAMP
content (Chen et al., 1997b), and (100 nM) shown to enhance cAMP accumulation in
hippocampal nerve terminals of aged rats (Rebola et al., 2003). Therefore, the A2B
adenosine receptor is an active receptor with regards to cAMP modulation. Regarding
A2Aadenosine receptor, the lack of response for A2Aadenosine receptors might indicate
that the number of A2Aadenosine receptors might be too small to elicit adenylyl cyclase
activation. As indicated above for the ~-adrenoceptors, another explanation for the lack
of effect of A2Aadenosine receptor activation is the mismatch between mRNA and
protein expression. Also as suggested above, since skeletal muscle contains multiple
cell types (satellites, myoblasts and myotubes), receptor expression might be restricted
to a specific cell type. Further work to assess A2Aadenosine receptor expression might
involve immunoblotting, immunocytochemistry or radioligand binding assay.
The mRNA expression of adenosine receptors, together with the functional coupling of
the A2Badenosine receptor, suggests a role for adenosine in skeletal muscle function
(Figure 4-9).
A2Badenosine receptor activation was found to increase NR4A expression in smooth
muscle (Mayer et al., 2011), it is possible, therefore, that A2Badenosine receptors affect
NR4A through the cAMP pathway in skeletal muscle, and consequently, A2Breceptors
might modulate fat and glucose metabolism in skeletal muscle tissue. This is supported
by the fact that 1) NR4A mRNA was found to be expressed in skeletal muscle using
microarray in this study. 2) cAMP was found to be involved in increase of expression of
NR4A in skeletal muscle (Kawasaki et al., 2011; Pearen et al., 2008; Pearen et al.,
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2006). 3) NR4A was shown to be reduced in skeletal muscle of diabetic animals (Fu et
al., 2007). 4) NR4A was associated with genes related to glucose and fatty acid
utilization through up-regulating the mRNA expression ofPDK4, FOXOI, PGC-la and
Iipin-l o (Pearen et al., 2008). 5) NR4A null mice after high-fat feeding compared with
wild-type animals was shown to exhibit decreased mRNA expression of GLUT4 and
PDK4 and Lipin la and impaired insulin receptor substrate 1 (IRS-I) phosphorylation
and insulin resistance in skeletal muscle, and slower blood glucose clearance and
increased body weight and decreased energy usage (Chao et al., 2009). 6) In C2C12
cells, C2C12 siRNA-NR4A cells were shown to decrease mRNA expression of fatty
acid translocase (CD36/fat), uncoupling protein-3 (UCP3) and GLUT4 compared to
wild type native C2CI2 cells (Maxwell et al., 2005). 7) In C2C12 cells transfected with
adenovirus-mediated NR4A expression, non-insulin glucose uptake was shown to be
increased significantly compared to normal C2CI2 cells (Chao et al., 2007). Taken
together, modulation of A2Badenosine receptor by ligands might affect glucose and
fatty acid utilization in skeletal muscle. Therefore, the implication of this is that A2B
adenosine receptor agonists should be recommended to be investigated as a therapeutic
option in diabetes or obesity.
Adenosine could reach skeletal muscle either from the bloodstream, the motor neuron
innervations or the skeletal muscle itself. As skeletal muscle expressed ecto-S'-
nucleotidase (ecto-5'-NT) and ecto-phosphodiesterases in this study (Table 4-1), it is
possible that skeletal muscle mediates adenosine generation through the extracellular
cAMP-adenosine pathway. This is supported by the fact that interstitial accumulation of
5'-AMP (intermediary metabolite of adenosine synthesis) and adenosine was observed
after incubation newborn rat skeletal muscle cells with exogenous cAMP (Chiavegatti
et al., 2008). This effect was inhibited by using the ecto-phosphodiesterase (1, 3-
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dipropyl-8-sulfophenylxanthine (DPSPX» and ecto-5' -NT (alpha, beta-methylene
adenosine 5'-diphosphate (AMPCP» inhibitors (Chiavegatti et al., 2008; Tofovic et al.,
1991; Zimmermann, 1992) in which ecto-phosphodiesterase inhibitors inhibit the
conversion of cAMP to 5'-AMP and ecto-5'-NT inhibitors inhibit the conversion of 5'-
AMP to adenosine.
Furthermore, adenosine could be also transported into or out of the rat primary skeletal
muscle cells through an equilibrative nucleoside transporter, ENTI (SLC29Al)
transporter. This may be due to the fact that when incubation rat primary skeletal
muscle cells with the adenosine transporter inhibitor nitrobenzylthioinosine, the ENTI
transporter inhibitor (Ackley et al., 2003; Geiger et al., 1985), the rate of extracellular
adenosine accumulation in the electro-stimulated muscle cells was larger compared with
control cells (Lynge et al., 2001).
In addition, adenosine can be metabolized in skeletal muscle through adenosine kinase
and adenosine deaminase, producing adenosine monophosphate (AMP) and inosine,
respectively. Inosine was shown to be implicated in cellular proinflammatory responses
to ischemia in mice skeletal muscle and was also reported to activate A3 adenosine
receptor in mast cells (Jin et al., 1997; Wakai et al., 2001). However, this issue is not
understood yet. AMP generated by the action of adenosine kinase, can be used to
regenerate ATP in skeletal muscle. However, intracellular adenosine and homocysteine
can be produced from S-adenosylhomocysteine (AdoHcy) through S-
adenosylhomocysteine hydrolase (ahcy). Homocysteine could be then recycled into
cysteine. Indeed, low plasma cysteine level was reported to be associated with
progressive loss of human skeletal muscle mass (Droge et al., 1998).
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Another family of receptors, the P2Y receptors, was investigated using Ca2+-imaging.
P2Y receptors are a family of plasma membrane GPCRs involved in several cellular
functions and are divided into P2Y" P2Y2, P2Y4, P2Y6, P2Yll, P2Y12, P2Y'3 and P2Y'4.
In this study, mRNA for P2Y" P2Y2, and P2Y6 receptors were detected in skeletal
muscle using the microarray. This is consistent with a previous study that these
receptors were also expressed in mouse C2C12 myoblast and myotubes (Banachewicz
et al., 2005). However, in one study in the literature, the expression of P2Y, and P2Y2
was not detected in human skeletal muscle fibre using immunoblotting and
immunohistochemistry. Nevertheless, these receptors were expressed in the vasculature
(Borno et al., 2011). This might be ascribed to the difference in physiology between
human and rat species or the disconnect between mRNA and protein levels, as
suggested previously.
The vasodilatatory effect of the purinergic system was shown to be -50% lower in
diabetic patients compared to control subjects, although the distribution and mRNA
expression of receptors were similar in both groups (Borno et al., 2011). Moreover,
AIP, localized at the nerve terminal, may be released after stimulation of the
prejunctional neurones, leading to activation of P2Y receptors. ATP was also shown to
activate glucose uptake in mouse C2C12 skeletal muscle cells through P2 receptors
(Kim et al., 2002). Taken together, P2Y receptors might have a therapeutic role in
skeletal muscle and diabetes. It is possible, therefore, that the activation of P2Y" P2Y2
and P2Y 6 receptors by agonists in skeletal muscle might be therapeutic targets for
diabetic patients.
Little is known about the effects of P2Y receptor activation on skeletal muscle. The
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effects of P2Y agonists (ATP and UTP) were tested on levels of intracellular calcium.
Intracellular calcium concentration was increased by UTP, which was mainly attributed
to P2Y receptors, since UTP is a selective agonist for P2Y2 receptors (EI-Tayeb et al.,
2006). The explanation behind the fewer number of cells (77%) responding to UTP is
possibly due to the fact that the P2Y2 receptors expression might be different during the
stage of differentiation for the cells or relative RNA expression level might not reflect
the protein expression level in all cells population. Ionomycin was used as a positive
control. Ionomycin is supposed to produce a maximum calcium response. However, in
the protocol I followed, in which I used ionomycin at the end of the protocol, it is
possible that the small response of ionomycin and the differences in the background
colour (Figure 4-14) are due to issues regarding the loading of the fura-2 dye. Further
work is suggested to be performed regarding identification ofP2Y2 receptors expression
in skeletal muscle cells using siRNA- P2Y2receptors or P2Y2receptor antagonists.
As UTP was shown to increase calcium level in skeletal muscle cells in this study, and
UTP was shown to activate ERK dependant on calcium in mouse C2C12 myoblasts
(Banachewicz et al., 2005), and ERK was shown to have a role in myoblast
proliferation (Bennett et al., 1997; Jones et 01.,2001), it is possible that UTP through
P2Y2receptor playa role in skeletal muscle growth. Moreover, as P2Y., P2Y2 and P2Y6
receptors mRNA was detected in skeletal muscle in this study, and it was also shown
that at least UTP as a selective P2Y2 receptor increase calcium level in skeletal muscle
cells in this study, it is possible that P2Y receptor might playa role in contraction in
skeletal muscle. The implication of this is that P2Y receptors might improve
contraction-stimulated glucose uptake. Therefore, P2Y receptor agonists should be
recommended to be investigated for diabetes.
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The response for ATP was found to be higher than the response for VTP. This possibly
suggests that ATP might work through the P2Y. receptor, not through the P2Y2. and
that VTP might work through the P2Y2. MRS2179, the P2Y1 receptor-selective
antagonist (Boyer et al., 1998) was investigated to block the effect of ATP. MRS2179
did not inhibit the effect of ATP.
The concentration which was used in this study for MRS2179 is consistent with that (10
J.lM)shown to prevent ERK activation induced by oxygen and glucose deprivation in rat
hippocampal slices (Traini et al., 2011), and is also consistent with that observed to
block P2YI receptors associated with endogenous calcium activity in mouse astrocytic
processes (Di Castro et al., 2011). It might be that other receptors contributed to the
response of ATP, such as P2Y2,P2Y6 and P2Xs. The concentration used in this study for
ATP (1 mM) was possibly too high relative to concentration used for MRS2179 (10
J.lM),in particular ATP and MRS2179 has similar relative affinity for P2YI receptors,
Ki=48 nM and Ki=84 nM, respectively (Waldo et al., 2002; Webb et al., 1996). In other
words, the concentration used for MRS2179 did not block the effect of ATP. Therefore,
it is suggested to take the concentration used for ATP into consideration and perform
concentration response curve for ATP or try different concentrations of both ATP and
MRS2179. Further selective antagonists for P2YI receptors, such as MRS2500
(Cattaneo et al., 2004; Hechler et al., 2006) could be also used to clarify the
involvement of P2YI receptors. Alternatively, siRNA investigations might allow
definition of the role of particular P2 receptors in ATP- and VTP-evoked calcium
responses. Further experimental work is also recommended to support the P2Y
signalling and exclude the P2Xs signalling such as repeating the same experiments using
buffer without calcium ions to ascertain the source of calcium.
As ATP increase calcium level in skeletal muscle in this study, and ATP was shown to
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stimulate the proliferation of cancer cells (Deli et al., 2008), and to stimulate the
proliferation of astrocytes via P2Y receptors (Neary et al., 2009), it is possible that P2Y
receptors playa role in skeletal muscle growth.
A series of investigations of cAMP levels was performed for CBI. OPR119 and NPY
Yl receptors. It is well known that the CBI receptor is coupled to OJin many tissues
(Demuth et al., 2006). In this study, the mRNA expression of CBI was detected in rat
skeletal muscle culture and tissue using QRT-PCR (Taqman) (see Chapter 3). The CBI
receptor is very highly expressed in the brain (Tsou et al., 1998), but also many studies
have found that the CBI receptor is expressed in peripheral tissues, including adipose
and skeletal muscle tissues. However, to date, no specific role(s) of CBI in the skeletal
muscle has been fully understood.
Neither basal nor forskolin (1 J.lM)-evoked elevation of cAMP was altered significantly
in myotube cells in the presence of ACEA (10 nM), AEA (10 J.lM)or RIM (100 nM) for
10minutes. Indeed, the concentration which was used for ACEA and AEA in this study
is in line with that (10 nM) and (10 J.lM),respectively shown to activate ERK in rat
myotube cells (Chapter 5, Figure 5-3), and the concentration which was used for RIM in
this study is also in line with that (100 nM) shown to block ERK phosphorylation
(Chapter 5, Figure 5-3). However, it was shown that cannabinoid receptor ligands
produce a CBI receptor-dependent reduction in cAMP levels in transfected CHO cells
(Hillard et al., 1999) and different rat brain regions (Bidaut-Russell et al., 1990), and
treatment of rat L6 myotube cells with 100 nM RIM for 24 hour was also shown to
increase intracellular cAMP production (Esposito et al., 2008). The Esposito et al study
is not consistent with the present study. This is due to the fact that rat L6 cells are
different from rat primary skeletal muscle cells, and the exposure time of RIM is also
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different between two studies. It is worth noting that CBI receptor is functionally-active
receptor depending on cnrl was detected in skeletal muscle tissue using QRT-PCR
(Taqman), and the activation of CBI receptor by ACEA phosphorylates ERK.1I2in CBI
dependent manner (data was presented in Chapter 5 (Figure 5-3) for convenience).
NPY Yl receptors are expressed throughout the central and peripheral nervous systems,
where the receptor mediates a variety of responses such as the regulation of metabolism
and food intake (Gerald et al., 1996; Larsen et al., 1999). Several NPY Yl receptor
antagonists were developed as potential anti-obesity agents (MacNeil, 2007). NPY Yl
receptor mRNA is also expressed primarily in kidney, heart and skeletal muscle and
vascular smooth muscle (Nakamura et al., 1995). Activation of NPY Yl receptors
mainly inhibits adenylyl cyclase via OJproteins (Kassis et al., 1987).
Nothing is known in the literature about possible roles for the NPY Yl receptor in
skeletal muscle. However, neither basal nor forskolin-evoked elevation of cAMP
concentration was altered after treatment of myotubes with the selective NPY Yl
receptor agonist [Leu31, Pr034] Neuropeptide Y (Fuhlendorff et al., 1990) . The
concentration which was used in this study for NPY is in line with that (300 nM) shown
to inhibit cAMP accumulation in rat slices of the dorsomedial medulla (Fuxe et al.,
1987; Harfstrand et al., 1987).
GPR119 is of particular interest since its activation leads to reduced food intake and
body weight gain in rodents (Overton et al., 2006). Little is known about OPR119
downstream signalling. However, it is coupled to the Gs-protein (Ning et al., 2008; Soga
et al., 2005). In the literature, OPR119 was found to raise intracellular cAMP
concentrations through Gs-coupled in which increase cAMP levels would be expected to
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potentiate glucose-stimulated insulin secretion (GSIS) in pancreatic p-ce1ls (Furman et
al., 2010; Overton et al., 2008; Soga et al., 2005).
GPRI19 was previously found to be expressed in skeletal muscle from both rats and
humans using RT-PCR (Soga et al., 2005). In this study, it was also detected in skeletal
muscle tissue using QRT-PCR (Taqman). Therefore, GPRl19 signalling was
investigated using the cAMP assay. Neither AZ359 nor OEA affected cAMP
accumulation in rat primary skeletal muscle cells. Moreover, AZ359 did not increase
cAMP in the presence of IBMX. The concentration of IBMX which was used in this
study is in line with (30 JlM) shown to increase cAMP levels in cultured human breast
cancer cells (Eilon et al., 1983). Moreover, IBMX was used as a control for the assay
and as a potentiating agent for AZ359. The concentrationof OEAwhich was used in this
study is in line with that (10 J.1M) shown to increase cAMP levels in the murine GLUTag
intestinal L-cell line. In these cells, GPRl19-specific siRNA was shown to reduce OEA-
inducedcAMP levels (Laufferet al., 2009).
However, somewhat unexpectedly, AZ359 was shown to inhibit the forskolin-evoked
elevation of cAMP concentration in the adipocyte cell line, 3T3-LI. Therefore, GPRI19
might couple with the Gj since it showed an inhibition for forskolin in 3T3-LI
adipocytes. To investigate that, further work is suggested to test if GPRI19 is Gj-
coupled in 3T3-LI using pertussis toxin. Indeed, pertussis toxin should be expected to
inhibit AZ359-induced inhibition of forskolin-stimulated cAMP level, indicating that
GPRI19 is Gj-coupled in 3T3-Ll.
As GPR119 was detected in adipose tissue in this study, and AZ359 was also found to
decrease cAMP level induced by forskolin (Figure 4-3), it is expected that OEA should
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inhibit cAMP level induced by forskolin via GPR119. The implication of this. is that
GPRI19 agonists might be a therapeutic option for obesity due to the fact that OEA is a
hypophagic agent (Overton et al., 2006).
GPRI19 was also investigated for ERK signalling in rat primary skeletal muscle cells
using immunoblotting. However, no phosphorylation was observed following GPRI19
activation at any time point. It is possible that GPR119 did not couple to Gs in rat
primary skeletal muscle culture. It is also possible that mRNA might not reflect the
proteins level in skeletal muscle. Further investigation is suggested to examine the
protein expression level for this receptor such as immunoblotting or
immunocytochemistry.
Regarding signalling via Gj-GPCRs (including (l2A-adrenoceptors, Al adenosine
receptor, CBl receptor and NPY Yl receptor), the activation of these GPCRs did not
inhibit forskolin-evoked cAMP. The different explanations behind the lack of response
for the activation of Gj-GPCRs might be due to: I) As skeletal muscle expressed adcy2
and adcy6, it is possible that decrease in cAMP level by inhibition of AC2 and AC6
through Gjprotein might be neutralized by activation of AC through GJtysubunit. This is
supported by the fact that Gpysubunit was found to increase AC2 activity in insect
ovarian Sf9 cells infected with recombinant baculovirsus (B-rACII) (Tang et al., 1991),
and coexpressed G,protein in Sf9 cells was also found to inhibit AC2 and AC6 activity
(Taussig et al., 1994).2) The receptors might not couple to G, protein subunit, therefore,
no effect was observed for ligands. 3) G, protein might not be expressed in skeletal
muscle; a potential significant influence is that the conditions for culturing myotubes
are different from those in vivo, including intermittent innervation and variable (time,
concentration, etc.) exposure to hormones. 4) The mismatch between mRNA and
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protein expression of these receptors, as suggested previously. As activation of any of
the identified Gi GPCRs failed to decrease cAMP levels, it is strongly supported that
these GPCRs did not couple to G, subunit. However, further investigation is suggested
to examine the protein expression of these receptors and Gi subunit using
immunoblotting and immunocytochemistry. Moreover, investigation is recommended to
test the signalling of these receptors using cAMP assay in presence of electrode to
mimic the in vivo conditions for this primary cell culture. Further investigation is also
suggested to examine the coupling of these receptors to G, protein using pertusis toxin,
for example, the effect u2A-adrenoceptorsof ERK phosphorlyation can be examined if
ERK phosphorlyation occurred through coupling to Gi protein. Indeed, inhibition of
ERK phosphorlyation should be observed in the presence of pertusis toxin. Furthermore,
siRNA for GJ3ysubunit is suggested to examine the effect of these GPCRs activation on
the cAMP level.
These findings provided evidence for functionally-active A2Badenosine receptors, CBI
receptors and (potentially) a2-adrenoceptors in skeletal muscle which might be
important for skeletal muscle fat and glucose metabolism and skeletal muscle growth.
These findings also provide evidence for Gs-coupling for the A2Badenosine receptor
and Gq-coupling for P2YIIP2Y21P2Y6receptors. However, these findings did not
provide direct evidence for Gi-coupling for any Gj-GPCR tested, including the CBI
receptor (Table 4-2). The impact of the CBI receptor in skeletal muscle will be the
subject of further investigation in the following chapter.
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Table 4-2: Summary of findings for Chapter 4.
Receptors cAMP level ERK Calcium level
phos_p_horylation
CBI no effect increase ( j)
A2B increase (j)
A2A no effect
Al no effect
a2A no effect increase ( j)
P2Y increase (t
GPR119 no effect
NPY no effect
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Chapter 5
Cannabinoid Signalling
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5 Chapter Five: Cannabinoids and insulin signalling in rat
primary skeletal muscle cells
5.1 Introduction
Obesity has grown in the United States and throughout the world at an unprecedented
rate in recent decades (Ogden et al., 2006; Singh et al., 2011). Obesity, especially fat
accumulation in the intra-abdominal region is linked to disease states such as: type 2
diabetes mellitus (Colditz et al., 1995), hypertension (Witteman et al., 1989),
cardiovascular disease (Rimm et al., 1995), osteoarthritis, steatohepatitis, and cancer
(Calle et al., 2004a; Calle et al., 2003; Calle et al., 2004b). Indeed, obesity has been
linked to the development of insulin resistance and other metabolic abnormalities
underlying the pathology of Type 2 diabetes mellitus. The pathogenesis of Type 2
diabetes mellitus is the failure of insulin action on metabolic tissues - known as insulin
resistance. In other words, insulin resistance is the reduced ability of insulin to
effectively stimulate glucose transport due to alteration of insulin receptor expression or
insulin release in response to food ingestion (Del Prato et al., 2002; Ferrannini, 1998;
Mosthaf et al., 1991). Moreover, insulin resistance can be associated with altered
insulin receptor sensitivity which might be modulated by potential pharmacological
agents such as RIM (Kahn, 1978).
Skeletal muscle is the largest tissue in the human body and represents -40% of the
human body mass and 35-40% of the total body weight in the rat (Delbono et al., 2007;
Pedersen, 2011). Indeed, it plays a crucial role in maintaining body glucose homeostasis
(James et al., 1985) and it clears out the majority (70-80%) of ingested glucose since it
is the main site for insulin-dependent and non-insulin-dependent or contraction-
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mediated glucose uptake (Baron et al., 1988; Ferrannini et al., 1983; Toft et al., 1998).
Therefore, skeletal muscle is generally considered as the most important site of insulin
resistance. Insulin resistance in skeletal muscle participates in glucose intolerance and
consequently in compensatory hyperinsulinemia (Nistala et al., 2006).
Because of the crucial role of skeletal muscle in the etiology of glucose transport,
interventions to ameliorate the dysfunction in insulin dependent or non-insulin-
dependent pathways were suggested (Zierath et al., 2000).
A novel therapeutic intervention in the treatment of obesity and hyperglycemia might
occur through the antagonism of the endocannabinoid system. Indeed, studies from
animals and humans have shown that the endocannabinoids are increased in the obese
state. In addition, obese animal models showed that levels of endocannabinoids were
elevated in the hypothalamus and peripheral tissues (Di Marzo et al., 2001; Matias et
al., 2006; Osei-Hyiaman et al., 2005). Moreover, studies showed that circulating levels
of AEA and 2-AG were raised, and 2-AG was also found to be elevated in visceral
adipose tissue in obese and hyperglycaemic type 2 diabetic patients (Bluher et al., 2006;
Engeli et al., 2005; Matias et al., 2006). Furthermore, CBI knock-out mice were found
to be resistant to diet-induced obesity (Osei-Hyiaman et al., 2005; Ravinet Trillou et al.,
2004). Originally, CBI receptor antagonism was investigated as a mediator of the
hypophagic effect which leads to weight loss (Di Marzo et al., 2001; Vickers et al.,
2003). However, independent to hypophagic weight loss attributed to CBI receptor
antagonism, CBI receptor antagonism was also discovered to improve metabolic
parameters, such as increased glucose uptake in skeletal muscle (Liu et al., 2005),
increased glucose tolerance (Bermudez-Siva et al., 2006; Nogueiras et al., 2008) and
decreased hyperinsulinemia (Doyon et al., 2006) as well as effects on lipids (increased
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HDLILDL ratio and increased triglyceride) (Despres et al., 2005).
As previously stated, skeletal muscle is the primary tissue for glucose uptake. CBI
receptor mRNA and protein expression has been detected in skeletal muscle myotubes
and tissues of rodents and humans (Cavuoto et al., 2007b; Pagotto et al., 2006). In
addition, in mice fed a high fat diet (HFD), the expression of CB, in skeletal muscle
was found to be up-regulated (Pagotto et al., 2006).
From agonist and antagonist studies, both in vitro and in vivo, it seems that the
endocannabinoid system plays a role in glucose transport in skeletal muscle. In vitro,
using cell culture models (L6 mouse myotube cell line and human primary skeletal
muscle cells), Esposito et al and Eckardt et al, respectively showed that CB, receptor
antagonism using RIM enhanced basal and insulin-stimulated glucose transport activity
(Eckardt et al., 2008b; Esposito et al., 2008). In vivo, chronic CB, receptor antagonism
was found to increase insulin-stimulated glucose transport activity in obese mice (Liu et
al., 2005). Furthermore, chronic CB, receptor antagonism during euglycemic
hyperinsulinemic clamp increased glucose uptake in diet-induced obese rats by several
skeletal muscle groups (Nogueiras et al., 2008). These data suggest that the
endocannabinoid system can playa role regarding glucose transport in skeletal muscle.
The glucose transport into the skeletal muscle is facilitated mainly by the GLUT4
isoform. The mechanism, through which CB, antagonists affects glucose levels is
unknown. AKT, GSK3, AMPK, and P38 are proteins associated with insulin-stimulated
and non-insulin-stimulated signalling involved in glucose transport activity. From the
literature, many researchers showed that CB, receptor might affect these proteins.
Regarding P38 and AMPK, treatment of myotubes with a CB, receptor agonist
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increased the phosphorylation ofP38 (Eckardt et al., 2008b). Even though it was shown
that CBI receptor modulation did not affect AMPK in skeletal muscle in Zucker rats
(Lindborg et al., 2011), another group showed that chronic CBI receptor antagonism in
obese mice increased AMPK phosphorylation in the liver (Watanabe et al., 2009).
Indeed, it was shown that RIM activated AMPK in HepG2 cells (Wu et al., 2011). CBI
receptor antagonism was additionally suggested to have an effect on key signaling
proteins related to energy status, such as increased phospho-AMPK in cultured white
adipose cells (Tedesco et al., 2008). CBI receptor antagonism was also shown to
increase mRNA expression of AMPK in human primary myotubes (Cavuoto et al.,
2007a). Regarding AKT and GSK3, there are controversial data about the
phosphorylation of AKT in L6 cells, primary skeletal muscle cells and tissues. Addition
of the cannabinoid HU-210 was associated with increased phosphorylation of AKT as
well as GSK3p in granule cell precursors during early cerebellar development (Trazzi et
al., 2010). Furthermore, it was shown that THC was associated with increased
phosphorylation of AKT as well as GSK3p in the central nervous system, but not with
low dose-treatment of RIM (Ozaita et al., 2007). However, another study showed that
HU-210 induced a reduction in whole-body glucose disposal and impaired insulin-
stimulated AKT phosphorylation in skeletal muscle (Song et al., 2011).
The effects of CBI cannabinoid receptor agonism and antagonism in terms of glucose
uptake, metabolism and insulin signalling on peripheral targets, particularly skeletal
muscle are unclear (Eckardt et al., 2009; Lindborg et al., 2011; Lipina et al., 2010). In
an attempt to address this issue, the signalling events underlying the activation and
inhibition of the CBI receptor in rat primary skeletal muscle cells were investigated.
Furthermore, the effects of pharmacological activation or blockade of CBI receptor on
insulin signalling were investigated. The effect of RIM and ACEA on gene expression
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was also investigated in rat primary skeletal muscle cells.
5.2 Aims
5.2.1 General aim
The main aim of this series of experiments was to investigate the impact of CB I
activation and inhibition upon insulin signaling and to characterize the molecular
mechanisms that mediate the direct effects of ACEA and/or RIM on skeletal muscle.
5.2.2 Specific aims
-To assess whether activation of CBI receptor with both physiological and
pharmacological cannabinoids (AEA and ACEA) affects ERK, P38 and AMPK
phosphorylation.
-To assess whether activation of CBI receptor with ACEA and AEA and their inhibition
with RIM and AM251 affects insulin-induced phosphorylation of AKT, aSK, ERK,
and P38.
-To compare gene expression in rat primary skeletal muscle cells in response to the
following treatments: ACEA, ACEA+RIM, RIM alone and ACEA + V0126 (MEK
inhibitor). The comparison of the effects of V0126 versus vehicle and RIM versus
vehicle will provide information about the direct effects of VO 126 and RIM on gene
expression. The independent and combined effects of ACEA and RIM will be examined
by comparison of the following conditions:
- Comparison of condition (ACEA versus vehicle) and (ACEA+RIM versus
RIM) wil provide information about the effect of ACEA in the presence and absence of
RIM.
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- Comparison of condition (ACEA versus vehicle) and (ACEA+U0126 versus
U0126) wil provide information about the effect of ACEA in the presence and absence
ofU0126.
- Comparison of condition (ACEA versus vehicle) and (ACEA+U0126 versus
ACEA) will reveal to what extent the effects of ACEA on gene expression are mediated
via ERK pathway.
- Comparison of condition (ACEA versus vehicle) and (ACEA+RIM versus
ACEA) will reveal to what extent the effects of ACEA on gene expression are mediated
via CBI receptor.
5.3 Experimental design and methods
5.3.1 Experiments for ERK and P38 phosphorylation
Primary Wistar rat vastus lateralis 90% confluent myotubes (5 weeks in culture) (n=6
wells) were serum-starved (Ham-F 10 medium alone) for 3 hours. Then, the cells were
treated for 10 minutes with vehicle (0.05% ethanol), ACEA 10 nM, ACEA 100 nM,
RIM 100 nM for 40 minutes, ACEA 10 nM+ RIM (cells were pretreated with RIM for
30 minutes before addition of ACEA), AEA 10 J.lMand AEA 10 J.lM+ RIM (cells were
pretreated with RIM for 30 minutes before addition of AEA). After treatment, cells
were washed with ice-cold PBS, and then were lysed with Trizol (800 J.lIper well). P-
ERKIERK and P-P381P38 ratios were used to compare the activation of ERK and p38
between conditions.
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5.3.2 Experiments for AMPK phosphorylation.
Primary Wistar rat vastus lateralis 90% confluent myotubes (5 weeks old) in 25 cm2
flasks were incubated with charcoal stripped fetal bovine serum 6% for 24 hours before
treated for 1 or 2 hours with either AICAR 1 mM, vehicle (ethanol 0.01%), ACEA 10
nM, RIM 100 nM, ACEA+AICAR (cells were preincubated with ACEA for 30 minutes
prior to treatment with AICAR). After treatment, cells were washed with ice-cold PBS,
and then were lysed with Trizol (2 ml per 25 cm2 flask). P-AMPKlcyclophilin ratio was
used to compare the activation of AMPK among various conditions.
5.3.3 Experiments for the effect of ACEA, RIM, AM251 and insulin
Primary Wistar rat vastus lateralis 90% confluent myotubes (5 weeks old) (grown in 6%
delipidated serum) were treated for 22 hours with vehicle (ethanol 0.01%), ACEA 100
nM, RIM 100 nM, AM251 100 nM and AEA 10 11M. Then, the cells were serum-
starved for 2 hours, and this was followed by the cells being treated with insulin 100
nM for 10 minutes. After treatment, the cells were washed with ice-cold PBS, and then
were lysed with Trizol. P-AKT/AKT, P-ERKlERK, P-P381P38 and P-GSKIGSK ratios
were used to compare the activation of AKT, ERKI and 2, P38 and GSK3 among
various conditions.
5.3.4 Glucose uptake assay
Myotubes, differentiated as detailed in Chapter 2, Section 2.10, were serum-starved for
2 hours and then were treated with 2.5 nM, 5 nM, 10 nM, 50 nM and 100 nM insulin for
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10 minutes, followed by addition of27.8 KBq 3H 2-DOG and 1.5 mM cold 2-DOG for
10 minutes. Glucose uptake was carried out as described in Chapter 2.
Calculation:
Uptake percentage = total amount of disintegrations per minute (DPM) measured per
well (absorbed) Itotal amount ofDPM added per well • 100%
(pmoles of glucose multiply by uptake percentage )/incubation time=pmole/minutes
5.3.5 Microarray
5.3.5.1 Experimental design
Myotubes were cultured in 25 cm2 flasks and incubated with ACEA 10 nM, RIM 100
nM and UOI26 10 J.lMfor 24 hours (four flasks/condition). Ethanol 0.01% was used as
a vehicle control. Fresh charcoal stripped fetal bovine serum 6% was replaced for four
hours before performing the treatment. RIM and UOI26 were used for 30 minutes
before the relevant treatments.
5.3.5.2 Procedure for the microarray
The treated myotubes were lysed using Trizol and stored at -80°C, then total RNA was
extracted and cleaned up with the Qiagen Rneasy kit according to the manufacturer's
instructions.
All RNA samples were examined using Agilent Bioanalyzer. Samples that had a RIN
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greater than 8 were included in the analysis. These values indicated that RNA
degradation did not occur. Distinct bands of 28S and I8S RNA were visualized in all
RNA samples isolated from the vehicle, ACEA, RIM and UOI26-treated myotubes to
confirm that the RNA was suitable for microarray procedure (Table 5-1).
Table 5-1: Quality of RNA isolated from myotubes.
Samples RIN Samples RlN
Vehicle I 9.8 RIM I 9.5
Vehicle2 9.5 RIM2 9.7
Vehicle3 9.8 RIM3 9.8
Vehicle4 10 RIM4 10
ACEAI 8.7 ACEA+UOI26 I 9.8
ACEA2 9.3 ACEA+U01262 9.6
ACEA3 9.8 ACEA+U01263 9.7
ACEA4 9.5 ACEA+U01264 9.9
ACEA+RlMI 9.S UOl26 I 9.6
ACEA+RIM2 9.9 UOl262 9.6
ACEA+RIM3 9.8 UOl263 9.5
ACEA+RIM4 8.1 U01264 8.9
Briefly, synthesis of labelled cRNA, hybridization, and scanning of microarrays were
carried out as described (Schafer et al.; Voss et al., 2005) according to established
methods in the manufacturer's protocols (Affymetrix, Santa Clara, CA) by staff at the
Nottingham Arabidopsis Stock Centre (NASC).
5.3.5.3 Gene expression profiling, data processing and analysis
Global changes in gene expression induced by ACEA, RIM and U0126 were
determined using Affymetrix Rat Genome 230 PM Array.
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5.3.5.4 Pre-analysis data treatment
Before analysis took place, the raw microarray (Cel files) data was pre-processed
through RMA (Robust Multichip Averaging) algorithm. RMA has the following
components; background correction, normalization and probe summarization.
A) Background correction was based on the distribution of perfect match (PM)
values amongst probes on an Affymetrix array. Plate and exon (PM only) arrays
contain a set of antigenomic background probes that are not matched to any
putative transcript region. By default, the Affymetrix software estimates probe
background signal by the median response of all background probes with
matching GC content to the probe in question. This background signal is then
subtracted from the probe intensity to yield a background-corrected intensity.
B) Quantile normalization was performed within all arrays based on the raw
intensities (Raymond et al., 2010). Normalization was performed to remove
nonbiological effect among all arrays. This makes all arrays comparable. The
RMA used quantile normalization. In this normalization, 1) probe intensities
were ranked for each array, 2) the average across all arrays was taken and 3) the
corresponding values of probe intensities were all set to the average.
Consequently, these steps force the distribution of measurements on all arrays to
be equal.
C) Probe summarization was performed through observing probe behavior [Le., log
transformed (PM) after background correction; any values attributed to
background were eliminated] on the log scale as the sum of the actual
expression value on the log scale (a probe specific term).
The summary of the final steps of data transformation were:
1) Log2 transformation of the intensities.
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2) Tukey's median polish was used to summarize the intensity values of
individual probes into a single measurement for the corresponding gene.
After raw data was normalized, genespring GX 11 software was used to identify
differentially expressed genes.
5.3.5.5 Initial characterisation of micro array gene expression data
The microarray data were summarized using Principal Components Analysis (PCA)
based on gene expression patterns for each of the experimental conditions (Figure 5-1).
All four replicates treated with ACEA, RIM and U0126 were grouped in the scatter plot.
Color by Treatment
• ACEA
• ACEA+RIM
• ACEA+U0216
• RIMZ-Axis
-_
• U0216..
• Vehicle
Figure 5-1: Three-dimensional scatter plot view of technical replicates of myotubes. Myotubes (four
flasks, n=l rat) were cultured and treated with 10 nM ACEA, lOO nM RIM or 10 u'M U0126 for 24 hours.
The Whole-Transcript Expression Analysis was performed by hybridizing RNA to the Affymetrix Rat
Genome 230 PM Array. The dataset was visualized using Principal Components Analysis (PCA).
Samples were displayed in respect to the first three components and coloured by the treatment parameter.
As shown in Figure 5-2; normalized intensity values (y-position) shows reasonable
variability across the conditions. All boxes had relatively similar interquartile range and
median of the distribution.
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Figure 5-2: Box-plots of probe intensities before (A) and after (B) normalization. The raw intensity
values were background-corrected, quantile-normalized and log (base 2)-transformed at the probe level
using the Robust Multi-array Average (RMA).
Correlation was performed between pairs of conditions using Affymetrix IDs common
to all microarrays. In order to test the reproducibility of these data, the correlation co-
efficient of technical replicates were calculated between conditions on the normalized
data. All correlation coefficients were found to be higher than 0.98 across all conditions.
The normalized data (not transfonned to the median of all samples) was used in all
subsequent analyses.
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5.4 Statistical analysis
Western Blot: Data were analyzed using one or two-way ANOVA and Bonferroni's
multiple comparisons post-hoc test unless otherwise stated. Analysis was performed
using OraphPad Prism, version 5.03 (OraphPad Software Inc). The difference was
considered significant at P < 0.05. All experiments were repeated at least twice from
two different animals.
Microarray: After preprocessing the microarray raw data, genespring OX 11 was used
to identify differentially expressed genes. Using the normalized microarray data,
conditions were compared using one-way ANOVA and Benjamini-Hochberg test. A
statistically significant difference was accepted when the treatment effect yielded a P <
0.05 to correct for the likelihood of false positives. This p-value was used as a cut off
for differentially expressed genes. Then, the 2 fold-change approach (increase or
decrease) was utilized.
Data were further analysed usmg Ingenuity Pathways Analysis (IPA)
http://www.ingenuity.com. The list of differentially regulated genes identified by the
microarray analysis using genespring OX 11 was exported into IPA, which predicted
biological functions of genes that are associated with particular biological processes.
Statistics was performed from low number of repeats (n=2 rats) (no statistical difference
was observed among the replicates within the same treatment) for western blot and
glucose uptake experiments and (n=1 rat (4 flasks» for microarray experiment in this
chapter due to cost implications. Indeed, it is recommended to perform more repeats to
support the results deduced in this chapter, in particular it is hard to depend on statistical
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analysis from 1 or 2 repeats due to variations in species or technical work. More repeats
will solidate the data statistically.
Due to the limitations of time and cost, a complete concentration response curve or time
response curve were not performed for every drug. Instead, a single concentration and a
single time point were used based on the previous literature. Different concentrations
and time points are required to have a clear comprehensive image about the nature of
the response. Depending on a single time point and a single ligand concentration is not
sufficient to completely exclude a potential cross-talk between insulin and cannbinoids
or a potential effect for RIM or ACEA in these primary skeletal muscle cells. Regarding
the experimental designs for the micro array or western blot, the use of 24 hours
treatment may miss potential changes in insulin sensitivity or the effects of ACEA and
RIM. Indeed, repeating the microarray experiment and western blot is required at
different time points such as 3 minutes, 5 minutes, 10 mintues, 30 minutes, one hour, 6
hours, 12 hours, 18 hours and 24 hours.
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5.5 Results
5.5.1 Effect of ACEA, AEA, and RIM on ERK phophorylation
In order to assess the signalling of the CB) receptor, ERK phosphorylation was
investigated (Figure 5-3).
Cells treated with ACEA (10 nM and 100 nM) and AEA (10 J.lM)for 10 minutes
showed a significant increase in P-ERKlIERKl and P-ERK2IERK2 ratio compared to
vehicle (P<O.OOl).Pretreatment of the myotubes with 100nMRIM for 30 minutes prior
the addition of either 10 nM ACEA or 10 J.lMAEA inhibited these effects. However,
there was no significant difference between 100 nM RIM and vehicle (0.01% ethanol).
It is worth mentioning that ACEA, AEA and RIM did not activate (phosphorylate) AKT.
The treatment of muscle culture with 100 nM ACEA and 100nMRIM for 24 hours did
not alter the phosphorylation for ERK1I2 compared to vehicle (Figure 5-8). The
molecular weight of the bands for P-ERKlIERKl and P-ERK2IERK2 was detected at
44 kDa and 42 kDa, respectively, as expected.
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Figure 5-3: Effect of ACEA, AEA and RIM on phosphorylation ofERK in rat primary muscle cells (n=2
rats). A) Myotubes were treated with vehicle (0.01% ethanol), ACEA (10 and 100 nM) or AEA (10 11M)
for 10 minutes; RIM only for 40 minutes; RIM for 30 minutes before the addition of either ACEA or
AEA. *** denotes P<O.OOI when compared to vehicle, RIM and agonist+RIM conditions. B and C)
Representative blots showing rat primary muscle cells treated with vehicle (0.01% ethanol), ACEA (10
nM) in B figure, ACEA (lOO nM) in C figure, and AEA (10 11M) for 10 minutes and RIM for 30 minutes.
Phospho-ERK 112 is shown in green bands and total ERK 1/2 in red bands. Data were analyzed using one
way ANOV A test followed by Bonferroni post-hoc.
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5.5.2 Effect of ACEA, RIM on P38 phosphorylation
In order to test the signalling for CBI receptor, P38 phosphorylation was investigated
(Figure 5-4).
Cells treated with ACEA (10 nM) for 10 minutes showed a significant increase in P-
P38/P38 ratio compared to vehicle (P<O.OOl). Interestingly, pretreatment of the
myotubes with 100 nM RIM for 30 minutes prior the addition of 10 nM ACEA
inhibited this effect. However, there was no significant difference between 100 nM
RIM and vehicle (0.01 % ethanol). The molecular weight of the bands for P-P38/P-38
was detected at 43 kDa as expected.
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Figure 5-4: Effect of ACEA and RIM on phosphorylation of in rat primary muscle cells (n=2 rats). A)
Myotubes were treated with vehicle (0.01% ethanol), ACEA (l0 nM) for 10 minutes; RIM only for 40
minutes; RIM for 30 minutes before the addition of ACEA *** denotes P<O.OOIwhen compared to
vehicle, RIM and ACEA+RIM conditions. B) Representative blots showing rat primary muscle cells
treated with vehicle (0.0 I% ethanol), ACEA (10 nM) for 10 minutes and RIM for 30 minutes. Phospho-
P38 is shown in green bands and total P38 in red bands. Data were analyzed using one way ANOVA test
followed by Bonferroni post-hoc.
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5.5.3 Effect of ACEA, RIM on AMPK phosphorylation
AMPK is a protein that might play a role in glucose uptake, increase cell surface
GLUT4 levels and fatty acid oxidation (Aschenbach et al., 2002). The effect of
cannabinoids on AMPK phosphorylation was investigated (Figure 5-5).
The AMPK agonist AICAR (1 mM) produced a significant 3-6 fold stimulation of P-
AMPK levels at 1 hour and 2 hours compared to vehicle (P<O.OOl),two-way ANOVA,
Bonferroni post-hoc. However, there was no significant difference between ACEA or
RIM and vehicle. Pre-treatment with ACEA did not alter the AICAR-induced increase
in AMPK phosphorylation. The molecular weight of the bands for P-AMPK and
cyclophilin was detected at 62 kDa and 21 kDa, respectively, as expected.
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Figure 5-5: Effect of ACEA, RIM and AICAR on phosphorylation of AMPK in rat primary muscle cells
(n=2 rats). A and B) Myotubes were treated with vehicle (0.01% ethanol), ACEA (100 nM), RIM (lOO
nM), AICAR (1 mM) and ACEA+AICAR for 1 and 2 hours. *** denotes P<O.OOI when compared to
vehicle, ACEA, RIM and AICAR. C and D) Representative blots showing rat primary muscle cells
treated for 1 hour. F and G) Representative blots showing rat primary muscle cells treated for 2 hours. P-
followed by Bonferroni post-hoc.
AMPK and cyclophilin are shown in green bands. Data were analyzed using two way ANOV A test
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5.5.4 Effect of ACEA, AEA, RIM and AM251 on insulin signalling; AKT.
Given that AKT is a downstream protein of insulin signalling (Jiang et al., 2003b), the
effect of cannabinoids on AKT phosphorylation was investigated (Figure 5-6). In
addition to ACEA and RIM, AEA and AM251 were used to compare with other
researchers regarding AKT (Eckardt et al., 2009).
Pretreatment of cells with 100 nM ACEA, 100 nM RIM, 10 flM AEA and 100 nM
AM251 for 24 hours did not affect the phosphorylation of AKT induced by treatment
with 100 nM insulin for 10 minutes. The molecular weight of the bands for P-
AKT/AKT was detected at 62 kDa as expected.
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Figure 5-6: Effect of ACEA, AEA, RIM and AM251 on insulin-induced phosphorylation of AKT in rat
primary muscle cells (n=2 rats). A and B) Myotubes were treated with vehicle (0.01 % ethanol), ACEA
(100 nM), AEA (lOuM), RIM (100 nM) and AM251 (100 nM) for 24 hours before the addition of insulin
for 10 minutes. *** denotes P<O.OOI when compared to vehicle. C and D) Representative blots showing
rat primary muscle cells treated with different conditions. Phospho-AKT is shown in green bands and
AKT in red bands. Data were analyzed using one way ANOV A test followed by Bonferroni post-hoc.
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5.5.5 Effect of ACEA and RIM on insulin signalling; GSK.
GSK, a downstream target for AKT, inhibits glycogen synthesis (Cross et al., 1995).
Therefore, the effect of cannabinoids on GSK phosphorylation was investigated (Figure
5-7). The reason behind using ACEA and RIM, not AEA and AM251, was to compare
this study with what a previous study found regarding GSK in rat (Lindborg et al.,
2011). The pretreatment of cells with 100 nM ACEA, 100 nM RIM for 24 hours did not
alter the insulin-induced phosphorylation state of GSK. The molecular weight of the
bands for P-GSKal GSKa and P-GSK~/GSK~ was detected at 44 kDa and 42 kDa,
respectively as expected.
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Figure 5-7: Effect of ACEA and RIM on insulin-induced phosphorylation of GSK in rat primary muscle
cells (n=2 rats). A) Myotubes were treated with vehicle (0.01 % ethanol), ACEA (100 nM) and RIM (lOO
nM) for 24 hours before the addition of insulin for 10 minutes. *** P<O.OO 1 when compared to vehicle. B)
Representative blots showing rat primary muscle cells treated with different conditions. Phospho-GSK is
shown in green bands and GSK in red bands. Data were analyzed using one way ANOV A test followed
by Bonferroni post-hoc.
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5.5.6 Effect of ACEA and RIM on insulin signalling; ERK.
Another downstream protein of insulin signaling is ERK (Holt et al., 1996). Therefore,
the effect of cannabinoids on ERK phosphorylation was investigated (Figure 5-8).
The pretreatment of cells with 100 nM ACEA and 100 nM RIM for 24 hours did not
alter the insulin-induced phosphorylation of ERK1I2. The molecular weight of the
bands for P-ERKI/ERKI and P-ERK2/ERK2 was detected at 44 kDa and 42 kDa,
respectively, as expected.
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Figure 5-8: Effect of ACEA and RIM on insulin-induced phosphorylation of ERK in rat primary muscle
cells (n=2 rats). A and B) Myotubes were treated with vehicle (0.01% ethanol), ACEA (100 nM) and
RIM (100 oM) for 24 hours before the addition of insulin for 10 minutes. *** denotes P<O.OOI when
compared to vehicle and ACEA. C and D) Representative blots showing rat primary muscle cells treated
with different conditions. Phospho-ERK is shown in green bands and total ERK in red bands. Data were
analyzed using one way ANOV A test followed by Bonferroni post-hoc.
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5.5.7 Effect of ACEA and RIM on insulin signalling; P38
Another downstream protein of insulin is P38 (Somwar et al., 2000). Therefore, the
effect of cannabinoids on P38 phosphorylation was investigated (Figure 5-9).
The pretreatment of cells with 100 nM ACEA or 100 nM RIM given 24 hours prior to
insulin treatment did not affect the insulin-induced phosphorylation of P38. The
molecular weight of the bands for P-P38/P-38 was detected at 43 kDa as expected.
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Figure 5-9: Effect of ACEA and RIM on insulin-induced phosphorylation of P38 in rat primary muscle
cells (n=2 rats). A) Myotubes were treated with vehicle (0.01% ethanol), ACEA (lOO nM) and RIM (100
nM) for 24 hours before the addition of insulin for 10 minutes. *** denotes P<O.OOI when compared to
vehicle. B) Representative blots showing rat primary muscle cells treated with different conditions.
ANOV A test followed by Bonferroni post-hoc.
Phospho-P38 is shown in green bands and total P38 in red bands. Data were analyzed using one way
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5.5.8 The effect of cannabinoids on glucose uptake
It was shown in this study (this Chapter, Section 5.5.4) that 100 nM insulin, when
incubated with skeletal muscle cell culture, resulted in an increase in AKT
phosphorylation. It was also shown in previous studies that cannabinoids affect glucose
uptake (Eckardt et al., 2008b; Lindborg et al., 2011). In order to understand the effects
of cannabinoids on skeletal muscle myotubes, glucose uptake was examined in this
model of skeletal muscle cell culture as an index of glucose uptake.
Increasing insulin concentrations (2.5nM, 5nM, 10nM, 50nM and 100nM) used did not
increase glucose uptake compared to control. Therefore, it was decided to increase the
ratio of hot glucose/cold glucose by decreasing the cold 2-DOG concentration to 10 IlM
(hot: radioactive versus cold: non-radioactive). At 10 IlM cold glucose, the experiment
was repeated for insulin at concentration 100 nM. Insulin did not induce glucose uptake
compared to vehicle. Therefore, it was decided to modify the method by increasing the
starvation period (5-6 hours), using media instead of reaction buffer, increasing the
incubation time for insulin to one hour at a concentration of 200nM and incubation in
hot glucose to 15minutes.
In the previous conditions, insulin gave only a slight response in some wells compared
to control. Unfortunately, this experiment was repeated many times, and the results
were reproducible; we saw a slight but non-significant change in glucose uptake or no
change. In other words, insulin did not induce glucose uptake compared to vehicle.
Therefore, it was decided to modify the method of utilizing the cell culture; after
collecting satellite cells (pellet), cells were plated in 75 cm2 flask and grown in 25 mM
glucose, 10% FBS DMEM. After they became 70% confluent, cells were trypsinized 2-
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3 times with trypsin and then plated in 6 well plates. After around 3-4 days, glucose
uptake assay was performed. Insulin did not induce glucose uptake compared to vehicle
(Vehicle 1=19.56, Vehicle 2 = 18.74, Insulin 1 = 18.02 and Insulin 2 = 19.05
pmol/minlmg). Taking all experiments into consideration which were performed for
glucose uptake in rat primary myotubes, it was decided to use 3T3-Ll adipocytes as
positive control for the original and modified technique.
3T3-Ll adipocytes were serum-starved for 24 hours with 12.5mM glucose or 5 hours
with 5.5 mM glucose; and then glucose uptake assay was conducted as discussed in
chapter 2 section 2.11.2 and 2.11.4. 200nM insulin was shown to significantly increase
glucose uptake compared to vehicle (4-6 fold) (Figure 5-10).
Figure 5-10: 2-DOG uptake by mature 3T3-Ll adipocytes in response to insulin (n=2 experiments). A)
2-DOG uptake, using protocol (adjusted protocol)-DMEM in 6 well plates (See Chapter 2 Section 2.11.4).
3T3-Ll adipocytes were treated with 200 nM insulin for one hour. Data was analyzed using a t-test, *
p<O.05. B) 2-DOG uptake, using original protocol in 6 well plates (see Chapter 2, Section 2.11.2). 3T3-
LI adipocytes were treated with 200 nM insulin for 10 minutes. Data was analyzed using a Hest, ***
p<O.OOl. Uptake was measured as pmol per minute per well in both figures (A+B).
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The mRNA expression of GLUT4 was detected in skeletal muscles using Agilent
microarray (Table 5-2). Therefore, it was decided to do the immunocytochemistry to
investigate GLUT4 translocation induced by insulin in 3T3-L1 adipocytes and
myotubes using the same conditions as for glucose uptake. Using immunofluorescence
microscopy, the translocation and localization of the GLUT4 was visualized in 3T3-Ll
adipocytes cells, upon insulin signalling (Figure 5-11). In the quiescent adipocytes, the
cytoplasm vesicle was stained by anti-GLUT4 antibody (Figure 5-11-A). On the other
hand, in insulin-treated adipocytes, cell membrane was stained by anti-GLUT4 antibody
(Figure 5-11-8). However, no obvious cell membrane translocation of GLUT4 was
observed in insulin-treated myotubes.
Table 5-2: Intensity values for mRNA expression for GLUT from skeletal muscle tissue using Agilent
microarray.
RatA Rat B
Site
A B C A B C Description
solute carrier family 2 (facilitated glucose
6.81 6.18 6.71 7.34 7.00 6.77 transporter), member 4 (Slc2a4)/GLUT4
solute carrier family 2 (facilitated glucose
1.58 1.37 1.33 2.16 1.65 1.40 transporter), member 4 (Slc2a4)/GLUT4
solute carrier family 2 (facilitated glucose
0.65 0.30 0.44 0.78 1.61 0.34 transporter), member 1 (Slc2al)/ GLUTl
solute carrier family 2, (facilitated glucose
0.11 0.25 0.22 1.38 0.99 0.07 transporter) member 8 (SIc2a8)/GLUT8
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A)
Figure 5-11: Immunofluorescence staining of GLUT4 in 3T3-Ll adipocytes using DMR fluorescent
microscope (n=2 experiments). A) Microscope image of day 9 adipocytes stained with anti-GLUT4
antibody. B) Microscope image of Day 9 adipocytes were treated with 200 nM insulin for one hour. They
were stained with anti-GLUT4 antibody.
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5.5.9 The effect of the ACEA and RIM on gene expression
The phospho-ERK was activated with treatment of myotubes with ACEA. This
response was inhibited by RIM. The influence of ACEA on gene expression and
whether the differential genes expression affected by ACEA are CB) receptor
dependent (blocked by RIM) and/or ERK dependant (blocked by U0126) was
investigated using Affymetrix microarray.
Treatment with ACEA up-regulated frizzled-related protein (FRZD) mRNA gene
expression and down-regulated early growth response 2 (EGR2), hyaluronan synthase 2
(HAS2), oxidized low density lipoprotein (lectin-like) receptor 1 (OLR1) and regulator
ofG-protein signaling 2 (RGS2) mRNA gene expression (Figure 5-12) (see (Table 9-13)
in Appendix for complete data).
ACEA vs Vehicle
FRZB
OLR1
HAS2
RGS2
EGR2
-3 -2 -1 o
Fold change
2 3 4
Figure 5-12. The effect of ACEA on mRNA gene expression in rat primary skeletal muscle cells (fold
changes) (n=1 rat). RGS2; regulator of G-protein signaling 2, 24kDa, OLRI; oxidized low density
lipoprotein (lectin-like) receptor 1, HAS2; hyaluronan synthase 2, FRZB; frizzled-related protein and
EGR2; early growth response 2. Data were analyzed using one way ANOV A test followed by Benjamini-
Hochberg test.
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The mRNA expression of EGR2, RGS2 and HAS2 were down-regulated by ACEA;
interestingly these responses were blocked by RIM (ACEA+RIM compared to ACEA).
However, in the presence of RIM (ACEA+RIM vs RIM), ACEA up-regulated the
mRNA expression of ERG2, RGS2 and HAS2. Interestingly, RIM alone down-
regulated the expression of these genes. In other words, the influence of ACEA on
ERG2, RGS2 and HAS2 are CB1 dependent. The expression of these genes was not
blocked by U0126. U0126 down-regulated mRNA expression of EGR2, RGS2, HAS2
and OLRI. However, the influence of ACEA in the presence of U0126 is different to
that of ACEA alone. In the presence of U0126, ACEA up-regulated the mRNA
expression of RGS2 and HAS2 and down-regulated OLRI mRNA expression (Figure
5-13).
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mRNA expression change
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Figure 5-13: Fold changes in gene expression ofEGR2, RGS2, HAS2, OLRl and FRZB in response to
different conditions in rat primary skeletal muscle cells (n=l rat). EGR2; early growth response 2, RGS2;
regulator ofG-protein signaling 2, 24kDa, OLR1; oxidized low density lipoprotein (lectin-like) receptor 1,
HAS2; hyaluronan synthase 2 and FRZB; frizzled-related protein. Data were analyzed using one way
ANOV A test followed by Benjamini-Hochberg test.
Interestingly, treatment with RIM altered mRNA expression of a number of genes.
These genes represent transcription regulators (ANKRD57, BCL3, CEBPD, EGR2,
GBX2, HIVEP1, ID4, IRX3), cytokines (CCL20, CXCL6), transporters (AQP1, LCN2,
RBP1, SLCI6A7), peptidases (C3, PRSS35), nuclear receptors (NR4Al, NR4A2,
NR4A2, NR4A3, NR4A3), GPCR (PTGER4) and growth factor (BMP6). In particular,
LCN2 and NPY were up-regulated by RIM compared to vehicle while NR4A were
down-regulated by RIM compared to vehicle (Table 5-3).
213
Table 5-3: The fold change in the expression of genes influenced by RIM in rat primary skeletal muscle
cells (n= 1 rat).
Fold Change Symbol Entrez Gene Name
3.79 LCN2 l.!Q_ocalin2
3.71 NPY neur~tideY
2.77 CCL20 chemokine (C-C motif) ligand 20
2.75 C3 com~lementcomponent3
2.58 GBX2 gastrulation brain homeobox 2
2.53 RBPI retinol binding protein 1, cellular
transglutaminase 1 (K polypeptide epidermal type I, protein-
2.46 TGMI _gIutam ine-gamma-glutamyltransferase)
2.42 RASDI RAS, dexamethasone-induced 1
2.39 BCL3 B-cell CLUlymphoma 3
2.31 CEBPD CCAAT/enhancer binding protein (CIEBP), delta
2.30 GOS2 GO/G Iswitch 2
chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein
2.26 CXCL6 2)
2.17 MGP matrix Gla protein
2.16 C90rfl6 chromosome 9 open reading frame 16
2.14 APLN apelin
2.13 RNDI Rho family GTPase 1
2.10 BMP6 bone morphogenetic protein 6
2.08 RASLl2 RAS-Iike, family 12
2.08 KRTl8 keratin 18
-2.01 ANKRD57 ankyrin repeat domain 57
-2.02 PRSS35 __Qrotease,serine, 35
-2.03 RGS2 r~ulator ofG-protein signaling 2, 24kDa
-2.06 RAD51 RAD51 homolog (So cerevisiae)
-2.07 TRIO triple functional domain (PTPRF interacting)
-2.09 NR4A2 nuclear receptor subfamily 4, group A, member 2
-2.09 BUBI budding uninhibited by benzimidazoles 1 homolog (yeast)
-2.09 PTGER4 ~rost,!&landin E receptor 4 (subtype EP4)
-2.10 STARDl3 StAR-related lipid transfer (START) domain containiJ!g 13
-2.11 KIF20B kinesin family_member 20B
guanine nucleotide binding protein (G protein), alpha inhibiting
-2.12 GNAI3 activ!!Y_p_olypeptide3
solute carrier family 16, member 7 (monocarboxylic acid transporter
-2.13 SLCI6A7 2)
-2.14 EFEMPI EGF containing fibulin-Iike extracellular matrix protein 1
-2.18 LRRN4CL LRRN4 C-terminal like
-2.21 IRX3 iro_9._uoishomeobox 3
-2.21 NR4A2 nuclear rec~tor subfamily 4, group A, member 2
-2.21 ITGBLI integrin, beta-like 1 (with EGF-Iike repeat domains)
-2.24 MKI67 antiKen identified by monoclonal antibodyKi-67
-2.33 HlVEPI human immunodeficiency virus type I enhancer bindit~g_l~rotein1
-2.35 KIFII kinesin family member 11
-2.42 ARL4C ADP-ribo~Iation factor-like 4C
-2.56 TRIB3 tribbles homol~ 3 (Drosophila)
-2.56 AQPI aqu~orin I_{_Coltonblood group)
-2.58 ECn e_p_ithelialcell transforming sequence 2 oncogene
-2.72 CIQTNF3 C!.g_and tumor necrosis factor related protein 3
-2.84 NR4A3 nuclear rec~tor subfamily 4, group A, member 3
-3.23 NR4A3 nuclear rec~or subfamily 4, group A, member 3
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-3.56 EGR2 early_growth response 2
-3.88 HAS2 h_y_aluronansynthase 2
inhibitor of DNA binding 4, dominant negative helix-loop-helix
-4.23 1D4 protein
-5.22 NR4AI nuclear receptor subfamily 4, group A, member 1
The treatment with RIM affected the expression of a number of genes involved in the
activation of the following biological functions; adipogenesis of cells, inflammatory
response, activation of phagocytes, proliferation of smooth muscle cells and impairment
of tumorigenesis (Table 5-4).
Table 5-4: The biological functions ascribed to genes that were altered by treatment with RIM (n=l rat).
For the gene abbreviation, see (Table 5-3).
Predicted
Functions Activation
Category Annotation State Molecules
Cellular adipogenesis C3,CEBPD,NPY,NR4Al,NR4A2,
Development of cells Increased NR4A3
Connective
Tissue
Development adipogenesis C3,CEBPD,NPY,NR4Al,NR4A2,
and Function of cells Increased NR4A3
Inflammatory inflammatory C3,CCL20,CXCL6,GNAI3,LCN2,NPY
Response response Increased ,NR4A2,PTGER4
Inflammatory activation of
Response phagocytes Increased C3,CXCL6,LCN2,NPY
Cell- To-Cell
Signaling and activation of
Interaction _1)_ha_g_ocY!_esIncreased C3,CXCL6,LCN2,NPY
Hematological
System
Development activation of
and Function
_1)_h~o~es Increased C3,CXCL6,LCN2,NPY
Immune Cell activation of
Trafficking phagocytes Increased C3,CXCL6,LCN2,NPY
Antigen activation of
Presentation
_1)_h~ocytes Increased C3,CXCL6,LCN2,NPY
Cell- To-Cell
Signaling and activation of BCL3,C3,CXCL6,EGR2,KRTI8,
Interaction cells Increased LCN2,NPY
Cellular proliferation
Growth and of smooth
Proliferation muscle cells Increased CEBPD,NR4Al,NR4A2,NR4A3
Skeletal and proliferation Increased CEBPD,NR4Al,NR4A2,NR4A3
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Muscular of smooth
System muscle cells
Development
and Function
AQPI,ARL4C,BCL3,BMP6,BUBI,C3,
CEBPD,CXCL6,ECT2,EFEMP 1,HAS2
,ID4,ITGBLI,KIFII,KIF20B,KRTI8,L
CN2,MGP,MKI67,NR4AI,NR4A2,NR
4A3,PTGER4,RAD51,RASLI2,RBP1,
Cancer tumorigenesis Decreased RGS2,STARD13,TRIO
The effect ofU0126 on gene expression in rat primary skeletal muscle cells is shown in
Table 9-18 in Appendix. The treatment with U0126 affected the expression ofa number
of genes involved in the activation of tumorigenesis (Table 5-5).
Table 5-5: The biological functions ascribed to genes that were altered by treatment with U0126 (n=1 rat).
For the gene abbreviation, see (Table 9-18) in Appendix.
Predicted
Functions Activation
Category Annotation State Molecules
Tissue quantity of tumor BHLHE40,BIRC5,CCNB 1,IGFB
Morphology cell lines Increased P3,JUN,KIF20B,PRCI
mitosis of cervical BIRC5,CCNB l,CDC20,DLGAP5
Cell Cycle cancer cell lines Increased ,PLK1,PTTG1,TOP2A
polyploidization of
Cell C_ycle cells Increased BIRC5,BUBIB,GPCl,TOP2A
cell death of ANGPT1,BIRC5,IGFBP3,NR4A3
Cell Death endothelial cells Increased ,OLR1,PDGFRB,TNFRSFI1B
Treatment with U0126 alone altered the expression of5 genes (JUN, KLFI0, PDGFRB,
CCNA2 and LAMA2) that have a role in the development of skeletal muscle cells
(Figure 5-14).
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Figure 5-14: Fold changes in gene expression of JUN, KLFIO, PDGFRB, CCNA2 and LAMA2 in
response to U0126 in rat primary skeletal muscle cells (n=I rat). JUN; jun proto-oncogene, KLF10;
Kruppel-Iike factor 10, PDGFRB; platelet-derived growth factor receptor, beta polypeptide, CCNA2;
cyclin A2 and LAMA2; laminin, alpha 2. Data were analyzed using one way ANOV A test followed by
Benjamini-Hochberg test.
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5.6 Discussion
In the present study, CBI receptor mRNA was detected in both skeletal muscle tissue
and rat primary cells using QRT-PCR (Taqman). In previous studies, CBI receptor was
found to be expressed in human and rodent skeletal muscle (Cavuoto et al., 2007b).
Interestingly, CBI receptor protein expression was found to be significantly decreased
in soleus muscle from obese compared to lean Zucker rats (Lindborg et al., 2011).
However, CBI receptor mRNA expression in soleus muscle was found to be increased
after high fat feeding in C56BLl6 mice (Pagotto et al., 2006). In the present study, the
functionality of CBI receptor was investigated by assessing the direct effect of CBI
receptor agonism (ACEA and AEA) or antagonism (RIM and AM251) on the activation
of key proteins involved in insulin signalling and glucose uptake in rat primary skeletal
muscle cells.
The main findings from these experiments showed that treatment with ACEA (10 nM)
for 10 minutes increased the activation of extracellular signal-regulated kinase 112and
p38 mitogen-activated protein kinase; these responses were significantly inhibited by
RIM (100 nM). Insulin (100 nM) treatment of myotubes for 10 minutes increased the
activation of AKT/protein kinase B, glycogen synthase kinase 3a and p, ERK1I2 and
p38 MAP kinase; pre-treatment with ACEA (10 nM) and RIM (100 nM) for 24 hours
failed to alter these responses. AICAR (1 mM)-stimulated AMP-activated protein
kinase activity was also unaltered by ACEA.
In the present study, AEA increased ERK phosphorylation in rat primary myotubes.
This activation could be due to CBI or CB2 receptor activation since AEA at this
concentration could work through both receptors (Lin et al., 1998). Indeed, CB2
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receptor was found to be expressed in rodent skeletal muscle (Cavuoto et al., 2007b).
To differentiate which receptor mediates this effect, ACEA was also used since ACEA
is more selective for CBI receptor than CB2 receptor by around 2000 times (Hillard et
al., 1999). ACEA was found to increase ERK phosphorylation in rat primary myotubes.
Interestingly, this effect induced by both AEA and ACEA was blocked by RIM, a
selective CBI receptor antagonist/inverse agonist (Rinaldi-Carmona et al., 1994). This
finding suggests that ERK activation was mediated by activation of the CBI receptor
since ACEA is a selective CBI receptor agonist at the concentration used in the present
study (Hillard et al., 1999). This study also provided strong evidence that CBI receptor
is a functionally active receptor in skeletal muscle. This is in line with a previous study
that also found that treatment of human primary myotubes with AEA (10~01l1) for 10
minutes induces a significant phosphorylation of ERK1I2 when compared to control
(Eckardt et al., 2008a).
In the present study, ACEA also increased P38 phosphorylation in rat primary
myotubes, which is in line with a previous study in human primary skeletal muscle cells
(Eckardt et al., 2008a). Interestingly, this effect induced by ACEA was blocked by RIM,
a selective CBI receptor antagonist/inverse agonist (Rinaldi-Carmona et al., 1994),
which suggests that the cannabinoid-induced activation of P38 in skeletal muscle is
mediated through activation of the CBI receptor. However, treatment ofmyotubes with
ACEA or RIM did not phosphorylate AMPK. AICAR (1 mM)-stimulated AMP-
activated protein kinase activity was also unaltered by ACEA. The time used for the
treatment of myotubes with ACEA, RIM and AICAR was due fact that the
phosphorlyation of AMPK in skeletal muscle was observed after one hour of AICAR
administration in mice (Leick et al., 2010). Futher work should be performed using
different time points for the treatment.
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The functionality of signalling proteins, which are involved in the regulation of insulin-
dependent (AKT, GSK3p, ERK1I2 and P38) or insulin-independent (AMPKu) glucose
uptake, was not altered by 24 hour CBI receptor antagonism (RIM) or agonism (ACEA).
In addition, the functionality of AKT was not altered by AM251 and AEA. This is in
line with a previous study that also found that insulin-induced phosphorylation of AKT,
GSK3p, AMPKu and P38 was not altered by ACEA or RIM in skeletal muscle tissue
from Zucker rats (Lindborg et al., 2011). However, it was shown that AKT
phosphorylation at Ser473 was increased in the presence of RIM in L6 myotubes
(Esposito et al., 2008). It was also shown that phosphorylation of AKT at Ser473 and
AMPK at Thr172 were also enhanced in the liver of ob/ob mice after systemic treatment
with RIM (Watanabe et al., 2009). Phosphorylation of AMPK at Thr172 was increased
in cultured white adipocytes in presence of RIM, as well as in epididymal fat pads from
high fat-fed wild type mice compared to CBI -/- mice (Tedesco et al., 2008). The
mRNA expression of AMPKu was significantly increased in primary cultured human
myotubes treated with RIM (Cavuoto et al., 2007a). Treatment of L6 cells with RIM
enhanced insulin-stimulated AKT while ACEA failed to do so (Lipina et al., 2010).
Moreover, treatment of L6 cells with ACEA inhibited insulin-stimulated ERK and this
response was prevented by RIM (Lipina et al., 2010). It has been demonstrated
previously that both activation and inhibition of the CBI receptor were associated with
modulation of the functionality of these signaling proteins in various tissues and cell
lines. The most likely reason these results from previous studies contradict the findings
from this study is that they used different model (for example, L6 cells), species or
tissues.
The CBI receptor system in skeletal muscle is an emerging area of investigation for
insulin-cannabinoids cross-talk. The endocannabinoid system has been shown to have a
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role in the modulation of whole-body and tissue glucose regulation in several lines of
investigation. Indeed, during a euglyemic-hyperinsulinemic clamp in human subjects,
circulating levels of 2-AG were found to be negatively correlated with glucose infusion
rates (Bluher et al., 2006). During a glucose tolerance test, CBI receptor agonism (AEA
10 mglkg or ACEA 3 mg/kg) was found to lead to elevated circulating glucose levels in
rats (Bermudez-Siva et al., 2006). It was shown that treatment of isolated mouse
pancreatic ~-cells with a CBI receptor agonist, lOO nM ACEA, inhibited glucose-
induced insulin secretion (Nakata et al., 2008), whereas, peripheral infusion of a CBI
receptor antagonist (RIM; 10 mglkg) in diet-induced obese rats decreased hepatic
glucose production (Nogueiras et al., 2008). Therefore, it appears that altering the
signalling or functionality of the CBI receptor in metabolically active tissues may playa
role in the endocannabinoid system's ability to modulate glucose metabolism. As
skeletal muscle is the largest tissue in the body and responsible for most of insulin-
stimulated glucose disposal, treatments that lead to CBI receptor antagonism might
improve glucose transport in skeletal muscle. Consequently, this might make the
endocannabinoid system a novel target in the treatment of insulin resistance and
hyperglycemia. Therefore, glucose uptake was investigated in primary skeletal muscle
cells.
This model of cells (rat primary skeletal muscle cells) did not show any significant
difference for glucose uptake between vehicle and insulin. However, 3T3-LI adipocytes
showed a consistent significant difference between vehicle and insulin (5-6 fold). In this
study, the explanations behind the no significant difference in glucose uptake between
insulin and vehicle using the cell culture for myotubes might be explained by many
suggested aspects; A) Glucose uptake in this model can occur not only through GLUT4
but also might occur through GLUTI or another transporter of which we do not yet
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know. B) Myotubes might reach the saturation level for glucose uptake in both vehicle
and insulin, or that GLUT4 was not coupled to insulin in these cells. D) Glucose uptake
might happen by sodium/glucose co-transporters (SOLT) (Castaneda et al., 2006).
However, the mechanism beyond this in skeletal muscle is unclear. Indeed, in this study,
mRNA expression of SGLT2 and SGLT3 was detected in skeletal muscle using
microarray (ranking out of 41,090 are 14944, 15445, respectively).
It is worth mentioning that it was shown a response to insulin regarding glucose uptake
in human primary muscle cells (Sarabia et al., 1990). However, the reason behind why
other researchers succeeded regarding glucose uptake assay might be due to the fact that
the difference in physiology between human and rat or differences in model used (such
as mouse C2C12 cells or rat L6 cells). Therefore, further investigation should be
recommended to examine glucose uptake in other conditions using electrode and/or
hypoxic conditions. Furthermore, it is recommended to examine another OLUT4
antibody to investigate the OLUT4 translocation in skeletal muscle cells as 3T3-Ll did
in response to insulin.
In a previous study investigating the effect of RIM in overweight or obese patients with
type 2 diabetes, RIM was found to reduce bodyweight and cause a clinically significant
reduction in HbA1clevels (Scheen et al., 2006). However, in this study, neither RIM nor
ACEA affected AKT phosphorylation in rat primary skeletal muscle cells. Indeed, RIM
blocked the stimulatory effect of ACEA on ERK and P38 phosphorylation. Gene
expression changes were studied in peripheral tissues such as liver and adipose from
diet-induced obese mice treated with AM251 (Zhao et al., 2010). They found down-
regulation of genes within fatty acid and cholesterol synthetic pathways such as sterol
regulatory element binding proteins 1 and 2 in both liver and adipose tissues. However,
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these gene expression changes have not been studied in skeletal muscle. Therefore, in
the present study a comprehensive analysis of differential gene expression in response
to ACEA, RIM and U0126 treatments in rat primary skeletal muscle cells was achieved
using Affymetrix Rat Genome 230 PM Array. The four technical replicates used for this
analysis were found to be reproducible since the Pearson correlations for normalized
intensity data for all replicates were above 0.98.
Treatment of myotubes with ACEA for 24 hours up-regulated the mRNA content of
FRZB and down-regulated the expression of OLRI. On the other hand, ACEA down-
regulated the expression of the RGS2, EGR2 and HAS2 genes in a CBI receptor
dependent manner. Indeed, the mRNA expression of RGS2, EGR2 and HAS2 genes
was blocked by RIM. Pertinent to the role of Wnt signalling in modulating the
developmental myogenic differentiation of fibre-type (Anakwe et al., 2003), this study
has demonstrated increased rat primary skeletal muscle mRNA content of FRZB in
response to ACEA. FRZB is considered as a Wnt-binding protein. ACEA decreases the
mRNA expression of these genes (RGS2, EGR2 and HAS2). RGS2 was shown to be
highly expressed in proliferating compared to differentiated MYOP7 (myogenic cell
line) (Zacchigna et al., 2008). However, another study found that RGS2 was highly up-
regulated in quiescent satellite cells compared to activated satellite cells (Fukada et al.,
2007). Overexpression of RGS2 in early xenopus embryos revealed histologically
reduced skeletal muscle tissue and inhibited trunk development (Wu et al., 2000).
Moreover, EGR2 was found to be highly expressed in rat soleus muscle after 3 hours of
mechanical overload-induced hypertrophy (Carson et al., 2002). Regarding HAS2,
hyaluronan synthase is an enzyme involved in synthesis of hyaluronan molecules (an
anionic, nonsulfated glycosaminoglycan). The synthesis of hyaluronan was shown in
myoblasts and myotubes (Ahrens et al., 1977; Angello et al., 1979). One study showed
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that differentiated multinucleated myotubes from chick embryo exhibit a specific
decrease of hyaluronic acid in their cell layer-associated fraction of the total synthesized
glycosaminoglycans (Carrino et al., 1999; Pacifici et al., 1980). Another study showed
that down-regulating of mRNA expression of OLRI was consistent with the
commitment of C2C12 to myogenic differentiation (Janot et al., 2009). There is little
information in the literature about the roles of these genes in skeletal muscle. Overall,
ACEA might have a role in skeletal myogenesis through regulating the expression of
those genes (FRZB, RGS2, EGR2, HAS2 and OLR1). Therefore, further research is
needed to address this issue.
ACEA, however, produced a different response in the presence of RIM. It is possible
that ACEA might give a response in a CBI independent manner (on other receptors)
when possibly almost all CBI receptors expressed in myotube was blocked by RIM.
There is also a suggestion that RIM might give a response as an agonist through other
receptors such as GPR55 (Godlewski et al., 2009). Therefore, the overall signalling in
response to ACEA and RIM compared to RIM alone was to down-regulate the mRNA
expression of the FRZB, RGS2 and HAS2. It is also worth noting that the serum used in
this experiment might also contain low endocannabinoid level that might interact with
signalling of ACEA, RIM or U0126. Therefore, it is very hard to explain the response
of ACEA in the presence of RIM (ACEA+RIM versus RIM). From this data, no
conclusion can also be made as to whether the ACEA effects depend on the activation
of the ERK pathway, in particular this experiment was performed from only one animal
due to cost and time implications. Further work should be performed to get a clear
comprehensive image in these issues, such as repeating this experiment from different
animals using either microarray or QRT-PCR (Taqman) or using delipidated serum
instead of charcoal stripped serum. Further work is also required to understand these
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responses such as using siRNA for CBI receptor or using GPR55 antagonist.
In this study, RIM up-regulated the mRNA content of NPY, APLN and LCN2, and
down-regulated GNAI3 and NR4Al. These genes were suggested to be related to
insulin resistance although the exact mechanisms are not known. There are limited
studies on these genes in skeletal muscle; acute administration of apelin in chow-fed
mice was associated with enhanced utilization of glucose in skeletal muscle (Dray et al.,
2008). Similarly, administration of NPY to rats was associated with increased glucose
utilization in skeletal muscle rvettor et al., 1998). Although the cross-talk between
cannabinoids and GNAI3 has not been studied in skeletal muscle, CBI receptor
activation was suggested to hinder insulin-stimulated IR autophosphorylation dependent
on the association between GNAI3 and IR in pancreatic beta-cells (Kim et al., 2011). It
is worth noting that GNAI2 in skeletal muscle was suggested to have a role in insulin
sensitivity through the suppression of protein-tyrosine phosphatase IB (PTPIB) (Tao et
al.,2001).
LCN2 knockout mice exhibit significant decrease in fasting glucose levels and insulin
sensitivity (Law et al., 2010). In addition, LCN2 concentrations correlated with
hyperglycemia and insulin resistance in humans (Wang et al., 2007), whereas mRNA
content of LCN2 was increased in liver and adipose tissue of diabetic/obese mice.
Moreover, it was reported that cAMP can affect the mRNA content of NR4Al in
skeletal muscle (Kawasaki et al., 2011; Pearen et al., 2008; Pearen et al., 2006). NR4Al
might modulate fat and glucose metabolism through regulating the expression of genes
related to oxidative metabolism in skeletal muscle (Pearen et al., 2008). It is worth
mentioning that all of the above genes (NR4Al, NPY, APLN, LCN2 and GNAI3) were
detected in rat skeletal muscle tissue using Agilent microarray at the following ranking
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(506, 12597, 1827, 12118 and 15033) out of 41000. However, more research is needed
to investigate the role of RIM in skeletal muscle metabolism. Moreover, measurement
of NPY and apelin in response to RIM should be recommended to be investigated in
skeletal muscle cells.
In this study, U0126 exerted an influence on gene expression in rat primary skeletal
muscle. Indeed, U0126 up-regulated CCNA2, LAMA2, PDGFRB and KLFI0 mRNA
expression and down-regulated JUN mRNA expression. CCNA2 is involved in cell
cycle control and C2C12 differentiation (Moran et al., 2002). There is some evidence
that PDGFRB is involved in skeletal and cardiac muscle development, however, its role
is not yet defined (Betsholtz et al., 2001; Kudla et al., 1998). LAMA2 may play a role
in muscle regeneration and the muscular dystrophy (Kamiguchi et al., 1998; Kuang et
al., 1999). JUN mRNA is expressed in the satellite cells, myoblasts and myotubes post-
trauma (Kami et al., 1995). KLFI0 mRNA expression was up-regulated during
myogenic differentiation (Miyake et al., 2011). It is worth noting that all of the above
genes (CCNA2, LAMA2, JUN, KLFI0 and PDGFRB) were detected in rat skeletal
muscle tissue using Agilent microarray at the following ranking (17108, 3101, 2054,
2278 and 3198) out of 41090. Little is known about the roles of these genes (CCNA2,
LAMA2, JUN, KLFI0 and PDGFRB) in skeletal muscle metabolsim. However, more
research is needed to examine U0126 in the proliferation and differentiation of skeletal
muscle cells.
In summary, the CBI receptor was found to be functional in rat skeletal muscle.
However, CBI receptor modulation for 24 hours did not alter the activation
(phosphorylation) of key insulin signalling proteins such as AKT, GSK-3p, AMPKa,
P38MAPK and ERK. The microarray findings revealed that ACEA might have a role in
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skeletal muscle proliferation and differentiation through altering the gene expression of
RGS2, EGR2, OLRl, HAS2 and FRZB. Moreover, treatment with RIM influenced the
mRNA content of genes (NPY, APLN, LCN2, NR4Al and GNAI3) related to insulin
resistance, glucose and fat metabolism. It is worth noting that the ERK1I2 pathway
might have a role in proliferation and differentiation in skeletal muscle cells by
regulating the expression of CCNA2, LAMA2, JUN, KLFIO and PDGFRB genes
(Table 5-6). Further research is warranted to establish the precise role of
endocannabinnoids in the regulation of gene expression in skeletal muscle and the
importance of this role in the development of insulin resisatnce and obesity.
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Table 5-6: Summary of findings for Chapter 5.
Conditions Findings
Treatment ofmyotubes with ACEA and ERK-phosphorylation in response to
AEA for 10 minutes ACEA and AEA; blocked by RIM.
Treatment of myotubes with ACEA or No AMPK phosphorylation.
RIM for one or two hours.
Treatment of myotubes with ACEA or No alteration in insulin signalling (AKT,
RIM for 24 hours GSK, ERK and P38 phosphorylation)
Treatment of myotubes with ACEA for 24 ACEA up-regulated frizzled-related
hours. protein (FRZD) mRNA gene expression
and down-regulated early growth response
2 (EGR2), hyaluronan synthase 2 (HAS2),
oxidized low density lipoprotein (lectin-
like) receptor 1 (OLRl) and regulator of
G-protein signaling 2 (RGS2) mRNA gene
expression.
Treatment of myotubes with RIM for 24 RIM up-regulated the mRNA content of
hours. neuropeptide Y (NPY), apelin (APLN) and
lipocalin 2 (LCN2), and down-regulated
guanine nucleotide binding protein (G
protein), alpha inhibiting activity
polypeptide 3 (GNAI3) and nuclear
receptor subfamily 4, group A (NR4A).
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Chapter 6
General Discussions
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6 Chapter Six: General Discussion
Skeletal muscle is a main site of fatty acid and glucose metabolism and involved in
energy balance (Zurlo et al., 1990). Skeletal muscle also produces skeletal movement
through its contraction and maintains body glucose homeostasis, and so
pharmacological tools that target the molecular mechanisms controlling skeletal muscle
metabolism, functions and physiological roles may be therapeutically useful for
metabolically related disorders.
Over the last few decades, significant advances in the understanding of GPCRs have
been made with deorphanization of generally orphan receptors. Therefore, investigation
of the functional role of GPCRs provides a promise of new targets in peripheral tissues,
especially skeletal muscle. The principal aims in the present thesis were to characterize
the mRNA expression of GPCRs and their partners' genes, and investigate their
signalling in skeletal muscle. Indeed, investigation of the GPCRs mRNA expressed in
skeletal muscle will aid in understanding the primary targets of many endogenous and
exogenous compounds affecting skeletal muscle metabolism and functions.
Understanding the signalling of GPCRs might help to determine their functionality and
possible roles in skeletal muscle tissue. Finally, understanding the direct effects of CBI
receptor agonists/antagonists will elucidate the possible roles of CBI receptor in skeletal
muscle and how RIM improves metabolic parameters such as glycaemia seen in both
rodent models (Cota et al., 2009) and human subjects (Pi-Sunyer et al., 2006).
These aims were illustrated and hopefully accomplished by using techniques such as
gene expression microarray and QRT-PCR (Taqman) to detect the relative levels of
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mRNA content of GPCRs, cAMP assay, calcium imaging and immunoblotting to
explicitly characterize the GPCRs signalling within myotubes, especially the CBI
receptors, a2A-adrenoceptors, A2Badenosine receptors and P2YI, P2Y2 and P2Y6
receptors.
As discussed in Chapter 3, GPCRs were detected in skeletal muscle tissues using QRT-
PCR (Taqman) and Agilent microarray. These GPCRs include LPAI lysophosphatidic
acid receptors, CXCR4, glucagon receptors, platelet-activating factors receptors,
GABABI receptors, SIP2 sphingosine-I-phosphate receptors, parathyroid hormone
receptors, mGlu2 and mGlu3 metabotropic glutamate receptors, dopamine D, receptors,
neurotensin receptors 2, opioid receptors delta 1, calcitonin receptors, arginine
vasopression receptors lA, bradykinin B2 receptors, C5al complement peptide
receptors, CBI receptor, GPRl19, a2-adrenoceptor, ~radrenoceptor, Al and A2A
adenosine receptors, NPY YI receptor, P2YI, P2Y2 and P2Y6 receptors genes mRNA.
To date, virtually no information is reported in the literature about the physiological
functions, pathophysiological roles, and regulation and gene expression patterns of such
GPCRs in skeletal muscle tissues. However, these receptors (see Chapter 3) might
affect a wide range of biological functions in skeletal muscle including glucose uptake
and metabolism, myogenesis, regeneration, growth and contraction. These findings
have identified targets which might be vital for many diseases or important to improve
many parameters in disease states. Further investigation is required to investigate these
receptors as potentially pharmacological targets to treat diabetes and skeletal muscle
regeneration disorders.
Moreover, as discussed in Chapter 3, mRNA expressions of various isoforms of GPCR
partners were also detected in skeletal muscle using Agilent microarray. These include
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G protein a, p and 'Y subunits (Gas.Gpl• Gp2,Gps,GylOand GyI2),regulators of G protein
signalling (RGS2, RGS5 and Axinl), adenylyl cyclase isoforms (AC2 and AC6),
phosphodiesterase (PDE4A and PDE4D), regulatory subunits of PKA (RIa),
phospholipase C isozymes (PLCo4 and PLCo1), diacylglycerol lipase and kinase
(DAGlp, DGK~ and DGKa), protein kinase C (PKCo and PKC9), low molecular weight
G protein (RhoA and RhoQ) and Rho-kinase 1 (ROCKI) gene mRNA expression.
These genes might be involved in a number of biological functions including skeletal
muscle fibre phenotypes, hypertrophy, contraction, fat and glucose metabolism,
hyperglycemia and weight gain. Interestingly, these targets might also be associated
with many diseases, and identify a large research area for GPCR partners in skeletal
muscle. Further investigation should also investigate these gene products as potential
therapeutic options to treat diabetes and skeletal muscle regeneration disorders such as
muscular dystrophy.
In the light of the data in this study, further investigations are needed to ultimately
understand GPCR expression and their signalling partners in individual elements of
muscle: fast and slow fibres and satellites, myoblasts, myotubes and tissues, as well as
investigating models of obesity in rats (for example, comparing Wistar, Zucker obese
and Zucker lean animals) and human disease (for example, comparing diabetic, obese
and normal conditions). Moreover, knockout mice model or siRNA for these targets
should also be investigated in skeletal muscle to understand the specific roles of these
GPCRs and their partners.
A limitation to the present study was employing the Wistar rat animal model to mimic
human. Even though the Wistar rat is widely used in the scientific research, it does not
exactly mimic the physiology in humans (Kotokorpi et al., 2007). Although several
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skeletal muscle.myogenic cell lines are commercially available, including rat L6 and
mouse C2C12 cells, and they are easy to grow in culture compared to primary culture,
rat primary skeletal muscle cells were chosen in these studies due to the fact that
primary cells are more representative of the cells in situ than the cell lines. Indeed,
cultured primary myotubes were widely used by many researchers to study the effects
of various factors such as pharmacological agents on muscle physiology, metabolism
and functions. This is due to the fact that cultured myotubes express protein and possess
functional characteristics of skeletal muscle (Pimenta et al., 2008; Stem-Straeter et al.,
2011). However, primary myotubes may have several limitations. First, primary
myotubes lose their capacity for proliferation (Renault et al., 2000). Satellite cells also
proliferate for a certain period of time and then lose their ability for proliferation
(Renault et al., 2000). Second, cells in culture gradually lose their capacity to preserve
the phenotype (Thompson, 1994). Third, contamination with fibroblasts may affect the
specificity of the myotube response (Thompson, 1994; Yaffe, 1968). Fourth, the fibre
composition of the muscle is not preserved in myotube culture. For example, myotubes
cultured from humans co-expressed both fast and slow myosin heavy chains regardless
of the fibre type of donor muscle (Bonavaud et al., 2001). Fifth, primary skeletal muscle
cell culture is not able to completely mimic the in vivo model including cross-talk
between other tissues such as adipose tissue and skeletal muscle. Therefore, using
primary skeletal muscle cell culture is of restricted physiological relevance. Regardless
of these limitations, the primary skeletal muscle cell cultures were required to determine
the direct effect of the GPCRs ligands, in particular CBI receptor agonists/antagonists,
on the skeletal muscle cells in controlled settings. Moreover, it is crucial to consider that
skeletal muscle tissue contains other cells including macrophages, epithelial and
fibroblasts in particular, in the literature, serotonin (5-hydroxytryptamine (5-HT» was
shown to cause a rapid stimulation in glucose uptake after 30 minutes exposure via the
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5-HT2Areceptor in isolated rat skeletal muscle (Hajduch et al., 1999). Therefore, the
primary skeletal muscle cell cultures were used in this study.
As discussed in Chapter 4, A2Badenosine receptor, a2-adrenoceptor and P2Y receptor
were found to be functional using cAMP assay, immunoblotting and calcium imaging.
Consistent with a previous report showing a functional role of A2Badenosine receptors
in skeletal muscle (Lynge et al., 2003), the present study found that NECA, a non-
selective adenosine receptor agonist (Castanon et al., 1994; Klotz et al., 1998),
enhanced cAMP production in rat primary skeletal muscle cells through A2Badenosine
receptors. However, COS21680, an A2Aadenosine receptor-selective agonist (Ongini et
al., 1999), and S-ENBA, an AI receptor-selective agonist (Haynes et al., 1998; Hussain
et al., 1995). failed to affect cAMP production in rat primary skeletal muscle cells in the
present study. Since A2Badenosine receptor was found to increase NR4A expression in
smooth muscle, which was blocked by an antagonist (Mayer et al., 2011), it is possible
that A2B adenosine receptors affect NR4A through cAMP in skeletal muscle.
Consequently, A2Badenosine receptors might improve fat and glucose metabolism in
skeletal muscle tissue through NR4A. This is supported by the fact that 1) NR4A
mRNA was found to be expressed in skeletal muscle using microarray in this study. 2)
cAMP was found to be involved in increase of expression of NR4A in skeletal muscle
(Kawasaki et al., 2011; Pearen et al., 2008; Pearen et al., 2006). 3) NR4A was shown to
be reduced in skeletal muscle of diabetic animals (Fu et al., 2007). 4) NR4A was
associated with genes related to glucose and fatty acid utilization through up-regulating
the mRNA expression ofPDK4, FOXOI, POC-Ia and lipin-In (Pearen et al., 2008).5)
NR4A null mice after high-fat feeding compared with wild-type animals were shown to
exhibit decreased mRNA expression of OLUT4 and PDK4 and Lipin la and impaired
insulin receptor substrate 1 (IRS-I) phosphorylation and insulin resistance in skeletal
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muscle, and slower blood glucose clearance and increased body weight and decreased
energy usage (Chao et al., 2009). 6) In C2C12 cells, C2C12 siRNA-NR4A cells were
shown to decrease mRNA expression of fatty acid translocase (CD36/fat), uncoupling
protein-3 (UCP3) and GLUT4 compared to wild type native C2CI2 cells (Maxwell et
al., 2005). 7) In C2CI2 cells transfected with adenovirus-mediated NR4A expression,
non-insulin glucose uptake was shown to be increased significantly compared to normal
C2CI2 cells (Chao et al., 2007). Taken together, modulation of A2Badenosine receptor
by ligands might affect glucose and fatty acid utilization in skeletal muscle. The
implication of this finding is that A2Badenosine receptor agonists may be a therapeutic
target for diabetes or obesity. However, NECA (0.3 mg/kg) was shown to increase
fasting glucose level in C57BLl6 mice which was not observed in A2B receptor
knockout mice (Figler et al., 2011). Moreover, NECA gavage in wild-type fasted mice
" was shown to delay glucose disposal during an oral glucose tolerance test (GTT) which
was abolished in A2Breceptor knockout mice (Figler et al., 2011). As discussed above,
A2B adenosine receptor agonists may be a therapeutic target for diabetes. The
discrepancy between the theory regarding NR4A and A2Breceptor described above and
studies in rodents published in the literature regarding NECA (Figler et al., 2011) might
be explained by the fact that NECA mediated the Al adenosine receptor expressed in
pancreas and A2 adenosine receptor expressed in liver (Arias et al., 2001). Therefore,
the effect of NECA in skeletal muscle through A2B receptor might improve glucose
uptake. Further work is required to assess the level of protein and mRNA expression of
NR4A in skeletal muscle and the exact molecular mechanism underlying the induction
of NR4A in response to activation of the A2B adenosine receptors. There is no
commercially selective A2B adenosine receptor agonist. However, Adenocard I.M.
(Adenosine) might be developed to examine the glucose tolerance despite the side
effects of this drug which include facial flushing, lightheadedness and diaphoresis due
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to its vasodilatory effects.
There are controversial data regarding the effect of A2Badenosine receptor activation
regarding the cellular proliferation. Although A2Badenosine receptor activation was
shown to inhibit the proliferation of murine vascular smooth muscle cells (Dubey et al.,
2000), its activation was shown to stimulate MAP kinase activity in human embryonic
kidney cells (Gao et al., 1999) and stimulate human endothelial cells growth (Grant et
al., 1999). Employing A2Badenosine receptor knockout mice was used for investigation
of vascular injury (Yang et al., 2008), and A2Badenosine receptor si-RNA was also
used for investigation of hepatocellular carcinoma (Xiang et al., 2011). However,
nothing is reported regarding skeletal muscle. Therefore, knockout mice or si-RNA for
A2Badenosine receptors is required to understand potential roles of these receptors in
skeletal muscle at both normal and diabetic/muscle atrophy states.
Surprisingly, the functionality of (l2-adrenoceptor and P2Y receptors has not been
studied in skeletal muscle. In the present study, the functionality of the (l2-adrenoceptor
was shown through the inhibition ofUK14304, an (l2-adrenenoceptoragonist (Jasper et
al., 1998), stimulation of ERK phosphorylation by rauwolscine, the selective (l2-
adrenoceptor antagonist (Convents et al., 1989; Uhlen et al., 1994) (see Chapter 4). As
activation of ERK signal transduction was suggested to induce differentiation of
skeletal muscle and growth-related processes (Bennett et al., 1997; Jones et al., 2001;
Lopez-Ilasaca, 1998), it is possible that (l2-adrenoceptorshave a role in skeletal muscle
myogenesis and growth. This result might hopefully open a question about what is the
effect of (l2-adrenoceptor in skeletal muscle. Moreover, there is a growing number of
reports suggesting (l2-adrenoceptor may represent a novel therapeutic target through
regulation of insulin secretion by noradrenaline in pancreatic islets by reducing cAMP
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formation (Ahren, 2000; Nakaki et al., 1981). Since u2A-adrenoceptorknockout mice
were shown to have lower blood glucose level compared to control mice (Savontaus et
al., 2008), further work including knockout mice or si-RNA for u2A-adrenoceptorsin
skeletal muscle should be performed to understand potential physiological and
pathophysiological roles of this receptor in skeletal muscle in terms of glucose uptake,
oxidation and myogenesis.
Previous reports have identified P2Yl. P2Y2 and P2Y6 receptor mRNA expression in
mouse C2C12 cells (Banachewicz et al., 2005). The present study revealed that mRNA
encoding P2Yl. P2Y2 and P2Y6 receptors are detected in skeletal muscle tissue and the
possibility of activation of these receptors coupled to calcium ion elevations was
assessed in primary skeletal muscle cells. Intracellular calcium concentration was
increased by UTP and ATP in this study, which was mainly attributed to activation of
the P2Y receptors, since UTP is a selective agonist for P2Y2 receptors (El-Tayeb et al.,
2006) and the profile of the response is typical for Gq-GPCRs (James et al., 2001). ATP,
localized at the nerve terminal, may be released after stimulation of the prejunctional
neurones, leading to activation ofP2Y receptors. Moreover, ATP and UTP may also be
released from many cell types including endothelium, fibroblasts, epithelium, blood
borne cells (RBC and platelets), smooth muscle cells and damaged tissues (Burnstock,
2008; Lazarowski et al., 2003; Schwiebert et al., 2003). Once ATP is released, it can be
hydrolyzed by ectonucleotidases, cell surface-located enzymes, into ADP, AMP and
adenosine (Huang et al., 1998; Zimmermann, 2006). Furthermore, ATP can be used to
produce UTP via a transphosphorlyation reaction catalyzed by extracellular nucleoside
diphosphokinase (NDPK) (Lazarowski et al., 2003) which was detected in this study in
skeletal muscle tissue using gene expression microarray (ranking 3894 out of 41090).
Indeed, ATP is considered as the source of cellular energy, and UTP is considered as an
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activator of substrates. For example, once UTP activates glucose-I-phosphate, UDP-
glucose is formed by UDP-glucose pyrophosphorylase, and then UDP-glucose is
involved in the synthesis of glycogen (Lazarowski et al., 2003).
The P2Y receptors may play a role in modulating skeletal muscle functions. Indeed,
UTP was shown to activate ERK in mouse C2C12 cells in a calcium dependent manner
(Banachewicz et al., 2005), and ATP was shown to stimulate the proliferation of
astrocyes via P2Y (Neary et al., 2009) and to stimulate the proliferation of cancer cells
(Deli et al., 2008). As ERK was shown to have a role in myoblast proliferation (Bennett
et al., 1997; Jones et al., 2001), it is possible that the P2Y receptors play a role in
skeletal muscle growth. Indeed, skeletal muscle P2Y receptors may present new
opportunities in the treatment of muscle growth disorders including muscle atrophy.
The P2Y receptors may also play a role in muscle contraction through calcium
modulation. Calcium might improve contraction-stimulated glucose uptake through
activating GLUT4 translocation, calmodulin-dependent protein kinases, calmodulin and
protein kinase Cs (Ihlemann et al., 1999; Jessen et al., 2005; Wright et al., 2004; Youn
et al., 1991). However, the mechanism behind this issue is unclear. Since muscle
contraction enhances glucose uptake, and ATP was also shown to activate glucose
uptake in mouse C2C12 skeletal muscle cells through P2 receptors (Kim et al., 2002);
P2Y receptor agonists might be a therapeutic option to treat diabetes through increasing
the calcium level in skeletal muscle. Further work is required to determine the P2Y
receptor subtypes which are possibly responsible for these effects. There are no clinical
drugs available to specifically target the activation of P2Y., P2Y2 or P2Y6receptors.
However, ATP and its breakdown products have been reported to mediate the
pathophysiology of pulmonary hypertension, hypertension and atherosclerosis
(Burnstock, 2008; Sprague et al., 2003).
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As discussed in Chapter 5, investigation of CBI receptor signalling and insulin
signalling in skeletal muscle has produced controversial findings. One study (Lindborg
et al., 2011) showed no modulation of phosphorylation of AKT, GSK and ERK induced
by insulin in response to ACEA and RIM, while other studies (Esposito et al., 2008;
Lipina et al., 2010) showed that treatment with either ACEA or RIM altered the
phosphorylation of these proteins induced by insulin. Long-term incubation studies,
where myotubes were co-incubated with cannabinoids, were thought to be feasible
means to assess the effects of prolonged CBI receptor signalling on myotubes. However,
the functionality of signalling proteins that might be involved in the regulation of either
insulin-dependent (AKT, GSK3p, ERK1I2 and p38) or insulin-independent (AMPKa)
glucose uptake, was not altered by direct CBI receptor antagonism (RIM) or agonism
(ACEA) in the present study. As discussed in Chapter 5, the difference between
previous studies and the findings from the present study could have been due to
physiological difference between rat and human, different representative model (L6 and
C2C12 cells) employed and previously uncharacterized activities of the ligands at non-
CB receptors and/or a reduced specificity at the concentrations used. Assuming the
results are physiologically-relevant, the findings from this thesis suggest that
cannabinoid signalling does not play a major role in insulin signalling in myotubes.
Indeed, the present study demonstrated that ACEA and RIM failed to alter AKT, p38,
GSK and ERK phosphorylation induced by insulin. Nevertheless, ACEA was able to
induce ERK and p38 phosphorylation. This effect was only observed acutely at 10
minutes while itwas not observed at extended time periods (24 hours).
As discussed in Chapter 5, the ERK phosphorylation in response to AEA was assumed
to be acting in a CBI receptor selective manner. As published in the literature, AEA
displays a higher affinity for recombinant CBI receptors over CB2receptors (Alexander
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et al., 2007; Lin et al., 1998). ACEA, used at CBI receptor-selective concentrations
(Hillard et al., 1999), was also found to increase ERK phosphorylation in rat primary
myotubes. Interestingly, this effect induced by both AEA and ACEA was blocked by
the selective CBI receptor antagonist/inverse agonist, RIM (Rinaldi-Carmona et al.,
1994). Given that CBI mRNA expression in skeletal muscle cells and tissue was
detected using QRT-PCR in the present study, these findings suggests that ERK
activation was mediated via activation of the CBI receptor.
The present study also revealed that the effects of the cannabinoids were limited to
ERKlp38 phosphorylation. Therefore, a comprehensive analysis of the effect of ACEA
and RIM on gene expression was performed. The findings indicate, for the first time,
that ACEA, synthetic compound, might affect skeletal muscle proliferation and
differentiation through altering the gene expression of regulator of G-protein signaling 2
(RGS2), early growth response 2 (EGR2), hyaluronan synthase 2 (HAS2), oxidized low
density lipoprotein (lectin-like) receptor 1 (OLR1) and frizzled-related protein (FRZB)
(see Chapter 5). The mRNA expression of RGS2, EGR2 and HAS2 was reversed by
RIM, suggesting that CBI receptors might be responsible for this effect. With several
reports showing that CBI receptors are expressed throughout central and peripheral
tissues where they mediate a wide range of therapeutic effects, it is possible that the
CBI receptors in skeletal muscle might provide a target for the development of
pharmacological strategies to modify skeletal muscle growth.
The findings from the present study indicate, for the first time, that RIM up-regulates
the mRNA content of neuropeptide Y (NPY), apelin (APLN) and lipocalin 2 (LCN2),
and down-regulate the mRNA content of G protein a subunit (GNAI3) and nuclear
receptor subfamily 4, group A (NR4A) (see Chapter 5). As discussed in Chapter 5,
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these genes were suggested to be related to insulin resistance although their exact roles
are not known. The investigation in this thesis has showed that cannabinoid signalling
might be more sophisticated than previously thought; indeed, the findings from the
present study showed that CBl receptor is functionally expressed, although they did not
fully characterize the cannabinoid machinery.
Further work is required to investigate the effect of cannabinoid signalling on skeletal
muscle metabolism such as glucose uptake and oxidation and beta-oxidation in both in
vivo and in vitro. Further work is also required to assess the ability of skeletal muscle
cells to synthesize endogenous cannabinoids based on that NAPE-PLD, DAGL, FAAH
and MAGL gene mRNA expression was classified as "present" (ranking out of 41090;
16632, 7018, 16568 and 8139, respectively) in skeletal muscle tissue in this study using
gene expression microarray. Furthermore, the potential interaction between CBI
receptor ligands and glucose uptake could facilitate future research aiming to develop a
novel class of drugs to increase glucose and fat metabolism in skeletal muscle. Future
efforts will have to be concentrated on understanding the exact mechanisms that
mediate CBl receptor modulation in skeletal muscle under normal and, of likely more
interest, under pathological conditions. Moreover, investigation of calcium level in
response to the modulation of CBI receptors might be useful in skeletal muscle to
examine the signalling pathway which might be involved in regulation of glucose
uptake activation.
Furthermore, molecular protein expression and functional approaches, such as
proliferation and differentiation assays and glucose uptake and oxidation and beta-
oxidation assays in vivo and in vitro, are required to confirm the suggested interactions
and relationships between the genes (NPY, APLN, LCN2, GNAI3, NR4A, RGS2,
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EGR2, OLR1, HAS2 and FRZB) that were differentially expressed by RlMlACEA. As
RIM might give a response through mediating central and peripheral targets, and RIM
diffuses across blood brain barrier (BBB) and induces side effects such as depression
(Oliviero et al., 2011), novel CBI receptor antagonists (Fulp et al., 2012) which do not
cross BBB should also be evaluated regarding their effects on skeletal muscle.
The incidence of obesity and its complications, such as hyperglycemia, is increasing
globally. Indeed, pre-diabetes and type 2 diabetes have become more prevalent with
obese people. Type 2 diabetes causes many complications including blindness, kidney
disease and neuropathies. As discussed earlier in this thesis, many risk factors in obesity
can be improved by CBI receptor antagonists acting either centrally or peripherally. The
endocannabinoid system itself appears to be activated in obesity. Skeletal muscle is the
principal tissue responsible for glucose uptake after food intake or during exercise.
Therefore, if skeletal muscle becomes insulin resistant, this might predispose towards
diabetes. Indeed, CBI receptor antagonists may become therapeutic agents for type II
diabetes since they have shown to improve glucose tolerance and reduce body weight in
clinical studies (Fulp et al., 2012; Nam et al., 2012; Scheen et al., 2008). However,
severe adverse effects, such as depression and high probable risk of suicide, limit and
prevent them from being used. Finding alternative pharmacological ways to reduce
insulin resistance in skeletal muscle is important for the prevention and treatment of
diabetes. A better understanding of the metabolic effects of the CBI receptor
modulation and the mechanism of this action in skeletal muscle in disease and normal
states may lead to reliable therapeutic solutions. Keeping this in mind, there has been
considerable interest in further understanding of the mechanisms of CBI receptor
modulation in skeletal muscle as a primary target for glucose uptake and insulin
signalling. Therefore, more research work is required to understand the cannabinoid
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signallings in peripheral tissue such as skeletal muscle. Even though the information
obtained from this thesis did not provide a direct and valid alternative way to improve
skeletal muscle insulin resistance, it is anticipated that the information will help future
investigators in this field to gain a more comprehensive understanding of the role of
cannabinoid signalling.
Finally, it is worth mentioning that modulation of skeletal muscle function with GPCR
ligands might be a possible therapeutic strategy for improving glucose uptake, skeletal
muscle growth and skeletal muscle fat metabolism.
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7 Future Work
In the present study, the effect of cannabinoid on glucose uptake in skeletal muscle and
the molecular signalling pathway through which the CBI receptor modulation might
affect glucose uptake activity in rat and human skeletal muscle cells were not
determined. Therefore, in the light of this thesis, further work is required to examine the
effects of CBt receptor agonists/antagonists in the presence of insulin to investigate any
potential unknown interaction between CB I receptor and insulin signalling and to
examine any potential unknown pathway for glucose uptake using gene expression
microarray in vivo and in vitro in both normal and diabetic/obese state.
Moreover, further work is needed to examine how A2Badenosine receptor and U2A-
adrenoceptor and P2Y receptors modulation might affect skeletal muscle myogenesis
using proliferation and differentiation assays and gene expression microarray.
Furthermore, selective agonists for u2A-adrenoceptor and A2B adenosine receptor are
required to be synthesized in order to examine the direct effect of these receptors in vivo
and in vitro, in particular skeletal muscle. Then, the response of these ligands should be
investigated to understand the potential roles of these receptors in skeletal muscle.
As CBI receptor is expressed in adipose tissue, and CBt receptor activation might affect
proliferation in skeletal muscle as discussed in this thesis, further work is required to
examine how CBt receptor modulation might affect the adipogenesis in adipose tissue
which might be useful for obesity.
The functionality of GPCRs detected in skeletal muscle in this study, in particular
244
bradykinin B2 receptors and CXCR4, is required to be investigated in skeletal muscle
using proliferation and differentiation assays, glucose uptake, oxidation and fat
oxidation assays, in vivo and in vitro, in normal and diabetic and muscle atrophy state to
understand the potential roles of these receptors in skeletal muscle.
Further work is also required to investigate the cross-talk between other tissues such as
adipose tissue and skeletal muscle using bioconductor apparatus. Using bioconductor
apparatus under electric electrode stimulation for skeletal muscle is required to be done
for primary myotubes to become more representative of cells in situ. Using this
apparatus, these GPCRs are required to be investigated in skeletal muscle under these
conditions to examine the direct effect of these receptors in skeletal muscle myogenesis,
glucose uptake, oxidation and fat oxidation. Moreover, examining the fibre phenotype
change in response to modulation of these receptors will be potentially useful for
diabetic patients.
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9 Appendix
9.1 Agilent microarray
9.1.1 Agilent bioanalyzer
The tables below represent RIN values for the samples (Table 9-1) and (Table 9-2).
Table 9-1: Characterizations of samples taken from rat A.
RIN (Agilent bioanalyzer) 7.7 7.7 7.7 9.3 9.7
Nanodrop
A260j280 ratio 2 1.9 1.9 2 1.9
A260j230 ratio 2.1 2.1 1.8 2.1 2.1
Cone (ngjIJI) 358.3 265.5 435.1 1243 194.7
Table 9-2: Characterizations of samples taken from rat B.
RIN (Agilent bioanalyzer) 7.6 8.4 8.6 8.9
Nanodrop
A260j280 ratio 1.9 1.9 2.1 2 2
A260j230 ratio 2.1 2.1 2.3 2 2
Cone (ngjIJI) 1405.6 607.6 669.32 343.79 1336.7
9.1.2 Sample preparation and labeling
Sample preparation includes four steps: Preparing One-Color Spike-Mix; prepanng
labeling reaction; purifying the labelled/amplified RNA and quantifying the cRNA.
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One-Color Spike-Mix was prepared according to the protocol on Agilent One-Color
RNA Spike-In Kit. Agilent One-Color Spike-Mix was thawed and mixed. The thawed
Agilent One-Color Spike-Mix was heated at 37 Co for 5 minutes and vortexed again.
1:10 dilution was then prepared as illustrated in the (Table 9-3).
Table 9-3: Dilutions of Agilent One-Color Spike-Mix for cyanine 3-labelling.
Starting amount of RNA Serial dilution Spike-mix volume to
Total RNA Maximum volume of First Second Third be used in each
(ng) RNA (IJL) labeling reaction
(IJL).
500 5.3 1:20 1:25 1:10 5
Labelling was performed using the Agilent Gene Expression system according to
protocol in Agilent Quick Amp Kit, One-Color. For the synthesis of eDNA, the low
-RNA input linear amplification kit (Agilent) was used to produce an initial RNA
amplification of at least 100 fold. This strategy utilizes an adapter T7 primer for first-
strand cDNA synthesis with MMLV reverse transcriptase, followed by in vitro
transcription using T7 RNA Polymerase to simultaneously amplify target material and
incorporate Cy3 labelled CTP (Perkin Elmer).
Template and T7 Promoter Primer Mix was prepared as illustrated in the (Table 9-4).
RNA sample, dilution Spike-Mix, T7 promoter primer and water were mixed. The
primer and the template were denatured by incubating the reaction at 65 Co for 10
minutes, and then placed on ice for 5 minutes.
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Table 9-4: Template and T7 promoter primer mix.
Total RNA Max RNA Third dilution T7 promoter Total volume
input (ng) volume (!-IL) of spike-mix primer (!-IL) (!-IL)
volume (!-IL)
500 5.3 5 1.2 11.5
eDNA master mix was prepared by mixing the reagents in order as illustrated in the
(Table 9-5). eDNA master mix was then added and mixed to each sample tube. Samples
were incubated at 40 Co in a circulating water bath for 2 hours, then incubated at 65 Co
circulating water bath for 15 minutes, placed on ice for 5 minutes.
Table 9-5: eDNA master mix.
Component Volume (!-IL) per reaction
SX First Strand Buffer 4
0.1 M DTT 2
10 mM dNTP mix 1
MMLV-RT 1
RNaseOut 0.5
Total Volume 8.5
Transcription Master Mix was prepared by mixing the reagents in order as illustrated in
the (Table 9-6). Transcription Master Mix was then added and mixed to each sample
tube. Foiled samples were incubated at 40 Co in a circulating water bath for 2 hours.
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Table 9-6: Transcription master mix.
Component Volume (IJL) per reaction
Nuclease-free water 15.3
4X Transcription Buffer 20
0.1 M OTT 6
NTP mix 8
50% PEG 6.4
RNaseOUT 0.5
Inorganic pyrophosphatase 0.6
T7 RNA Polymerase 0.8
Cyanine 3-CTP 2.4
Total Volume 60
The labelled/amplified RNA was then purified using Qiagen's RNeasy rmru spm
columns.
The concentrations of cRNA (ng/ul.) and cyanine 3 (pmol/ul.) were measured using the
NanoDrop ND-I000 Spectrophotometer, labelling efficiency was determined using the
yield and specific activity of each reaction. The yield and specific activity were
determined as follows:
The yield (ug cRNA) was calculated from the concentration of cRNA (ng/ul.):
(Concentration of cRNA) • 30 ul, (elution volume)11000 = ug of cRNA.
The specific activity was calculated from the concentrations of cRNA (ng/ul.) and
cyanine 3 (pmol/ul.) as follows:
(Concentration of Cy3) 1(Concentration of cRNA) • 1000= pmol ey3 per Jlg cRNA.
cRNA preparation will be repeated if the yield is less than 1.65 ug and the specific
activity is less than 9.0 pmol Cy3 per ug cRNA, as illustrated in the (Table 9-7) and
(Table 9-8).
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Table 9-7: Yield and specific activity for the samples taken from rat A.
9.1 18.6 9.5Specific activity (pmol
Cy-3/ug)
9.3 9.9
Table 9-8: Yield and specific activity for the samples taken from rat B.
Specific activity (pmol
Cy-3/ug)
13.4 13.8 16.215.3 17.6
Labelling was examined by the yield and specific activity of the reaction. None of the
samples yielded less than 1.65 ug and specific activity less than 9.0 pmol Cy3 per ug
cRNA.
9.1.3 Hybridization
Of each sample, 1.65 ug labelled cRNA was fragmented and hybridized on the Whole
Rat Genome Expression Array (4x44K, Agilent). Fragmentation mix was prepared by
mixing the reagents shown in the (Table 9-9).
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Table 9-9: Fragmentation mix for 4x44K microarrays.
Component Volume/Mass
Labelled, linearly amplified cRNA 1.651-1g
Agilent Blocking Agent (lOx) 111-11
Nuclease free water Bring volume to 52.81-11
Fragmentation Buffer (25x) 2.21-11
The samples were incubated at 60 Co for exactly 30 minutes in order to fragment RNA.
Afterwards the fragmentation was stopped by adding of 2x Hybridization buffer. The
final hybridization mixture for the 4x44k (4 array/slide; total volume llOJlI each)
Whole Rat Genome microarrays was prepared by adding cRNA from fragmentation
mix to Agilent hybridization buffer (2x), (2xGE, HI-RPM) as shown in the (Table 9-10).
Table 9-10: Hybridization mix for 4x44 K microarrays.
Component Volume
cRNA from Fragmentation Mix 551-11
Agilent Hybridization Buffer (2x), (2xGE, HI-RPM) 551-11
The sample was spun down for one minute at room temperature and kept on ice until
loading onto the array, which was performed immediately. The (Table 9-11) below
shows the hybridization sample volume.
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Table 9-11: Hybridization sample.
Component Volume
Volume prepared 110 IJL
Hybridization sample volume 100 IJL
Hybridization on microarray slides (Agilent) was then carried out at 65 Co for 17 hours
using an Agilent sureHyb chamber and an Agilent hybridization oven.
9.1.4 Microarray wash
Slides were washed in Gene Expression Wash Buffer I (Agilent) at room temperature
for one minute and in Gene Expression Wash Buffer II (Agilent, prewarmed to 37 CO)
for an additional minute. Afterwards slides were dried; they were assembled into an
appropriate slide holder for scanning.
9.1.5 Scanning
TIFF (Tagged Image File Format) images were immediately generated by the Agilent
scanner. Scans were made with a pixel resolution of Sum and sixteen-bit TIFF image.
The TIFF images were processed with feature extraction software 9.5.3 (Agilent) using
default parameters (protocol One-Color_GE_S.7) to obtain background subtracted
processed signal intensities. Feature extraction software converted these digital TIFF
images of hybridization intensity to the numerical measures of the hybridization
intensity of each feature that quantified gene expression (Figure 9-1).
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Figure 9-1: Representative TIFF image from the micro array.
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9.1.6 Agilent QC
Figure 9-2: The quality control from the feature extraction software after scanning.
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9.3 Affymetrix results
Table 9-13: Fold changes in the expression of genes influenced by ACEA in rat primary skeletal muscle
cells.
Fold Change Symbol Entrez Gene Name
2.1 FRZB frizzled-related protein
-2.1 RGS2 regulator of G-protein signaling 2, 24kDa
-2.1 HAS2 hyaluronan synthase 2
-2.2 OLR1 oxidized low density lipoprotein (lectin-like) receptor 1
-2.2 EGR2 early growth response 2
Table 9-14: Fold changes in the expression of genes influenced by ACEA+RIM vs ACEA in rat primary
skeletal muscle cells.
Fold
Change Symbol Entrez Gene Name
4.0 EGR1 early growth response 1
4.0 IL6 interleukin 6 (interferon beta 2)
3.1 EGR2 early growth response 2
2.9 HAS2 hyaluronan synthase 2
2.5 DUSPG dual specificity phosphatase 6
2.5 FOS FB] murine osteosarcoma viral oncogene homolog
2.4 HES1 hairy and enhancer of split 1 (Drosophila)
2.3 DUSPG dual specificity phosphatase 6
inhibitor of DNA binding 1, dominant negative
2.2 ID1 helix-loop-helix protein
2.2 NR4A1 nuclear receptor subfamily 4, group AI member 1
2.1 RGS2 regulator of G-protein signalinQ 2, 24kDa
2.0 BHLHE40 basic helix-loop-helix family, member e40
2.0 DUSPG dual s_pecificity phosphatase 6
Table 9-15: Fold changes in the expression of genes influenced by ACEA+RIM vs RIM in rat primary
skeletal muscle cells.
Fold
Change Symbol Entrez Gene Name
G.1 NR4Al nuclear receptor subfamily 4 group A, member 1
5.4 HAS2 hyaluronan synthase 2
5.0 EGR2 early growth response 2
ChaC, cation transport regulator homolog 1 (E.
3.2 CHAC1 coli)
3.1 ARL4C ADP-ribosylation factor-like 4C
inhibitor of DNA binding 4, dominant negative
3.0 104 helix-loop-helix protein
2.9 LOC2s7G42 rRNA promoter binding protein
2.7 EGR1 ear!y_growth response 1
2.7 HES1 hairy and enhancer of split 11 (Drosophila)
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2.5 DPT dermatopontin
2.4 DUSP6 dual specificity phosphatase 6
2.4 KLF10 Kruppel-like factor 10
oligonucleotide/oligosaccharide-binding fold
2.3 OBFC2A containing 2A
2.2 BHLHE40 basic helix-loop-helix family, member e40
2.2 DUSP6 dual specificity phosphatase 6
2.2 BHLHE40 basic helix-loop-helix family, member e40
EGF containing fibulin-like extracellular matrix
2.2 EFEMP1 protein 1
2.2 LRRN4CL LRRN4C-terminal like
2.1 KIF11 kinesin family member 11
2.1 PTGER4 prostaglandin E receptor 4 (subtype EP4)
integrin, beta-like 1 (with EGF-like repeat
2.1 ITGBL1 domains)
2.1 PLAU plasminogen activator urokinase
2.1 ECT2 epithelial cell transforming sequence 2 oncogene
2.1 ERRFIl ERBB receptor feedback inhibitor 1
2.0 RGS2 regulator of G-protein signaling 21 24kDa
GTP binding protein overexpressed in skeletal
2.0 GEM musele
2.0 AKR1CL1 aldo-keto reductase family 1, member C-like 1
-2.0 LOC100363014 RESTcorepressor 1-like
-2.0 HMGXB4 HMG box domain containing 4
-2.0 CCNG2 cvclln G2
-2.0 HP haptoglobin
doublesex and mab-3 related transcription factor
-2.0 DMRT2 2
-2.1 ANKRD37 ankvrln repeat domain 37
-2.1 Gm12253 predicted gene 12253
-2.1 MSL1 male-specific lethal 1 homolog (Drosophila)
-2.2 RBP1 retinol binding protein 1 cellular
-2.2 RASL12 RAS-like, family 12
-2.2 C9orf16 chromosome 9 open reading frame 16
-2.2 Fam60a (rat) family with seauence similarity 60 member A
-2.4 Cd24a CD24a antigen
-2.4 ANGPTL4 angiopoietin-like 4
-2.4 BMP6 bone morphogenetic protein 6
chemokine (C-X-C motif) ligand 6 (granulocyte
-2.5 CXCL6 chemotactic protein 2)
-2.6 MGP matrix Gla protein
-2.8 GBX2 gastrulation brain homeobox 2
-3.3 DPYSL3 dihydropyrimidinase-like 3
-4.6 C3 complement component 3
-4.7 NPY neuropeptide Y
-4.7 CCL20 chemokine (C-C motif) ligand 20
-4.8 LCN2 lipocalin 2
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Table 9-16: Fold changes in the expression of genes influenced by ACEA+UOI26 vs ACEA in rat
primary skeletal muscle cells.
Fold
Change Symbol Entrez Gene Name
9.4 ALOH3Al aldehyde dehydrogenase 3 fami~ member Al
7.2 AHRR aryl-hydrocarbon receQ_tor re_Qressor
3.1 ASPN asporin
BMP and activin membrane-bound inhibitor
2.5 BAMBI homolog (Xenopus laevis)
2.5 BMP6 bone morphogenetic protein 6
2.4 CSorf42 chromosome S open readin_q frame 42
2.3 BOKRBI brad_ykinin rece_QtorBl
2.2 CCNLI cvclln Ll
2.2 CA4 carbonic anhydrase IV
2.1 CIQTNF3 Clq and tumor necrosis factor related _Qrotein 3
2.1 ASPN asporin
-2.0 CCNOI cyclin 01
-2.1 CCNOI cvclln 01
-2.1 cise-rza chromosome 15 open reading frame 23
-2.1 ANXA3 annexin A3
-2.1 COCA2 cell division ~cle associated 2
-2.2 BMPER BMP binding endothelial regulator
cyclin-dependent kinase inhibitor 2C (pIS, inhibits
-2.2 COKN2C COK4)
budding uninhibited by benzimidazoles 1 homolog
-2.2 BUBI (yeast)
-2.2 ARHGEF3 Rho_guanine nucleotide exchange factor (GEI2 3
-2.2 C13orf33 chromosome 13 oQ_enreadin_g_frame 33
-2.2 C0200 C0200 molecule
-2.3 AFAPIL2 actin filament associated protein t-ltke 2
-2.4 AURKB aurora kinase B
-2.4 ALOHIA2 aldehyde dehydrogenase 1 famil'iL_member A2
-2.4 COKNIC cyclin-dependent kinase inhibitor ic (ps7, KiQ2_l
-2.4 AURKA aurora kinase A
-2.4 ANXAS/ ANXASLI annexin AS
-2.5 cisc-ras chromosome 15 open readin_g_frame 4S
-2.6 AMP03 adenosine monophosphate deaminase 3
-2.6 ARHGAPIIA Rho GTPase activatin_g__protein llA
ASFI anti-silencing function 1 homolog B (5.
-2.6 ASF1B cerevisiael
-3.0 C13orf33 chromosome 13 o_Qenreading frame 33
-3.1 BIRCs baculoviral lAP repeat containin_q 5
-3.1 COC20 cell division cycle 20 homolog__{S. cerevisiael
-3.1 BMP3 bone morphogenetic_protein 3
-3.2 AKAP12 A kinaselPRKA) anchor protein 12
-3.3 COCAS cell division cycle associated S
-3.4 ARG2 arginase, type II
-3.5 ciscrrza chromosome 15 oR_enreading frame 23
-3.6 AQPl aquaportn 1 (Colton blood groupl
-3.S COK1 cyclin-dependent kinase 1
budding uninhibited by benzimidazoles 1 homolog
-3.9 BUB1B beta lYeast)
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-4.1 CDCA3 cell division cycle associated 3
-4.6 AGTR2 angiotensin II receptor, type 2
-4.9 CCNBl cvclln B1
-5.4 CCNA2 cyclin A2
-5.6 CDC20 cell division cycle 20 homolog (5. cerevisiae)
-7.2 CCNBl cyclin B1
-7.6 CCNB2 cvctln B2
Table 9-17: Fold changes in the expression of genes influenced by ACEA+UOI26 vs U0126 in rat
primary skeletal muscle celIs.
Fold
Change Symbol Entrez Gene Name
4.4 NR4A1 nuclear receptor subfamily 4, group A, member 1
3.1 IL6 interleukin 6_(_interferon beta 2)
2.9 RGS2 regulator of G-protein signaling 2 24kDa
2.7 RGS2 regulator of G-protein signaling 2 24kDa
inhibitor of DNA binding 1, dominant negative helix-
2.5 IDl loop-helix protein
2.4 HAS2 hyaluronan synthase 2
2.1 HMGCR 3-hydroxy-3-methylglutarvl-CoA reductase
2.1 EGRl early growth response 1
2.0 ALDH3Al aldehyde dehydrogenase 3 family, member A1
-2.0 CCNG2 cvclln G2
-2.0 KIAA0101 KIAAOI01
-2.0 CCNBl cvcltn Bl
oxidized low density lipoprotein (lectin-like) receptor
-2.0 OLRl 1
-2.0 TRIM59 tripartite motif containing 59
-2.1 KRT18 keratin 18
alcohol dehydrogenase 7 (class IV), mu or sigma
-2.1 ADH7 polYQ_e_ptide
C430048L16Rik/
-2.1 Rbm12b RIKEN cDNA C430048L16 gene
-2.1 LARP4B La ribonucleoprotein domain family, member 4B
N(alpha)-acetyltransferase 40, NatD catalytic subunit,
-2.1 NAA40 homolog (5. cerevisiae)
budding uninhibited by benzimidazoles 1 homolog
-2.1 BUB1 (yeast)
-2.1 GRAMD3 GRAMdomain containing 3
-2.1 CCNB1 cyclin B1
-2.1 CKAP2 cvtoskeleton assoclated protein 2
cytochrome P450, family 1, subfamily A, polypeptide
-2.2 CYPIAl 1
-2.2 TBX5 T-box 5
-2.3 CCNB2 cyclin B2
-2.3 MAGEH1 melanoma antigen family HL1
-2.4 ECT2 epithelial cell transforming_ sequence 2 oncogene
-2.5 KIF23 kinesin family member 23
-2.5 TXNIP thioredoxin interacting protein
-2.6 RACGAP1 Rac GTPase activating protein 1
-2.7 SIX4 SIX homeobox 4
-3.1 CCNA2 cvclln A2
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Table 9-18: Fold changes in the expression of genes influenced by U0126 in rat primary skeletal muscle
cells.
Fold
Change Symbol Entrez Gene Name
9.04 GSTAs glutathione S-transferase alpha 5
8.53 AHRR aryl-hydrocarbon receptor repressor
7.11 CYP1A1 cytochrome P450 family 1 subfamilv A nolvnentlde 1
6.24 RASDl RAS dexamethasone-induced 1
solute carrier family 7 (anionic amino acid transporter
4.10 SLC7All light chain xc- system) member 11
3.94 ALDH3A1 aldehyde dehydrogenase 3 family, member A1
3.73 RBP4 retinol binding protein 4 plasma
DNA segment on chromosome 4 (unique) 234 expressed
3.17 D4S234E sequence
3.09 WNT4 wingless-type MMlV integration site familv. member 4
3.05 TIPARP TCDD-inducible poly(ADP-ribose) polymerase
endonuclease/exonuclease/phosphatase family domain
2.92 EEPD1 containing 1
2.86 LBP lipopolysaccharide binding protein
2.83 CSRP2 cysteine and qlvclne-rlch protein 2
2.80 ZNF423 zinc finger protein 423
2.67 BMP6 bone morphogenetic protein 6
2.59 ZBTB41 zinc finger and BTB domain containing 41
2.56 GOS2 GO/Glswitch 2
2.56 ASPN asoorln
BMP and activin membrane-bound inhibitor homolog
2.48 BAMBI (Xenopus laevis)
2.43 NQ01 NAD(P)H dehydrogenase quinone 1
2.43 GPC1 qlvplcan 1
2.39 C80rf42 chromosome 8 open reading frame 42
alcohol dehydrogenase 7 (class IV), mu or sigma
2.36 ADH7 polypeptide
2.29 JUN tun proto-oncogene
2.26 NOG noggin
2.23 C1QTNF3 C1q and tumor necrosis factor related protein 3
2.22 ASPN asporin
LOC1003s99
2.21 45 rCG41562-like
2.20 CYP1Bl cytochrome P450 family 1 subfamily B polypeptide 1
2.18 TMEM100 transmembrane protein 100
2.17 RCAN2 regulator of calcineurin 2
2.15 ZNF385A zinc finqer protein 385A
2.13 TMEM140 transmembrane protein 140
2.13 JUN tun proto-oncogene
2.12 DMRT2 doublesex and mab-3 related transcription factor 2
2.10 PTGES prostaglandin E synthase
2.09 KRT18 keratin 18
2.08 CTHRCl collaqen triple helix repeat containing 1
2.08 TGFBI transforming growth factor beta-induced 68kDa
2.06 RBMs RNA binding motif protein 5
2.05 Gsta4 glutathione S-transferase, alpha 4
2.04 C130rf15 chromosome 13 open reading frame 15
2.01 MRGPRF MAS-related GPR, member F
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-2.02 C130rf33 chromosome 13 open reading frame 33
-2.02 TKl thymidine kinase 1, soluble
-2.03 AKAP12 A kinase (PRKA) anchor protein 12
-2.03 DLGAP5 discs large (Drosophila) hornolon-assocleted protein 5
-2.03 LOC257642 rRNA promoter binding protein
chemokine (C-X-C motif) ligand 6 (granulocyte
-2.04 CXCL6 chemotactic protein 2)
-2.04 MTMR10 myotubularin related protein 10
-2.04 ECMl extracellular matrix protein 1
-2.04 ENPPl ectonucleotide pyrophosphatase/phosphodiesterase 1
-2.04 LTBPl latent transforming growth factor beta binding protein 1
-2.05 THYl Thy-l cell surface antigen
-2.05 C130rf33 chromosome 13 open reading frame 33
-2.05 KLF10 Krunnel-llke factor 10
-2.05 THYl Thy-l cell surface antigen
-2.06 EFEMPl EGF containing fibulin-like extracellular matrix protein 1
-2.06 C130rf33 chromosome 13 open reading frame 33
-2.07 NR4A2 nuclear receptor subfamily 4 group A, member 2
-2.07 DPYSL3 dlhvdropvrlrnldlnase-llke 3
-2.08 GPR126 G protein-coupled receptor 126
-2.09 CDCA2 cell division cy_cleassociated 2
-2.09 KIF4A kinesin family member 4A
-2.10 STARD13 StAR-related lipid transfer (START) domain containing 13
-2.10 ARG2 arginase, type II
-2.10 TNFAIP6 tumor necrosis factor alpha-induced protein 6
-2.10 PDGFRB platelet-derived growth factor receptor beta polypeptide
-2.10 ZDHHC2 zinc finger DHHC-type containing 2
-2.11 DUSP14 dual specificity phosphatase 14
-2.12 STMN2 stathmin-like 2
inhibitor of DNA binding 4, dominant negative helix-loop-
-2.12 ID4 helix protein
-2.12 C150rf23 chromosome 15 open reading frame 23
-2.12 CENPW centromere PJotein W
-2.13 TOP2A topoisomerase (DNA) II alpha 170kDa
-2.15 LOC687121 similar to Shc SH2-domain binding protein 1
-2.16 THBS4 thrornbospondln 4
serpln peptidase inhibitor, clade B (ovalbumin), member
-2.16 SERPINB9 9
-2.17 HMMR hyaluronan-mediated motility receptor (RHAMM)
-2.17 AFAP1L2 actin filament associated protein 1-like 2
-2.18 KIF18B kinesin family member 18B
asp (abnormal spindle) homolog, microcephaly associated
-2.18 ASPM (Drosophila)
serpin peptidase inhibitor, clade B (ovalbumin), member
-2.18 SERPINBl 1
-2.19 SPON2 spondln 2 extracellular matrix protein
chemokine (C-X-C motif) ligand 1 (melanoma growth
-2.20 CXCLl stimulating activity, alpha)
-2.20 SOX4 SRY_(sex determining region Y)-box 4
-2.22 SKAl spindle and kinetochore associated complex subunit 1
-2.23 SPPl secreted phosphoprotein 1
-2.23 C150rf48 chromosome 15 open reading frame 48
-2.23 PKP2 nlakophtltn 2
-2.23 KIF20B kinesin family member 20B
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-2.26 C3 complement component 3
AKAP2/PALM
-2.26 2-AKAP2 A kinase (PRKA) anchor protein 2
-2.27 ARHGAP11A Rho GTPase activating protein 11A
-2.27 CDCA3 cell division cycle associated 3
-2.29 UPP1 uridine phosphorylase 1
-2.31 TNFRSFllB tumor necrosis factor receptor superfamily, member llb
chemokine (C-X-C motif) ligand 1 (melanoma growth
-2.31 CXCL1 stimulating activity, alpha)
-2.33 ILlRL1 interleukin 1 receptor-like 1
-2.33 TOP2A topolsornerase (DNA) II alpha 170kDa
-2.34 ARHGEF3 Rho guanine nucleotide exchange factor(GEF) 3
-2.34 KIFC1 kinesin family member Cl
-2.36 CD200 CD200 molecule
-2.36 RRM2 ribonucleotide reductase M2
-2.37 LAMC2 laminin gamma 2
-2.37 SOX4 SRY (sex determining region Y)-box 4
-2.38 SFRP4 secreted frizzled-related protein 4
-2.38 CCNA2 cvclln A2
-2.38 CKS2 CDC28 protein kinase regulatory subunit 2
chemokine (C-X-C motif) ligand 1 (melanoma growth
-2.40 CXCLl stimulating activity, alpha)
-2.41 NUSAP1 nucleolar and spindle associated protein 1
solute carrier family 16, member 7 (monocarboxylic acid
-2.41 SLC16A7 transporter 2)
-2.42 BIRCS baculoviral lAP repeat containing S
-2.42 LAMA2 laminin alpha 2
-2.44 PLK1 polo-like kinase 1
-2.44 PLSCR1 phospholipid scramblase 1
-2.44 FOSL1 FOS-like antigen 1
-2.44 ANGPT1 an_giopoietin 1
-2.48 MTMR10 rnvotubularln related protein 10
-2.50 IFITM1 interferon induced transmembrane protein 1 (9-27)
-2.51 COL8A1 collagen, type VIII, alpha 1
-2.52 CRABP1 cellular retinoic acid binding protein 1
-2.52 COL1SA1 cotlauen. type XV, alpha 1
-2.54 HAS2 hvaturonen synthase 2
-2.54 KIF11 kinesin family member 11
solute carrier family 2 (facilitated glucose transporter),
-2.56 SLC2A3 member 3
-2.56 COL1SA1 cottaoen. type XV, alpha 1
-2.57 KIF2C kinesin family member 2C
-2.57 TACC3 transforming, acidic coiled-coil containin_gprotein 3
-2.58 IRS2 insulin receptor substrate 2
-2.61 IL1RL1 interleukin 1 rece_Qtor-like1
-2.62 BHLHE40 basic helix-loop-helix family, member e40
NUF2, NDC80 kinetochore complex component, homolog
-2.62 NUF2 (5. cerevisiae)
-2.62 C1Sorf23 chromosome 1S open reading frame 23
-2.68 RACGAP1 Rac GTPase activating protein 1
-2.72 CDC20 cell division cycle 20 homolog (5. cerevisiae)
AKAP2/PALM
-2.73 2-AKAP2 A kinase (PRKA) anchor protein 2
-2.74 CKAP2 cytoskeleton associated protein 2
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-2.75 DI03 deiodinase, todothvronlne. tvoe III
-2.78 BHLHE40 basic hellx-loop-hellx family, member e40
-2.79 CCNB1 cyclin Bl
-2.79 CENPF centromere protein F 3s0/400kDa (mitosin)
-2.80 RAMP3 receptor (G protein-coupled) activity modifying orotein 3
-2.82 UBE2C ubiQuitin-conluQatinQ enzyme E2C
-2.83 KIF23 kinesin family member 23
-2.85 ECT2 epithelial cell transforming sequence 2 oncooene
-2.85 CDK1 cyclin-dependent kinase 1
-2.89 PRCl protein reoulator of CYtokinesis 1
-2.89 BMP3 bone morphogenetic protein 3
-2.89 IGFBP3 insulin-like arowth factor bindina orotein 3
-2.90 TIK TIK protein kinase
budding uninhibited by benzimidazoles 1 homolog beta
-2.92 BUB1B (yeast)
-3.04 CDKN3 cvclln-dependent kinase inhibitor 3
-3.05 MKI67 antigen identified by monoclonal antibody Ki-57
-3.09 HMMR hyaluronan-mediated motility receotor (RHAMM)
-3.21 PTIG1 pituitary tumor-transforminQ 1
-3.23 AQPl aquaporln 1 (Colton blood crouo)
-3.29 KRT7 keratin 7
-3.33 FAM64A family with sequence similarity 64 member A
-3.38 NUSAPl nucleolar and spindle associated protein 1
-3.41 IGFBP3 Insulin-like growth factor binding protein 3
-3.42 EGR1 early qrowth response 1
-3.52 PRSS35 protease, serine 35
-3.55 GPR83 G protein-coupled receptor B3
-3.70 CDC20 cell division cycle 20 hornoloq (5. cerevisiae)
-3.72 Gm122s3 predicted cene 12253
-3.BO RGS2 requlator of G-protein stcnaunc 2 24kDa
-3.B3 CCNB1 cvclln B1
-3.B7 ERRFIl ERBB receptor feedback inhibitor 1
-3.96 CCNB2 cyclin B2
-3.95 KIF20A kinesin family member 20A
-3.98 AGTR2 angiotensin II receptor, type 2
Inhibitor of DNA binding 4, dominant negative helix-loop-
-4.10 ID4 helix protein
-4.10 RGS2 requlator of G-protein signalina 2 24kDa
-4.60 ESMl endothelial cell-specific molecule 1
-4.71 OLR1 oxidized low density lipoprotein (lectin-like) receptor 1
-4.76 AKAP12 A kinase (PRKA) anchor protein 12
-5.30 EGR2 early orowth response 2
-5.32 NR4A3 nuclear receptor subfamily 4. crouo A. member 3
-6.15 NR4A3 nuclear receptor subfamily 4, orouc A member 3
-6.25 PrlBa9 prolactin rarnuva subfamily a, member 9
-7.29 NR4A1 nuclear receptor subfamily 4, group A member 1
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